id	sid	tid	token	lemma	pos
dpc-3790	1	1	dermatology	dermatology	NOUN
dpc-3790	1	2	:	:	PUNCT
dpc-3790	1	3	practical	practical	ADJ
dpc-3790	1	4	and	and	CCONJ
dpc-3790	1	5	conceptual	conceptual	ADJ
dpc-3790	1	6	original	original	ADJ
dpc-3790	1	7	article	article	NOUN
dpc-3790	1	8	|	|	ADV
dpc-3790	1	9	dermatol	dermatol	ADJ
dpc-3790	1	10	pract	pract	NOUN
dpc-3790	1	11	concept	concept	NOUN
dpc-3790	1	12	.	.	PUNCT
dpc-3790	2	1	2024;14(2):e2024073	2024;14(2):e2024073	NUM
dpc-3790	2	2	1	1	NUM
dpc-3790	2	3	real	real	ADJ
dpc-3790	2	4	-	-	PUNCT
dpc-3790	2	5	world	world	NOUN
dpc-3790	2	6	experience	experience	NOUN
dpc-3790	2	7	of	of	ADP
dpc-3790	2	8	tofacitinib	tofacitinib	NOUN
dpc-3790	2	9	and	and	CCONJ
dpc-3790	2	10	baricitinib	baricitinib	NOUN
dpc-3790	2	11	use	use	VERB
dpc-3790	2	12	in	in	ADP
dpc-3790	2	13	alopecia	alopecia	NOUN
dpc-3790	2	14	areata	areata	ADJ
dpc-3790	2	15	in	in	ADP
dpc-3790	2	16	greek	greek	ADJ
dpc-3790	2	17	population	population	NOUN
dpc-3790	2	18	:	:	PUNCT
dpc-3790	2	19	a	a	DET
dpc-3790	2	20	 	 	SPACE
dpc-3790	2	21	retrospective	retrospective	ADJ
dpc-3790	2	22	analysis	analysis	NOUN
dpc-3790	2	23	with	with	ADP
dpc-3790	2	24	focus	focus	NOUN
dpc-3790	2	25	on	on	ADP
dpc-3790	2	26	safety	safety	NOUN
dpc-3790	2	27	zoe	zoe	PROPN
dpc-3790	2	28	apalla1	apalla1	PROPN
dpc-3790	2	29	,	,	PUNCT
dpc-3790	2	30	efterpi	efterpi	PROPN
dpc-3790	2	31	zafiriou2	zafiriou2	PROPN
dpc-3790	2	32	,	,	PUNCT
dpc-3790	2	33	effimia	effimia	PROPN
dpc-3790	2	34	zagkliverinou3	zagkliverinou3	PROPN
dpc-3790	2	35	,	,	PUNCT
dpc-3790	2	36	angeliki	angeliki	PROPN
dpc-3790	2	37	-	-	PUNCT
dpc-3790	2	38	viktoria	viktoria	PROPN
dpc-3790	2	39	roussaki	roussaki	PROPN
dpc-3790	2	40	-	-	PUNCT
dpc-3790	2	41	schulze2	schulze2	PROPN
dpc-3790	2	42	,	,	PUNCT
dpc-3790	2	43	polyxeni	polyxeni	ADJ
dpc-3790	2	44	gidarokosta2	gidarokosta2	PROPN
dpc-3790	2	45	,	,	PUNCT
dpc-3790	2	46	niki	niki	PROPN
dpc-3790	2	47	ntavari2	ntavari2	PROPN
dpc-3790	2	48	,	,	PUNCT
dpc-3790	2	49	stella	stella	PROPN
dpc-3790	2	50	sakellaropoulou1	sakellaropoulou1	PROPN
dpc-3790	2	51	,	,	PUNCT
dpc-3790	2	52	maria	maria	PROPN
dpc-3790	2	53	boziou1	boziou1	PROPN
dpc-3790	2	54	,	,	PUNCT
dpc-3790	2	55	anastasia	anastasia	PROPN
dpc-3790	2	56	emvalomati1	emvalomati1	PROPN
dpc-3790	2	57	,	,	PUNCT
dpc-3790	2	58	eirini	eirini	PROPN
dpc-3790	2	59	kyrmanidou1	kyrmanidou1	PROPN
dpc-3790	2	60	,	,	PUNCT
dpc-3790	2	61	elizabeth	elizabeth	PROPN
dpc-3790	2	62	lazaridou1	lazaridou1	PROPN
dpc-3790	3	1	*	*	PUNCT
dpc-3790	3	2	e.	e.	PROPN
dpc-3790	3	3	kyrmanidou	kyrmanidou	PROPN
dpc-3790	3	4	and	and	CCONJ
dpc-3790	3	5	e.	e.	PROPN
dpc-3790	3	6	lazaridou	lazaridou	PROPN
dpc-3790	3	7	equally	equally	ADV
dpc-3790	3	8	contributed	contribute	VERB
dpc-3790	3	9	in	in	ADP
dpc-3790	3	10	their	their	PRON
dpc-3790	3	11	role	role	NOUN
dpc-3790	3	12	as	as	ADP
dpc-3790	3	13	senior	senior	ADJ
dpc-3790	3	14	authors	author	NOUN
dpc-3790	3	15	.	.	PUNCT
dpc-3790	4	1	1	1	NUM
dpc-3790	4	2	second	second	ADJ
dpc-3790	4	3	dermatology	dermatology	NOUN
dpc-3790	4	4	department	department	NOUN
dpc-3790	4	5	,	,	PUNCT
dpc-3790	4	6	aristotle	aristotle	PROPN
dpc-3790	4	7	university	university	PROPN
dpc-3790	4	8	of	of	ADP
dpc-3790	4	9	thessaloniki	thessaloniki	PROPN
dpc-3790	4	10	,	,	PUNCT
dpc-3790	4	11	thessaloniki	thessaloniki	PROPN
dpc-3790	4	12	,	,	PUNCT
dpc-3790	4	13	greece	greece	PROPN
dpc-3790	4	14	2	2	NUM
dpc-3790	4	15	department	department	NOUN
dpc-3790	4	16	of	of	ADP
dpc-3790	4	17	dermatology	dermatology	NOUN
dpc-3790	4	18	,	,	PUNCT
dpc-3790	4	19	university	university	NOUN
dpc-3790	4	20	general	general	ADJ
dpc-3790	4	21	hospital	hospital	PROPN
dpc-3790	4	22	larissa	larissa	PROPN
dpc-3790	4	23	,	,	PUNCT
dpc-3790	4	24	university	university	PROPN
dpc-3790	4	25	of	of	ADP
dpc-3790	4	26	thessaly	thessaly	PROPN
dpc-3790	4	27	,	,	PUNCT
dpc-3790	4	28	larissa	larissa	PROPN
dpc-3790	4	29	,	,	PUNCT
dpc-3790	4	30	greece	greece	PROPN
dpc-3790	4	31	3	3	NUM
dpc-3790	4	32	internal	internal	ADJ
dpc-3790	4	33	medicine	medicine	NOUN
dpc-3790	4	34	department	department	NOUN
dpc-3790	4	35	,	,	PUNCT
dpc-3790	4	36	“	"	PUNCT
dpc-3790	4	37	theagenio	theagenio	ADJ
dpc-3790	4	38	”	"	PUNCT
dpc-3790	4	39	hospital	hospital	NOUN
dpc-3790	4	40	,	,	PUNCT
dpc-3790	4	41	thessaloniki	thessaloniki	PROPN
dpc-3790	4	42	,	,	PUNCT
dpc-3790	4	43	greece	greece	PROPN
dpc-3790	4	44	key	key	ADJ
dpc-3790	4	45	words	word	NOUN
dpc-3790	4	46	:	:	PUNCT
dpc-3790	4	47	alopecia	alopecia	NOUN
dpc-3790	4	48	areata	areata	NOUN
dpc-3790	4	49	,	,	PUNCT
dpc-3790	4	50	janus	janus	PROPN
dpc-3790	4	51	kinase	kinase	PROPN
dpc-3790	4	52	inhibitors	inhibitor	NOUN
dpc-3790	4	53	,	,	PUNCT
dpc-3790	4	54	tofacitinib	tofacitinib	NOUN
dpc-3790	4	55	,	,	PUNCT
dpc-3790	4	56	baricitinib	baricitinib	NOUN
dpc-3790	4	57	,	,	PUNCT
dpc-3790	4	58	real	real	ADJ
dpc-3790	4	59	-	-	PUNCT
dpc-3790	4	60	world	world	NOUN
dpc-3790	4	61	citation	citation	NOUN
dpc-3790	4	62	:	:	PUNCT
dpc-3790	4	63	apalla	apalla	PROPN
dpc-3790	4	64	z	z	NOUN
dpc-3790	4	65	,	,	PUNCT
dpc-3790	4	66	zafiriou	zafiriou	NOUN
dpc-3790	4	67	e	e	NOUN
dpc-3790	4	68	,	,	PUNCT
dpc-3790	4	69	zagkliverinou	zagkliverinou	PROPN
dpc-3790	4	70	e	e	PROPN
dpc-3790	4	71	,	,	PUNCT
dpc-3790	4	72	et	et	PROPN
dpc-3790	4	73	al	al	PROPN
dpc-3790	4	74	.	.	PUNCT
dpc-3790	5	1	real	real	ADJ
dpc-3790	5	2	-	-	PUNCT
dpc-3790	5	3	world	world	NOUN
dpc-3790	5	4	experience	experience	NOUN
dpc-3790	5	5	of	of	ADP
dpc-3790	5	6	tofacitinib	tofacitinib	NOUN
dpc-3790	5	7	and	and	CCONJ
dpc-3790	5	8	baricitinib	baricitinib	NOUN
dpc-3790	5	9	use	use	VERB
dpc-3790	5	10	in	in	ADP
dpc-3790	5	11	alopecia	alopecia	NOUN
dpc-3790	5	12	areata	areata	ADJ
dpc-3790	5	13	in	in	ADP
dpc-3790	5	14	greek	greek	ADJ
dpc-3790	5	15	population	population	NOUN
dpc-3790	5	16	:	:	PUNCT
dpc-3790	5	17	a	a	DET
dpc-3790	5	18	retrospective	retrospective	ADJ
dpc-3790	5	19	analysis	analysis	NOUN
dpc-3790	5	20	with	with	ADP
dpc-3790	5	21	focus	focus	NOUN
dpc-3790	5	22	on	on	ADP
dpc-3790	5	23	safety	safety	NOUN
dpc-3790	5	24	.	.	PUNCT
dpc-3790	6	1	dermatol	dermatol	NOUN
dpc-3790	6	2	pract	pract	PROPN
dpc-3790	6	3	concept	concept	NOUN
dpc-3790	6	4	.	.	PUNCT
dpc-3790	7	1	2024;14(2):e2024073	2024;14(2):e2024073	NUM
dpc-3790	7	2	.	.	PUNCT
dpc-3790	8	1	doi	doi	NOUN
dpc-3790	8	2	:	:	PUNCT
dpc-3790	8	3	https://doi.org/10.5826/dpc.1402a73	https://doi.org/10.5826/dpc.1402a73	PROPN
dpc-3790	8	4	accepted	accept	VERB
dpc-3790	8	5	:	:	PUNCT
dpc-3790	8	6	october	october	PROPN
dpc-3790	8	7	2	2	NUM
dpc-3790	8	8	,	,	PUNCT
dpc-3790	8	9	2023	2023	NUM
dpc-3790	8	10	;	;	PUNCT
dpc-3790	8	11	published	publish	VERB
dpc-3790	8	12	:	:	PUNCT
dpc-3790	9	1	april	april	PROPN
dpc-3790	9	2	2024	2024	NUM
dpc-3790	9	3	copyright	copyright	NOUN
dpc-3790	9	4	:	:	PUNCT
dpc-3790	9	5	©	©	PROPN
dpc-3790	9	6	2024	2024	NUM
dpc-3790	9	7	apalla	apalla	NOUN
dpc-3790	9	8	et	et	PROPN
dpc-3790	9	9	al	al	PROPN
dpc-3790	9	10	.	.	PUNCT
dpc-3790	10	1	this	this	PRON
dpc-3790	10	2	is	be	AUX
dpc-3790	10	3	an	an	DET
dpc-3790	10	4	open	open	ADJ
dpc-3790	10	5	-	-	PUNCT
dpc-3790	10	6	access	access	NOUN
dpc-3790	10	7	article	article	NOUN
dpc-3790	10	8	distributed	distribute	VERB
dpc-3790	10	9	under	under	ADP
dpc-3790	10	10	the	the	DET
dpc-3790	10	11	terms	term	NOUN
dpc-3790	10	12	of	of	ADP
dpc-3790	10	13	the	the	DET
dpc-3790	10	14	creative	creative	ADJ
dpc-3790	10	15	commons	common	NOUN
dpc-3790	10	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-3790	10	17	license	license	NOUN
dpc-3790	10	18	(	(	PUNCT
dpc-3790	10	19	by	by	ADP
dpc-3790	10	20	-	-	PUNCT
dpc-3790	10	21	nc-4.0	nc-4.0	NOUN
dpc-3790	10	22	)	)	PUNCT
dpc-3790	10	23	,	,	PUNCT
dpc-3790	10	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-3790	10	25	,	,	PUNCT
dpc-3790	10	26	which	which	PRON
dpc-3790	10	27	permits	permit	VERB
dpc-3790	10	28	unrestricted	unrestricted	ADJ
dpc-3790	10	29	noncommercial	noncommercial	ADJ
dpc-3790	10	30	use	use	NOUN
dpc-3790	10	31	,	,	PUNCT
dpc-3790	10	32	distribution	distribution	NOUN
dpc-3790	10	33	,	,	PUNCT
dpc-3790	10	34	and	and	CCONJ
dpc-3790	10	35	reproduction	reproduction	NOUN
dpc-3790	10	36	in	in	ADP
dpc-3790	10	37	any	any	DET
dpc-3790	10	38	medium	medium	NOUN
dpc-3790	10	39	,	,	PUNCT
dpc-3790	10	40	provided	provide	VERB
dpc-3790	10	41	the	the	DET
dpc-3790	10	42	original	original	ADJ
dpc-3790	10	43	authors	author	NOUN
dpc-3790	10	44	and	and	CCONJ
dpc-3790	10	45	source	source	NOUN
dpc-3790	10	46	are	be	AUX
dpc-3790	10	47	credited	credit	VERB
dpc-3790	10	48	.	.	PUNCT
dpc-3790	11	1	funding	funding	NOUN
dpc-3790	11	2	:	:	PUNCT
dpc-3790	11	3	none	none	NOUN
dpc-3790	11	4	.	.	PUNCT
dpc-3790	12	1	competing	compete	VERB
dpc-3790	12	2	interests	interest	NOUN
dpc-3790	12	3	:	:	PUNCT
dpc-3790	12	4	none	none	NOUN
dpc-3790	12	5	.	.	PUNCT
dpc-3790	13	1	authorship	authorship	NOUN
dpc-3790	13	2	:	:	PUNCT
dpc-3790	13	3	all	all	DET
dpc-3790	13	4	authors	author	NOUN
dpc-3790	13	5	have	have	AUX
dpc-3790	13	6	contributed	contribute	VERB
dpc-3790	13	7	significantly	significantly	ADV
dpc-3790	13	8	to	to	ADP
dpc-3790	13	9	this	this	DET
dpc-3790	13	10	publication	publication	NOUN
dpc-3790	13	11	.	.	PUNCT
dpc-3790	14	1	corresponding	correspond	VERB
dpc-3790	14	2	author	author	NOUN
dpc-3790	14	3	:	:	PUNCT
dpc-3790	14	4	zoe	zoe	NOUN
dpc-3790	14	5	apalla	apalla	PROPN
dpc-3790	14	6	,	,	PUNCT
dpc-3790	14	7	phd	phd	NOUN
dpc-3790	14	8	,	,	PUNCT
dpc-3790	14	9	address	address	NOUN
dpc-3790	14	10	:	:	PUNCT
dpc-3790	14	11	k.	k.	PROPN
dpc-3790	14	12	karamanli	karamanli	PROPN
dpc-3790	14	13	60	60	NUM
dpc-3790	14	14	,	,	PUNCT
dpc-3790	14	15	54643	54643	NUM
dpc-3790	14	16	,	,	PUNCT
dpc-3790	14	17	e	e	NOUN
dpc-3790	14	18	-	-	NOUN
dpc-3790	14	19	mail	mail	NOUN
dpc-3790	14	20	address	address	NOUN
dpc-3790	14	21	:	:	PUNCT
dpc-3790	14	22	zoimd@yahoo.gr	zoimd@yahoo.gr	NUM
dpc-3790	14	23	,	,	PUNCT
dpc-3790	15	1	tel	tel	PROPN
dpc-3790	15	2	.	.	PUNCT
dpc-3790	15	3	+306972916729	+306972916729	PROPN
dpc-3790	15	4	introduction	introduction	NOUN
dpc-3790	15	5	:	:	PUNCT
dpc-3790	15	6	the	the	DET
dpc-3790	15	7	introduction	introduction	NOUN
dpc-3790	15	8	of	of	ADP
dpc-3790	15	9	janus	janus	PROPN
dpc-3790	15	10	kinase	kinase	PROPN
dpc-3790	15	11	inhibitors	inhibitor	NOUN
dpc-3790	15	12	(	(	PUNCT
dpc-3790	15	13	jaki	jaki	PROPN
dpc-3790	15	14	)	)	PUNCT
dpc-3790	15	15	seems	seem	VERB
dpc-3790	15	16	to	to	PART
dpc-3790	15	17	revolutionize	revolutionize	VERB
dpc-3790	15	18	the	the	DET
dpc-3790	15	19	field	field	NOUN
dpc-3790	15	20	of	of	ADP
dpc-3790	15	21	alopecia	alopecia	NOUN
dpc-3790	15	22	areata	areata	ADJ
dpc-3790	15	23	(	(	PUNCT
dpc-3790	15	24	aa	aa	NOUN
dpc-3790	15	25	)	)	PUNCT
dpc-3790	15	26	therapeutics	therapeutic	NOUN
dpc-3790	15	27	.	.	PUNCT
dpc-3790	16	1	however	however	ADV
dpc-3790	16	2	,	,	PUNCT
dpc-3790	16	3	real	real	ADJ
dpc-3790	16	4	-	-	PUNCT
dpc-3790	16	5	world	world	NOUN
dpc-3790	16	6	data	datum	NOUN
dpc-3790	16	7	are	be	AUX
dpc-3790	16	8	still	still	ADV
dpc-3790	16	9	missing	miss	VERB
dpc-3790	16	10	.	.	PUNCT
dpc-3790	17	1	objectives	objective	NOUN
dpc-3790	17	2	:	:	PUNCT
dpc-3790	17	3	to	to	PART
dpc-3790	17	4	provide	provide	VERB
dpc-3790	17	5	evidence	evidence	NOUN
dpc-3790	17	6	about	about	ADP
dpc-3790	17	7	effectiveness	effectiveness	NOUN
dpc-3790	17	8	and	and	CCONJ
dpc-3790	17	9	safety	safety	NOUN
dpc-3790	17	10	of	of	ADP
dpc-3790	17	11	tofacitinib	tofacitinib	NOUN
dpc-3790	17	12	and	and	CCONJ
dpc-3790	17	13	baricitinib	baricitinib	NOUN
dpc-3790	17	14	in	in	ADP
dpc-3790	17	15	aa	aa	NOUN
dpc-3790	17	16	in	in	ADP
dpc-3790	17	17	real	real	ADJ
dpc-3790	17	18	-	-	PUNCT
dpc-3790	17	19	world	world	NOUN
dpc-3790	17	20	settings	setting	NOUN
dpc-3790	17	21	and	and	CCONJ
dpc-3790	17	22	describe	describe	VERB
dpc-3790	17	23	baseline	baseline	NOUN
dpc-3790	17	24	disease	disease	NOUN
dpc-3790	17	25	characteristics	characteristic	NOUN
dpc-3790	17	26	and	and	CCONJ
dpc-3790	17	27	patients	patient	NOUN
dpc-3790	17	28	profiles	profile	NOUN
dpc-3790	17	29	that	that	PRON
dpc-3790	17	30	are	be	AUX
dpc-3790	17	31	considered	consider	VERB
dpc-3790	17	32	good	good	ADJ
dpc-3790	17	33	candidates	candidate	NOUN
dpc-3790	17	34	for	for	ADP
dpc-3790	17	35	jaki	jaki	PROPN
dpc-3790	17	36	in	in	ADP
dpc-3790	17	37	the	the	DET
dpc-3790	17	38	daily	daily	ADJ
dpc-3790	17	39	practice	practice	NOUN
dpc-3790	17	40	.	.	PUNCT
dpc-3790	18	1	furthermore	furthermore	ADV
dpc-3790	18	2	,	,	PUNCT
dpc-3790	18	3	we	we	PRON
dpc-3790	18	4	intended	intend	VERB
dpc-3790	18	5	to	to	PART
dpc-3790	18	6	investigate	investigate	VERB
dpc-3790	18	7	potential	potential	ADJ
dpc-3790	18	8	correlations	correlation	NOUN
dpc-3790	18	9	between	between	ADP
dpc-3790	18	10	baseline	baseline	NOUN
dpc-3790	18	11	characteristics	characteristic	NOUN
dpc-3790	18	12	and	and	CCONJ
dpc-3790	18	13	treatment	treatment	NOUN
dpc-3790	18	14	outcomes	outcome	NOUN
dpc-3790	18	15	.	.	PUNCT
dpc-3790	19	1	methods	method	NOUN
dpc-3790	19	2	:	:	PUNCT
dpc-3790	19	3	we	we	PRON
dpc-3790	19	4	retrospectively	retrospectively	ADV
dpc-3790	19	5	reviewed	review	VERB
dpc-3790	19	6	the	the	DET
dpc-3790	19	7	databases	database	NOUN
dpc-3790	19	8	of	of	ADP
dpc-3790	19	9	two	two	NUM
dpc-3790	19	10	tertiary	tertiary	ADJ
dpc-3790	19	11	hospitals	hospital	NOUN
dpc-3790	19	12	in	in	ADP
dpc-3790	19	13	greece	greece	PROPN
dpc-3790	19	14	,	,	PUNCT
dpc-3790	19	15	to	to	PART
dpc-3790	19	16	identify	identify	VERB
dpc-3790	19	17	individuals	individual	NOUN
dpc-3790	19	18	of	of	ADP
dpc-3790	19	19	any	any	DET
dpc-3790	19	20	age	age	NOUN
dpc-3790	19	21	currently	currently	ADV
dpc-3790	19	22	being	be	AUX
dpc-3790	19	23	treated	treat	VERB
dpc-3790	19	24	with	with	ADP
dpc-3790	19	25	systemic	systemic	ADJ
dpc-3790	19	26	jaki	jaki	PROPN
dpc-3790	19	27	for	for	ADP
dpc-3790	19	28	severe	severe	ADJ
dpc-3790	19	29	aa	aa	PROPN
dpc-3790	19	30	.	.	PUNCT
dpc-3790	20	1	results	result	NOUN
dpc-3790	20	2	:	:	PUNCT
dpc-3790	20	3	we	we	PRON
dpc-3790	20	4	identified	identify	VERB
dpc-3790	20	5	42	42	NUM
dpc-3790	20	6	individuals	individual	NOUN
dpc-3790	20	7	,	,	PUNCT
dpc-3790	20	8	including	include	VERB
dpc-3790	20	9	3	3	NUM
dpc-3790	20	10	adolescents	adolescent	NOUN
dpc-3790	20	11	.	.	PUNCT
dpc-3790	21	1	in	in	ADP
dpc-3790	21	2	our	our	PRON
dpc-3790	21	3	cohort	cohort	NOUN
dpc-3790	21	4	,	,	PUNCT
dpc-3790	21	5	52.3	52.3	NUM
dpc-3790	21	6	%	%	NOUN
dpc-3790	21	7	(	(	PUNCT
dpc-3790	21	8	22/42	22/42	NUM
dpc-3790	21	9	)	)	PUNCT
dpc-3790	21	10	were	be	AUX
dpc-3790	21	11	under	under	ADP
dpc-3790	21	12	tofacitinib	tofacitinib	NOUN
dpc-3790	21	13	and	and	CCONJ
dpc-3790	21	14	47.6	47.6	NUM
dpc-3790	21	15	%	%	NOUN
dpc-3790	21	16	(	(	PUNCT
dpc-3790	21	17	20/42	20/42	NUM
dpc-3790	21	18	)	)	PUNCT
dpc-3790	21	19	under	under	ADP
dpc-3790	21	20	baricitinib	baricitinib	NOUN
dpc-3790	21	21	treatment	treatment	NOUN
dpc-3790	21	22	.	.	PUNCT
dpc-3790	22	1	efficacy	efficacy	NOUN
dpc-3790	22	2	analysis	analysis	NOUN
dpc-3790	22	3	was	be	AUX
dpc-3790	22	4	performed	perform	VERB
dpc-3790	22	5	on	on	ADP
dpc-3790	22	6	the	the	DET
dpc-3790	22	7	subgroup	subgroup	NOUN
dpc-3790	22	8	of	of	ADP
dpc-3790	22	9	30	30	NUM
dpc-3790	22	10	patients	patient	NOUN
dpc-3790	22	11	that	that	PRON
dpc-3790	22	12	had	have	AUX
dpc-3790	22	13	completed	complete	VERB
dpc-3790	22	14	at	at	ADP
dpc-3790	22	15	least	least	ADJ
dpc-3790	22	16	a	a	DET
dpc-3790	22	17	3	3	NUM
dpc-3790	22	18	-	-	PUNCT
dpc-3790	22	19	month	month	NOUN
dpc-3790	22	20	follow	follow	NOUN
dpc-3790	22	21	-	-	PUNCT
dpc-3790	22	22	up	up	NOUN
dpc-3790	22	23	on	on	ADP
dpc-3790	22	24	treatment	treatment	NOUN
dpc-3790	22	25	.	.	PUNCT
dpc-3790	23	1	in	in	ADP
dpc-3790	23	2	the	the	DET
dpc-3790	23	3	latter	latter	ADJ
dpc-3790	23	4	group	group	NOUN
dpc-3790	23	5	,	,	PUNCT
dpc-3790	23	6	mean	mean	VERB
dpc-3790	23	7	time	time	NOUN
dpc-3790	23	8	on	on	ADP
dpc-3790	23	9	treatment	treatment	NOUN
dpc-3790	23	10	was	be	AUX
dpc-3790	23	11	10	10	NUM
dpc-3790	23	12	months	month	NOUN
dpc-3790	23	13	.	.	PUNCT
dpc-3790	24	1	mean	mean	VERB
dpc-3790	24	2	severity	severity	NOUN
dpc-3790	24	3	of	of	ADP
dpc-3790	24	4	alopecia	alopecia	NOUN
dpc-3790	24	5	tool	tool	NOUN
dpc-3790	24	6	and	and	CCONJ
dpc-3790	24	7	mean	mean	VERB
dpc-3790	24	8	dermatology	dermatology	NOUN
dpc-3790	24	9	life	life	NOUN
dpc-3790	24	10	quality	quality	NOUN
dpc-3790	24	11	index	index	NOUN
dpc-3790	24	12	scores	score	NOUN
dpc-3790	24	13	decreased	decrease	VERB
dpc-3790	24	14	from	from	ADP
dpc-3790	24	15	84.46	84.46	NUM
dpc-3790	24	16	%	%	NOUN
dpc-3790	24	17	and	and	CCONJ
dpc-3790	24	18	12.86	12.86	NUM
dpc-3790	24	19	at	at	ADP
dpc-3790	24	20	baseline	baseline	NOUN
dpc-3790	24	21	,	,	PUNCT
dpc-3790	24	22	to	to	ADP
dpc-3790	24	23	43.26	43.26	NUM
dpc-3790	24	24	%	%	NOUN
dpc-3790	24	25	and	and	CCONJ
dpc-3790	24	26	6.63	6.63	NUM
dpc-3790	24	27	,	,	PUNCT
dpc-3790	24	28	respectively	respectively	ADV
dpc-3790	24	29	.	.	PUNCT
dpc-3790	25	1	complete	complete	ADJ
dpc-3790	25	2	response	response	NOUN
dpc-3790	25	3	(	(	PUNCT
dpc-3790	25	4	cr	cr	NOUN
dpc-3790	25	5	)	)	PUNCT
dpc-3790	25	6	was	be	AUX
dpc-3790	25	7	recorded	record	VERB
dpc-3790	25	8	in	in	ADP
dpc-3790	25	9	4	4	NUM
dpc-3790	25	10	(	(	PUNCT
dpc-3790	25	11	13.33	13.33	NUM
dpc-3790	25	12	%	%	NOUN
dpc-3790	25	13	)	)	PUNCT
dpc-3790	25	14	,	,	PUNCT
dpc-3790	25	15	partial	partial	ADJ
dpc-3790	25	16	in	in	ADP
dpc-3790	25	17	12	12	NUM
dpc-3790	25	18	(	(	PUNCT
dpc-3790	25	19	40	40	NUM
dpc-3790	25	20	%	%	NOUN
dpc-3790	25	21	)	)	PUNCT
dpc-3790	25	22	and	and	CCONJ
dpc-3790	25	23	no	no	DET
dpc-3790	25	24	response	response	NOUN
dpc-3790	25	25	in	in	ADP
dpc-3790	25	26	14	14	NUM
dpc-3790	25	27	 	 	SPACE
dpc-3790	25	28	patients	patient	NOUN
dpc-3790	25	29	(	(	PUNCT
dpc-3790	25	30	46.66	46.66	NUM
dpc-3790	25	31	%	%	NOUN
dpc-3790	25	32	)	)	PUNCT
dpc-3790	25	33	,	,	PUNCT
dpc-3790	25	34	correspondingly	correspondingly	ADV
dpc-3790	25	35	.	.	PUNCT
dpc-3790	25	36	 	 	SPACE
dpc-3790	26	1	seventeen	seventeen	NUM
dpc-3790	26	2	out	out	ADP
dpc-3790	26	3	of	of	ADP
dpc-3790	26	4	42	42	NUM
dpc-3790	26	5	(	(	PUNCT
dpc-3790	26	6	40.5	40.5	NUM
dpc-3790	26	7	%	%	NOUN
dpc-3790	26	8	)	)	PUNCT
dpc-3790	26	9	individuals	individual	NOUN
dpc-3790	26	10	in	in	ADP
dpc-3790	26	11	total	total	NOUN
dpc-3790	26	12	,	,	PUNCT
dpc-3790	26	13	reported	report	VERB
dpc-3790	26	14	at	at	ADP
dpc-3790	26	15	least	least	ADV
dpc-3790	26	16	1	1	NUM
dpc-3790	26	17	adverse	adverse	ADJ
dpc-3790	26	18	event	event	NOUN
dpc-3790	26	19	.	.	PUNCT
dpc-3790	27	1	no	no	DET
dpc-3790	27	2	patient	patient	NOUN
dpc-3790	27	3	required	require	VERB
dpc-3790	27	4	hospitalization	hospitalization	NOUN
dpc-3790	27	5	.	.	PUNCT
dpc-3790	28	1	among	among	ADP
dpc-3790	28	2	15	15	NUM
dpc-3790	28	3	patients	patient	NOUN
dpc-3790	28	4	(	(	PUNCT
dpc-3790	28	5	35.7	35.7	NUM
dpc-3790	28	6	%	%	NOUN
dpc-3790	28	7	)	)	PUNCT
dpc-3790	28	8	who	who	PRON
dpc-3790	28	9	got	get	VERB
dpc-3790	28	10	covid-19	covid-19	PROPN
dpc-3790	28	11	,	,	PUNCT
dpc-3790	28	12	one	one	NUM
dpc-3790	28	13	suffered	suffer	VERB
dpc-3790	28	14	from	from	ADP
dpc-3790	28	15	serious	serious	ADJ
dpc-3790	28	16	infection	infection	NOUN
dpc-3790	28	17	.	.	PUNCT
dpc-3790	29	1	the	the	DET
dpc-3790	29	2	3	3	NUM
dpc-3790	29	3	adolescents	adolescent	NOUN
dpc-3790	29	4	achieved	achieve	VERB
dpc-3790	29	5	cr	cr	NOUN
dpc-3790	29	6	with	with	ADP
dpc-3790	29	7	no	no	DET
dpc-3790	29	8	significant	significant	ADJ
dpc-3790	29	9	adverse	adverse	ADJ
dpc-3790	29	10	events	event	NOUN
dpc-3790	29	11	.	.	PUNCT
dpc-3790	30	1	conclusions	conclusion	NOUN
dpc-3790	30	2	:	:	PUNCT
dpc-3790	30	3	real	real	ADJ
dpc-3790	30	4	-	-	PUNCT
dpc-3790	30	5	world	world	NOUN
dpc-3790	30	6	data	datum	NOUN
dpc-3790	30	7	suggest	suggest	VERB
dpc-3790	30	8	efficacy	efficacy	NOUN
dpc-3790	30	9	and	and	CCONJ
dpc-3790	30	10	safety	safety	NOUN
dpc-3790	30	11	of	of	ADP
dpc-3790	30	12	jaki	jaki	PROPN
dpc-3790	30	13	in	in	ADP
dpc-3790	30	14	severe	severe	ADJ
dpc-3790	30	15	forms	form	NOUN
dpc-3790	30	16	of	of	ADP
dpc-3790	30	17	aa	aa	PROPN
dpc-3790	30	18	.	.	PUNCT
dpc-3790	31	1	tolerability	tolerability	NOUN
dpc-3790	31	2	is	be	AUX
dpc-3790	31	3	optimal	optimal	ADJ
dpc-3790	31	4	in	in	ADP
dpc-3790	31	5	younger	young	ADJ
dpc-3790	31	6	individuals	individual	NOUN
dpc-3790	31	7	.	.	PUNCT
dpc-3790	32	1	abstract	abstract	ADJ
dpc-3790	32	2	2	2	NUM
dpc-3790	32	3	original	original	ADJ
dpc-3790	32	4	article	article	NOUN
dpc-3790	32	5	|	|	ADV
dpc-3790	32	6	dermatol	dermatol	ADJ
dpc-3790	32	7	pract	pract	NOUN
dpc-3790	32	8	concept	concept	NOUN
dpc-3790	32	9	.	.	PUNCT
dpc-3790	33	1	2024;14(2):e2024073	2024;14(2):e2024073	NUM
dpc-3790	33	2	introduction	introduction	NOUN
dpc-3790	33	3	alopecia	alopecia	NOUN
dpc-3790	33	4	areata	areata	NOUN
dpc-3790	33	5	(	(	PUNCT
dpc-3790	33	6	aa	aa	NOUN
dpc-3790	33	7	)	)	PUNCT
dpc-3790	33	8	is	be	AUX
dpc-3790	33	9	a	a	DET
dpc-3790	33	10	non	non	ADJ
dpc-3790	33	11	-	-	ADJ
dpc-3790	33	12	scarring	scar	VERB
dpc-3790	33	13	alopecia	alopecia	NOUN
dpc-3790	33	14	that	that	PRON
dpc-3790	33	15	greatly	greatly	ADV
dpc-3790	33	16	affects	affect	VERB
dpc-3790	33	17	patients	patient	NOUN
dpc-3790	33	18	quality	quality	NOUN
dpc-3790	33	19	of	of	ADP
dpc-3790	33	20	life	life	NOUN
dpc-3790	33	21	.	.	PUNCT
dpc-3790	34	1	disease	disease	NOUN
dpc-3790	34	2	severity	severity	NOUN
dpc-3790	34	3	depends	depend	VERB
dpc-3790	34	4	on	on	ADP
dpc-3790	34	5	the	the	DET
dpc-3790	34	6	extend	extend	NOUN
dpc-3790	34	7	of	of	ADP
dpc-3790	34	8	the	the	DET
dpc-3790	34	9	body	body	NOUN
dpc-3790	34	10	area	area	NOUN
dpc-3790	34	11	involvement	involvement	NOUN
dpc-3790	34	12	,	,	PUNCT
dpc-3790	34	13	ranging	range	VERB
dpc-3790	34	14	from	from	ADP
dpc-3790	34	15	mild	mild	ADJ
dpc-3790	34	16	severity	severity	NOUN
dpc-3790	34	17	in	in	ADP
dpc-3790	34	18	localized	localized	ADJ
dpc-3790	34	19	forms	form	NOUN
dpc-3790	34	20	(	(	PUNCT
dpc-3790	34	21	plaque	plaque	NOUN
dpc-3790	34	22	type	type	NOUN
dpc-3790	34	23	aa	aa	NOUN
dpc-3790	34	24	)	)	PUNCT
dpc-3790	34	25	to	to	ADP
dpc-3790	34	26	severe	severe	ADJ
dpc-3790	34	27	generalized	generalized	ADJ
dpc-3790	34	28	clinical	clinical	ADJ
dpc-3790	34	29	types	type	NOUN
dpc-3790	34	30	of	of	ADP
dpc-3790	34	31	aa	aa	NOUN
dpc-3790	34	32	,	,	PUNCT
dpc-3790	34	33	such	such	ADJ
dpc-3790	34	34	as	as	ADP
dpc-3790	34	35	alopecia	alopecia	NOUN
dpc-3790	34	36	totalis	totali	NOUN
dpc-3790	34	37	(	(	PUNCT
dpc-3790	34	38	at	at	ADP
dpc-3790	34	39	)	)	PUNCT
dpc-3790	34	40	or	or	CCONJ
dpc-3790	34	41	alopecia	alopecia	NOUN
dpc-3790	34	42	universalis	universali	NOUN
dpc-3790	34	43	(	(	PUNCT
dpc-3790	34	44	au	au	ADJ
dpc-3790	34	45	)	)	PUNCT
dpc-3790	34	46	.	.	PUNCT
dpc-3790	35	1	topical	topical	ADJ
dpc-3790	35	2	and	and	CCONJ
dpc-3790	35	3	intralesional	intralesional	ADJ
dpc-3790	35	4	steroids	steroid	NOUN
dpc-3790	35	5	are	be	AUX
dpc-3790	35	6	considered	consider	VERB
dpc-3790	35	7	first	first	ADJ
dpc-3790	35	8	-	-	PUNCT
dpc-3790	35	9	line	line	NOUN
dpc-3790	35	10	therapeutic	therapeutic	ADJ
dpc-3790	35	11	modalities	modality	NOUN
dpc-3790	35	12	for	for	ADP
dpc-3790	35	13	localized	localized	ADJ
dpc-3790	35	14	plaque	plaque	NOUN
dpc-3790	35	15	type	type	NOUN
dpc-3790	35	16	aa	aa	NOUN
dpc-3790	35	17	,	,	PUNCT
dpc-3790	35	18	while	while	SCONJ
dpc-3790	35	19	systemic	systemic	ADJ
dpc-3790	35	20	use	use	NOUN
dpc-3790	35	21	of	of	ADP
dpc-3790	35	22	steroids	steroid	NOUN
dpc-3790	35	23	and	and	CCONJ
dpc-3790	35	24	other	other	ADJ
dpc-3790	35	25	immunomodulating	immunomodulating	ADJ
dpc-3790	35	26	agents	agent	NOUN
dpc-3790	35	27	are	be	AUX
dpc-3790	35	28	preserved	preserve	VERB
dpc-3790	35	29	for	for	ADP
dpc-3790	35	30	generalized	generalized	ADJ
dpc-3790	35	31	forms	form	NOUN
dpc-3790	35	32	of	of	ADP
dpc-3790	35	33	the	the	DET
dpc-3790	35	34	disease	disease	NOUN
dpc-3790	35	35	.	.	PUNCT
dpc-3790	36	1	despite	despite	SCONJ
dpc-3790	36	2	their	their	PRON
dpc-3790	36	3	beneficial	beneficial	ADJ
dpc-3790	36	4	effect	effect	NOUN
dpc-3790	36	5	on	on	ADP
dpc-3790	36	6	aa	aa	PROPN
dpc-3790	36	7	,	,	PUNCT
dpc-3790	36	8	conventional	conventional	ADJ
dpc-3790	36	9	treatments	treatment	NOUN
dpc-3790	36	10	have	have	AUX
dpc-3790	36	11	been	be	AUX
dpc-3790	36	12	linked	link	VERB
dpc-3790	36	13	to	to	ADP
dpc-3790	36	14	important	important	ADJ
dpc-3790	36	15	side	side	NOUN
dpc-3790	36	16	-	-	PUNCT
dpc-3790	36	17	effects	effect	NOUN
dpc-3790	36	18	and	and	CCONJ
dpc-3790	36	19	high	high	ADJ
dpc-3790	36	20	rates	rate	NOUN
dpc-3790	36	21	of	of	ADP
dpc-3790	36	22	recurrence	recurrence	NOUN
dpc-3790	36	23	after	after	ADP
dpc-3790	36	24	treatment	treatment	NOUN
dpc-3790	36	25	cessation	cessation	NOUN
dpc-3790	36	26	that	that	PRON
dpc-3790	36	27	limit	limit	VERB
dpc-3790	36	28	their	their	PRON
dpc-3790	36	29	use	use	NOUN
dpc-3790	36	30	.	.	PUNCT
dpc-3790	37	1	after	after	ADP
dpc-3790	37	2	many	many	ADJ
dpc-3790	37	3	years	year	NOUN
dpc-3790	37	4	of	of	ADP
dpc-3790	37	5	scant	scant	ADJ
dpc-3790	37	6	or	or	CCONJ
dpc-3790	37	7	no	no	PRON
dpc-3790	37	8	development	development	NOUN
dpc-3790	37	9	in	in	ADP
dpc-3790	37	10	the	the	DET
dpc-3790	37	11	area	area	NOUN
dpc-3790	37	12	of	of	ADP
dpc-3790	37	13	aa	aa	PROPN
dpc-3790	37	14	therapeutics	therapeutic	NOUN
dpc-3790	37	15	,	,	PUNCT
dpc-3790	37	16	the	the	DET
dpc-3790	37	17	introduction	introduction	NOUN
dpc-3790	37	18	of	of	ADP
dpc-3790	37	19	janus	janus	PROPN
dpc-3790	37	20	kinase	kinase	PROPN
dpc-3790	37	21	inhibitors	inhibitor	NOUN
dpc-3790	37	22	(	(	PUNCT
dpc-3790	37	23	jaki	jaki	PROPN
dpc-3790	37	24	)	)	PUNCT
dpc-3790	37	25	seems	seem	VERB
dpc-3790	37	26	to	to	PART
dpc-3790	37	27	revolutionize	revolutionize	VERB
dpc-3790	37	28	the	the	DET
dpc-3790	37	29	field	field	NOUN
dpc-3790	37	30	,	,	PUNCT
dpc-3790	37	31	providing	provide	VERB
dpc-3790	37	32	promising	promise	VERB
dpc-3790	37	33	treatment	treatment	NOUN
dpc-3790	37	34	outcomes	outcome	NOUN
dpc-3790	37	35	in	in	ADP
dpc-3790	37	36	severe	severe	ADJ
dpc-3790	37	37	forms	form	NOUN
dpc-3790	37	38	of	of	ADP
dpc-3790	37	39	the	the	DET
dpc-3790	37	40	disease	disease	NOUN
dpc-3790	37	41	[	[	X
dpc-3790	37	42	1	1	NUM
dpc-3790	37	43	]	]	PUNCT
dpc-3790	37	44	.	.	PUNCT
dpc-3790	38	1	the	the	DET
dpc-3790	38	2	mode	mode	NOUN
dpc-3790	38	3	of	of	ADP
dpc-3790	38	4	action	action	NOUN
dpc-3790	38	5	of	of	ADP
dpc-3790	38	6	jaki	jaki	PROPN
dpc-3790	38	7	implicates	implicate	VERB
dpc-3790	38	8	intracellular	intracellular	ADJ
dpc-3790	38	9	interruption	interruption	NOUN
dpc-3790	38	10	of	of	ADP
dpc-3790	38	11	the	the	DET
dpc-3790	38	12	jak	jak	PROPN
dpc-3790	38	13	-	-	PUNCT
dpc-3790	38	14	stat	stat	PROPN
dpc-3790	38	15	pathway	pathway	NOUN
dpc-3790	38	16	.	.	PUNCT
dpc-3790	39	1	tofacitinib	tofacitinib	PROPN
dpc-3790	39	2	is	be	AUX
dpc-3790	39	3	a	a	DET
dpc-3790	39	4	potent	potent	ADJ
dpc-3790	39	5	,	,	PUNCT
dpc-3790	39	6	selective	selective	ADJ
dpc-3790	39	7	inhibitor	inhibitor	NOUN
dpc-3790	39	8	of	of	ADP
dpc-3790	39	9	the	the	DET
dpc-3790	39	10	jak	jak	PROPN
dpc-3790	39	11	family	family	PROPN
dpc-3790	39	12	(	(	PUNCT
dpc-3790	39	13	jak	jak	PROPN
dpc-3790	39	14	1/3	1/3	NUM
dpc-3790	39	15	)	)	PUNCT
dpc-3790	39	16	,	,	PUNCT
dpc-3790	39	17	approved	approve	VERB
dpc-3790	39	18	for	for	ADP
dpc-3790	39	19	the	the	DET
dpc-3790	39	20	treatment	treatment	NOUN
dpc-3790	39	21	of	of	ADP
dpc-3790	39	22	psoriatic	psoriatic	ADJ
dpc-3790	39	23	arthritis	arthritis	NOUN
dpc-3790	39	24	,	,	PUNCT
dpc-3790	39	25	rheumatoid	rheumatoid	NOUN
dpc-3790	39	26	arthritis	arthritis	NOUN
dpc-3790	39	27	,	,	PUNCT
dpc-3790	39	28	ankylosing	ankylose	VERB
dpc-3790	39	29	spondylitis	spondylitis	NOUN
dpc-3790	39	30	,	,	PUNCT
dpc-3790	39	31	ulcerative	ulcerative	ADJ
dpc-3790	39	32	colitis	colitis	NOUN
dpc-3790	39	33	in	in	ADP
dpc-3790	39	34	adults	adult	NOUN
dpc-3790	39	35	and	and	CCONJ
dpc-3790	39	36	 	 	SPACE
dpc-3790	39	37	juvenile	juvenile	ADJ
dpc-3790	39	38	idiopathic	idiopathic	ADJ
dpc-3790	39	39	arthritis	arthritis	NOUN
dpc-3790	39	40	in	in	ADP
dpc-3790	39	41	patients	patient	NOUN
dpc-3790	39	42	≥	≥	NOUN
dpc-3790	39	43	2	2	NUM
dpc-3790	39	44	years	year	NOUN
dpc-3790	39	45	of	of	ADP
dpc-3790	39	46	age	age	NOUN
dpc-3790	39	47	.	.	PUNCT
dpc-3790	40	1	tofacitinib	tofacitinib	PROPN
dpc-3790	40	2	,	,	PUNCT
dpc-3790	40	3	though	though	SCONJ
dpc-3790	40	4	not	not	PART
dpc-3790	40	5	officially	officially	ADV
dpc-3790	40	6	indicated	indicate	VERB
dpc-3790	40	7	,	,	PUNCT
dpc-3790	40	8	was	be	AUX
dpc-3790	40	9	the	the	DET
dpc-3790	40	10	first	first	ADJ
dpc-3790	40	11	drug	drug	NOUN
dpc-3790	40	12	of	of	ADP
dpc-3790	40	13	the	the	DET
dpc-3790	40	14	group	group	NOUN
dpc-3790	40	15	of	of	ADP
dpc-3790	40	16	jaki	jaki	PROPN
dpc-3790	40	17	used	use	VERB
dpc-3790	40	18	in	in	ADP
dpc-3790	40	19	aa	aa	PROPN
dpc-3790	40	20	.	.	PUNCT
dpc-3790	41	1	recently	recently	ADV
dpc-3790	41	2	,	,	PUNCT
dpc-3790	41	3	fda	fda	PROPN
dpc-3790	41	4	approved	approve	VERB
dpc-3790	41	5	baricitinib	baricitinib	NOUN
dpc-3790	41	6	for	for	ADP
dpc-3790	41	7	the	the	DET
dpc-3790	41	8	treatment	treatment	NOUN
dpc-3790	41	9	of	of	ADP
dpc-3790	41	10	severe	severe	ADJ
dpc-3790	41	11	aa	aa	NOUN
dpc-3790	41	12	.	.	PUNCT
dpc-3790	42	1	baricitinib	baricitinib	NOUN
dpc-3790	42	2	  	  	SPACE
dpc-3790	42	3	exerts	exert	VERB
dpc-3790	42	4	its	its	PRON
dpc-3790	42	5	effects	effect	NOUN
dpc-3790	42	6	by	by	ADP
dpc-3790	42	7	inhibiting	inhibit	VERB
dpc-3790	42	8	jak1	jak1	NOUN
dpc-3790	42	9	and	and	CCONJ
dpc-3790	42	10	jak2	jak2	PROPN
dpc-3790	42	11	enzymes	enzyme	NOUN
dpc-3790	42	12	.	.	PUNCT
dpc-3790	43	1	data	datum	NOUN
dpc-3790	43	2	emerging	emerge	VERB
dpc-3790	43	3	from	from	ADP
dpc-3790	43	4	real	real	ADJ
dpc-3790	43	5	-	-	PUNCT
dpc-3790	43	6	world	world	NOUN
dpc-3790	43	7	settings	setting	NOUN
dpc-3790	43	8	in	in	ADP
dpc-3790	43	9	regards	regard	NOUN
dpc-3790	43	10	with	with	ADP
dpc-3790	43	11	the	the	DET
dpc-3790	43	12	 	 	SPACE
dpc-3790	43	13	use	use	NOUN
dpc-3790	43	14	of	of	ADP
dpc-3790	43	15	jaki	jaki	PROPN
dpc-3790	43	16	in	in	ADP
dpc-3790	43	17	aa	aa	PROPN
dpc-3790	43	18	are	be	AUX
dpc-3790	43	19	limited	limit	VERB
dpc-3790	43	20	[	[	PUNCT
dpc-3790	43	21	2	2	NUM
dpc-3790	43	22	-	-	SYM
dpc-3790	43	23	5	5	NUM
dpc-3790	43	24	]	]	PUNCT
dpc-3790	43	25	.	.	PUNCT
dpc-3790	44	1	objectives	objective	NOUN
dpc-3790	44	2	in	in	ADP
dpc-3790	44	3	the	the	DET
dpc-3790	44	4	current	current	ADJ
dpc-3790	44	5	study	study	NOUN
dpc-3790	44	6	,	,	PUNCT
dpc-3790	44	7	we	we	PRON
dpc-3790	44	8	aimed	aim	VERB
dpc-3790	44	9	to	to	PART
dpc-3790	44	10	provide	provide	VERB
dpc-3790	44	11	evidence	evidence	NOUN
dpc-3790	44	12	about	about	ADP
dpc-3790	44	13	effectiveness	effectiveness	NOUN
dpc-3790	44	14	and	and	CCONJ
dpc-3790	44	15	safety	safety	NOUN
dpc-3790	44	16	of	of	ADP
dpc-3790	44	17	the	the	DET
dpc-3790	44	18	use	use	NOUN
dpc-3790	44	19	of	of	ADP
dpc-3790	44	20	tofacitinib	tofacitinib	NOUN
dpc-3790	44	21	and	and	CCONJ
dpc-3790	44	22	baricitinib	baricitinib	NOUN
dpc-3790	44	23	for	for	ADP
dpc-3790	44	24	aa	aa	NOUN
dpc-3790	44	25	in	in	ADP
dpc-3790	44	26	real	real	ADJ
dpc-3790	44	27	-	-	PUNCT
dpc-3790	44	28	world	world	NOUN
dpc-3790	44	29	settings	setting	NOUN
dpc-3790	44	30	and	and	CCONJ
dpc-3790	44	31	describe	describe	VERB
dpc-3790	44	32	baseline	baseline	NOUN
dpc-3790	44	33	disease	disease	NOUN
dpc-3790	44	34	characteristics	characteristic	NOUN
dpc-3790	44	35	and	and	CCONJ
dpc-3790	44	36	patients	patient	NOUN
dpc-3790	44	37	profiles	profile	NOUN
dpc-3790	44	38	that	that	PRON
dpc-3790	44	39	are	be	AUX
dpc-3790	44	40	considered	consider	VERB
dpc-3790	44	41	good	good	ADJ
dpc-3790	44	42	candidates	candidate	NOUN
dpc-3790	44	43	for	for	ADP
dpc-3790	44	44	jaki	jaki	PROPN
dpc-3790	44	45	in	in	ADP
dpc-3790	44	46	the	the	DET
dpc-3790	44	47	daily	daily	ADJ
dpc-3790	44	48	practice	practice	NOUN
dpc-3790	44	49	.	.	PUNCT
dpc-3790	45	1	furthermore	furthermore	ADV
dpc-3790	45	2	,	,	PUNCT
dpc-3790	45	3	we	we	PRON
dpc-3790	45	4	intended	intend	VERB
dpc-3790	45	5	to	to	PART
dpc-3790	45	6	investigate	investigate	VERB
dpc-3790	45	7	potential	potential	ADJ
dpc-3790	45	8	correlations	correlation	NOUN
dpc-3790	45	9	between	between	ADP
dpc-3790	45	10	baseline	baseline	NOUN
dpc-3790	45	11	characteristics	characteristic	NOUN
dpc-3790	45	12	and	and	CCONJ
dpc-3790	45	13	treatment	treatment	NOUN
dpc-3790	45	14	outcomes	outcome	NOUN
dpc-3790	45	15	.	.	PUNCT
dpc-3790	46	1	methods	method	NOUN
dpc-3790	46	2	towards	towards	ADP
dpc-3790	46	3	the	the	DET
dpc-3790	46	4	aims	aim	NOUN
dpc-3790	46	5	of	of	ADP
dpc-3790	46	6	the	the	DET
dpc-3790	46	7	study	study	NOUN
dpc-3790	46	8	,	,	PUNCT
dpc-3790	46	9	we	we	PRON
dpc-3790	46	10	retrospectively	retrospectively	ADV
dpc-3790	46	11	reviewed	review	VERB
dpc-3790	46	12	the	the	DET
dpc-3790	46	13	databases	database	NOUN
dpc-3790	46	14	of	of	ADP
dpc-3790	46	15	two	two	NUM
dpc-3790	46	16	tertiary	tertiary	ADJ
dpc-3790	46	17	hospitals	hospital	NOUN
dpc-3790	46	18	in	in	ADP
dpc-3790	46	19	greece	greece	PROPN
dpc-3790	46	20	for	for	ADP
dpc-3790	46	21	the	the	DET
dpc-3790	46	22	last	last	ADJ
dpc-3790	46	23	five	five	NUM
dpc-3790	46	24	years	year	NOUN
dpc-3790	46	25	,	,	PUNCT
dpc-3790	46	26	to	to	PART
dpc-3790	46	27	identify	identify	VERB
dpc-3790	46	28	individuals	individual	NOUN
dpc-3790	46	29	of	of	ADP
dpc-3790	46	30	any	any	DET
dpc-3790	46	31	age	age	NOUN
dpc-3790	46	32	currently	currently	ADV
dpc-3790	46	33	being	be	AUX
dpc-3790	46	34	treated	treat	VERB
dpc-3790	46	35	with	with	ADP
dpc-3790	46	36	systemic	systemic	ADJ
dpc-3790	46	37	jaki	jaki	PROPN
dpc-3790	46	38	for	for	ADP
dpc-3790	46	39	severe	severe	ADJ
dpc-3790	46	40	aa	aa	NOUN
dpc-3790	46	41	.	.	PUNCT
dpc-3790	46	42	 	 	SPACE
dpc-3790	47	1	the	the	DET
dpc-3790	47	2	standard	standard	NOUN
dpc-3790	47	3	of	of	ADP
dpc-3790	47	4	care	care	NOUN
dpc-3790	47	5	for	for	ADP
dpc-3790	47	6	aa	aa	NOUN
dpc-3790	47	7	in	in	ADP
dpc-3790	47	8	both	both	DET
dpc-3790	47	9	centers	center	NOUN
dpc-3790	47	10	conforms	conform	VERB
dpc-3790	47	11	to	to	ADP
dpc-3790	47	12	the	the	DET
dpc-3790	47	13	published	publish	VERB
dpc-3790	47	14	guidelines	guideline	NOUN
dpc-3790	47	15	and	and	CCONJ
dpc-3790	47	16	depends	depend	VERB
dpc-3790	47	17	on	on	ADP
dpc-3790	47	18	the	the	DET
dpc-3790	47	19	clinical	clinical	ADJ
dpc-3790	47	20	type	type	NOUN
dpc-3790	47	21	,	,	PUNCT
dpc-3790	47	22	disease	disease	NOUN
dpc-3790	47	23	severity	severity	NOUN
dpc-3790	47	24	,	,	PUNCT
dpc-3790	47	25	age	age	NOUN
dpc-3790	47	26	of	of	ADP
dpc-3790	47	27	the	the	DET
dpc-3790	47	28	patient	patient	NOUN
dpc-3790	47	29	and	and	CCONJ
dpc-3790	47	30	response	response	NOUN
dpc-3790	47	31	to	to	ADP
dpc-3790	47	32	previous	previous	ADJ
dpc-3790	47	33	treatments	treatment	NOUN
dpc-3790	47	34	.	.	PUNCT
dpc-3790	48	1	the	the	DET
dpc-3790	48	2	study	study	NOUN
dpc-3790	48	3	received	receive	VERB
dpc-3790	48	4	institutional	institutional	ADJ
dpc-3790	48	5	ethical	ethical	ADJ
dpc-3790	48	6	committee	committee	NOUN
dpc-3790	48	7	approval	approval	NOUN
dpc-3790	48	8	.	.	PUNCT
dpc-3790	49	1	upon	upon	SCONJ
dpc-3790	49	2	their	their	PRON
dpc-3790	49	3	first	first	ADJ
dpc-3790	49	4	visit	visit	NOUN
dpc-3790	49	5	,	,	PUNCT
dpc-3790	49	6	all	all	DET
dpc-3790	49	7	patients	patient	NOUN
dpc-3790	49	8	provide	provide	VERB
dpc-3790	49	9	written	write	VERB
dpc-3790	49	10	informed	inform	VERB
dpc-3790	49	11	consent	consent	NOUN
dpc-3790	49	12	for	for	ADP
dpc-3790	49	13	collecting	collect	VERB
dpc-3790	49	14	their	their	PRON
dpc-3790	49	15	data	datum	NOUN
dpc-3790	49	16	,	,	PUNCT
dpc-3790	49	17	and	and	CCONJ
dpc-3790	49	18	history	history	NOUN
dpc-3790	49	19	and	and	CCONJ
dpc-3790	49	20	physical	physical	ADJ
dpc-3790	49	21	and	and	CCONJ
dpc-3790	49	22	dermatoscopic	dermatoscopic	ADJ
dpc-3790	49	23	examination	examination	NOUN
dpc-3790	49	24	is	be	AUX
dpc-3790	49	25	carried	carry	VERB
dpc-3790	49	26	out	out	ADP
dpc-3790	49	27	.	.	PUNCT
dpc-3790	50	1	disease	disease	NOUN
dpc-3790	50	2	severity	severity	NOUN
dpc-3790	50	3	is	be	AUX
dpc-3790	50	4	determined	determine	VERB
dpc-3790	50	5	by	by	ADP
dpc-3790	50	6	the	the	DET
dpc-3790	50	7	use	use	NOUN
dpc-3790	50	8	of	of	ADP
dpc-3790	50	9	the	the	DET
dpc-3790	50	10	severity	severity	NOUN
dpc-3790	50	11	of	of	ADP
dpc-3790	50	12	alopecia	alopecia	NOUN
dpc-3790	50	13	tool	tool	NOUN
dpc-3790	50	14	(	(	PUNCT
dpc-3790	50	15	salt	salt	NOUN
dpc-3790	50	16	)	)	PUNCT
dpc-3790	50	17	that	that	PRON
dpc-3790	50	18	estimates	estimate	VERB
dpc-3790	50	19	the	the	DET
dpc-3790	50	20	extent	extent	NOUN
dpc-3790	50	21	of	of	ADP
dpc-3790	50	22	alopecia	alopecia	NOUN
dpc-3790	50	23	in	in	ADP
dpc-3790	50	24	percentages	percentage	NOUN
dpc-3790	50	25	.	.	PUNCT
dpc-3790	50	26	  	  	SPACE
dpc-3790	50	27	δsalt	δsalt	ADJ
dpc-3790	50	28	score	score	NOUN
dpc-3790	50	29	was	be	AUX
dpc-3790	50	30	used	use	VERB
dpc-3790	50	31	as	as	ADP
dpc-3790	50	32	a	a	DET
dpc-3790	50	33	variable	variable	NOUN
dpc-3790	50	34	in	in	ADP
dpc-3790	50	35	order	order	NOUN
dpc-3790	50	36	to	to	PART
dpc-3790	50	37	assess	assess	VERB
dpc-3790	50	38	the	the	DET
dpc-3790	50	39	percentage	percentage	NOUN
dpc-3790	50	40	change	change	NOUN
dpc-3790	50	41	observed	observe	VERB
dpc-3790	50	42	in	in	ADP
dpc-3790	50	43	salt	salt	NOUN
dpc-3790	50	44	score	score	NOUN
dpc-3790	50	45	at	at	ADP
dpc-3790	50	46	baseline	baseline	NOUN
dpc-3790	50	47	and	and	CCONJ
dpc-3790	50	48	at	at	ADP
dpc-3790	50	49	the	the	DET
dpc-3790	50	50	most	most	ADV
dpc-3790	50	51	recent	recent	ADJ
dpc-3790	50	52	follow	follow	NOUN
dpc-3790	50	53	up	up	ADP
dpc-3790	50	54	visit	visit	NOUN
dpc-3790	50	55	for	for	ADP
dpc-3790	50	56	each	each	DET
dpc-3790	50	57	patient	patient	NOUN
dpc-3790	50	58	.	.	PUNCT
dpc-3790	51	1	treatment	treatment	NOUN
dpc-3790	51	2	response	response	NOUN
dpc-3790	51	3	was	be	AUX
dpc-3790	51	4	classified	classify	VERB
dpc-3790	51	5	as	as	ADP
dpc-3790	51	6	no	no	DET
dpc-3790	51	7	response	response	NOUN
dpc-3790	51	8	(	(	PUNCT
dpc-3790	51	9	nr	nr	NOUN
dpc-3790	51	10	)	)	PUNCT
dpc-3790	51	11	with	with	ADP
dpc-3790	51	12	<	<	X
dpc-3790	51	13	30	30	NUM
dpc-3790	51	14	%	%	NOUN
dpc-3790	51	15	of	of	ADP
dpc-3790	51	16	regrowth	regrowth	NOUN
dpc-3790	51	17	,	,	PUNCT
dpc-3790	51	18	partial	partial	ADJ
dpc-3790	51	19	response	response	NOUN
dpc-3790	51	20	(	(	PUNCT
dpc-3790	51	21	pr	pr	NOUN
dpc-3790	51	22	)	)	PUNCT
dpc-3790	51	23	with	with	ADP
dpc-3790	51	24	30%–90	30%–90	NUM
dpc-3790	51	25	%	%	NOUN
dpc-3790	51	26	of	of	ADP
dpc-3790	51	27	regrowth	regrowth	NOUN
dpc-3790	51	28	and	and	CCONJ
dpc-3790	51	29	complete	complete	ADJ
dpc-3790	51	30	response	response	NOUN
dpc-3790	51	31	(	(	PUNCT
dpc-3790	51	32	cr	cr	NOUN
dpc-3790	51	33	)	)	PUNCT
dpc-3790	51	34	with	with	ADP
dpc-3790	51	35	>	>	SYM
dpc-3790	51	36	90	90	NUM
dpc-3790	51	37	%	%	NOUN
dpc-3790	51	38	of	of	ADP
dpc-3790	51	39	regrowth	regrowth	NOUN
dpc-3790	51	40	.	.	PUNCT
dpc-3790	52	1	patients	patient	NOUN
dpc-3790	52	2	were	be	AUX
dpc-3790	52	3	also	also	ADV
dpc-3790	52	4	asked	ask	VERB
dpc-3790	52	5	to	to	PART
dpc-3790	52	6	fill	fill	VERB
dpc-3790	52	7	in	in	ADP
dpc-3790	52	8	a	a	DET
dpc-3790	52	9	dermatology	dermatology	NOUN
dpc-3790	52	10	life	life	NOUN
dpc-3790	52	11	quality	quality	NOUN
dpc-3790	52	12	index	index	NOUN
dpc-3790	52	13	(	(	PUNCT
dpc-3790	52	14	dlqi	dlqi	ADJ
dpc-3790	52	15	)	)	PUNCT
dpc-3790	52	16	questionnaire	questionnaire	NOUN
dpc-3790	52	17	in	in	ADP
dpc-3790	52	18	greek	greek	NOUN
dpc-3790	52	19	.	.	PUNCT
dpc-3790	53	1	clinical	clinical	ADJ
dpc-3790	53	2	and	and	CCONJ
dpc-3790	53	3	dermatoscopic	dermatoscopic	ADJ
dpc-3790	53	4	photos	photo	NOUN
dpc-3790	53	5	were	be	AUX
dpc-3790	53	6	collected	collect	VERB
dpc-3790	53	7	and	and	CCONJ
dpc-3790	53	8	saved	save	VERB
dpc-3790	53	9	in	in	ADP
dpc-3790	53	10	the	the	DET
dpc-3790	53	11	databases	database	NOUN
dpc-3790	53	12	.	.	PUNCT
dpc-3790	54	1	efficacy	efficacy	NOUN
dpc-3790	54	2	outcomes	outcome	NOUN
dpc-3790	54	3	were	be	AUX
dpc-3790	54	4	obtained	obtain	VERB
dpc-3790	54	5	from	from	ADP
dpc-3790	54	6	individuals	individual	NOUN
dpc-3790	54	7	that	that	PRON
dpc-3790	54	8	had	have	AUX
dpc-3790	54	9	completed	complete	VERB
dpc-3790	54	10	at	at	ADP
dpc-3790	54	11	least	least	ADJ
dpc-3790	54	12	a	a	DET
dpc-3790	54	13	3	3	NUM
dpc-3790	54	14	-	-	PUNCT
dpc-3790	54	15	month	month	NOUN
dpc-3790	54	16	follow	follow	NOUN
dpc-3790	54	17	-	-	PUNCT
dpc-3790	54	18	up	up	NOUN
dpc-3790	54	19	period	period	NOUN
dpc-3790	54	20	on	on	ADP
dpc-3790	54	21	treatment	treatment	NOUN
dpc-3790	54	22	,	,	PUNCT
dpc-3790	54	23	whilst	whilst	SCONJ
dpc-3790	54	24	safety	safety	NOUN
dpc-3790	54	25	outcomes	outcome	NOUN
dpc-3790	54	26	emerged	emerge	VERB
dpc-3790	54	27	from	from	ADP
dpc-3790	54	28	the	the	DET
dpc-3790	54	29	whole	whole	ADJ
dpc-3790	54	30	studied	study	VERB
dpc-3790	54	31	group	group	NOUN
dpc-3790	54	32	.	.	PUNCT
dpc-3790	55	1	according	accord	VERB
dpc-3790	55	2	to	to	ADP
dpc-3790	55	3	the	the	DET
dpc-3790	55	4	regulations	regulation	NOUN
dpc-3790	55	5	in	in	ADP
dpc-3790	55	6	greece	greece	PROPN
dpc-3790	55	7	,	,	PUNCT
dpc-3790	55	8	before	before	ADP
dpc-3790	55	9	prescribing	prescribing	NOUN
dpc-3790	55	10	jaki	jaki	PROPN
dpc-3790	55	11	to	to	ADP
dpc-3790	55	12	our	our	PRON
dpc-3790	55	13	patients	patient	NOUN
dpc-3790	55	14	for	for	ADP
dpc-3790	55	15	any	any	DET
dpc-3790	55	16	indication	indication	NOUN
dpc-3790	55	17	,	,	PUNCT
dpc-3790	55	18	we	we	PRON
dpc-3790	55	19	have	have	VERB
dpc-3790	55	20	to	to	PART
dpc-3790	55	21	ask	ask	VERB
dpc-3790	55	22	for	for	ADP
dpc-3790	55	23	approval	approval	NOUN
dpc-3790	55	24	by	by	ADP
dpc-3790	55	25	the	the	DET
dpc-3790	55	26	national	national	PROPN
dpc-3790	55	27	medical	medical	PROPN
dpc-3790	55	28	organization	organization	PROPN
dpc-3790	55	29	.	.	PUNCT
dpc-3790	56	1	spearman	spearman	NOUN
dpc-3790	56	2	correlation	correlation	NOUN
dpc-3790	56	3	and	and	CCONJ
dpc-3790	56	4	kruskal	kruskal	PROPN
dpc-3790	56	5	-	-	PUNCT
dpc-3790	56	6	wallis	wallis	PROPN
dpc-3790	56	7	tests	test	NOUN
dpc-3790	56	8	were	be	AUX
dpc-3790	56	9	used	use	VERB
dpc-3790	56	10	to	to	PART
dpc-3790	56	11	compare	compare	VERB
dpc-3790	56	12	the	the	DET
dpc-3790	56	13	variables	variable	NOUN
dpc-3790	56	14	using	use	VERB
dpc-3790	56	15	ibm	ibm	PROPN
dpc-3790	56	16	spss	spss	PROPN
dpc-3790	56	17	statistics	statistics	PROPN
dpc-3790	56	18	version	version	PROPN
dpc-3790	56	19	29.0	29.0	NUM
dpc-3790	56	20	.	.	PUNCT
dpc-3790	57	1	statistical	statistical	ADJ
dpc-3790	57	2	analyses	analysis	NOUN
dpc-3790	57	3	were	be	AUX
dpc-3790	57	4	performed	perform	VERB
dpc-3790	57	5	using	use	VERB
dpc-3790	57	6	ibm	ibm	PROPN
dpc-3790	57	7	spss	spss	PROPN
dpc-3790	57	8	statistics	statistics	PROPN
dpc-3790	57	9	version	version	PROPN
dpc-3790	57	10	29.0	29.0	NUM
dpc-3790	57	11	.	.	PUNCT
dpc-3790	58	1	results	result	VERB
dpc-3790	58	2	demographics	demographic	NOUN
dpc-3790	58	3	and	and	CCONJ
dpc-3790	58	4	baseline	baseline	VERB
dpc-3790	58	5	clinical	clinical	ADJ
dpc-3790	58	6	characteristics	characteristic	NOUN
dpc-3790	58	7	we	we	PRON
dpc-3790	58	8	identified	identify	VERB
dpc-3790	58	9	42	42	NUM
dpc-3790	58	10	individuals	individual	NOUN
dpc-3790	58	11	(	(	PUNCT
dpc-3790	58	12	25	25	NUM
dpc-3790	58	13	females	female	NOUN
dpc-3790	58	14	and	and	CCONJ
dpc-3790	58	15	17	17	NUM
dpc-3790	58	16	males	male	NOUN
dpc-3790	58	17	)	)	PUNCT
dpc-3790	58	18	,	,	PUNCT
dpc-3790	58	19	including	include	VERB
dpc-3790	58	20	3	3	NUM
dpc-3790	58	21	adolescents	adolescent	NOUN
dpc-3790	58	22	.	.	PUNCT
dpc-3790	59	1	the	the	DET
dpc-3790	59	2	mean	mean	ADJ
dpc-3790	59	3	age	age	NOUN
dpc-3790	59	4	was	be	AUX
dpc-3790	59	5	39.5	39.5	NUM
dpc-3790	59	6	(	(	PUNCT
dpc-3790	59	7	sd	sd	NOUN
dpc-3790	59	8	:	:	PUNCT
dpc-3790	59	9	14.4	14.4	NUM
dpc-3790	59	10	,	,	PUNCT
dpc-3790	59	11	range	range	NOUN
dpc-3790	59	12	:	:	PUNCT
dpc-3790	59	13	13	13	NUM
dpc-3790	59	14	-	-	SYM
dpc-3790	59	15	60	60	NUM
dpc-3790	59	16	years	year	NOUN
dpc-3790	59	17	)	)	PUNCT
dpc-3790	59	18	.	.	PUNCT
dpc-3790	60	1	all	all	DET
dpc-3790	60	2	participants	participant	NOUN
dpc-3790	60	3	suffered	suffer	VERB
dpc-3790	60	4	from	from	ADP
dpc-3790	60	5	severe	severe	ADJ
dpc-3790	60	6	aa	aa	NOUN
dpc-3790	60	7	(	(	PUNCT
dpc-3790	60	8	mean	mean	INTJ
dpc-3790	60	9	baseline	baseline	NOUN
dpc-3790	60	10	salt	salt	NOUN
dpc-3790	60	11	score	score	NOUN
dpc-3790	60	12	80.21	80.21	NUM
dpc-3790	60	13	%	%	NOUN
dpc-3790	60	14	[	[	X
dpc-3790	60	15	sd	sd	ADP
dpc-3790	60	16	24.09	24.09	NUM
dpc-3790	60	17	%	%	NOUN
dpc-3790	60	18	]	]	PUNCT
dpc-3790	60	19	)	)	PUNCT
dpc-3790	60	20	.	.	PUNCT
dpc-3790	61	1	patients	patient	NOUN
dpc-3790	61	2	sociodemographic	sociodemographic	ADJ
dpc-3790	61	3	and	and	CCONJ
dpc-3790	61	4	clinical	clinical	ADJ
dpc-3790	61	5	characteristics	characteristic	NOUN
dpc-3790	61	6	are	be	AUX
dpc-3790	61	7	summarized	summarize	VERB
dpc-3790	61	8	in	in	ADP
dpc-3790	61	9	table	table	NOUN
dpc-3790	61	10	1	1	NUM
dpc-3790	61	11	.	.	PUNCT
dpc-3790	62	1	the	the	DET
dpc-3790	62	2	mean	mean	ADJ
dpc-3790	62	3	time	time	NOUN
dpc-3790	62	4	since	since	SCONJ
dpc-3790	62	5	aa	aa	PROPN
dpc-3790	62	6	first	first	ADJ
dpc-3790	62	7	onset	onset	NOUN
dpc-3790	62	8	and	and	CCONJ
dpc-3790	62	9	last	last	ADJ
dpc-3790	62	10	aa	aa	PROPN
dpc-3790	62	11	episode	episode	NOUN
dpc-3790	62	12	were	be	AUX
dpc-3790	62	13	8.28	8.28	NUM
dpc-3790	62	14	and	and	CCONJ
dpc-3790	62	15	3.32	3.32	NUM
dpc-3790	62	16	years	year	NOUN
dpc-3790	62	17	,	,	PUNCT
dpc-3790	62	18	correspondingly	correspondingly	ADV
dpc-3790	62	19	.	.	PUNCT
dpc-3790	63	1	mean	mean	VERB
dpc-3790	63	2	baseline	baseline	ADJ
dpc-3790	63	3	salt	salt	NOUN
dpc-3790	63	4	score	score	NOUN
dpc-3790	63	5	was	be	AUX
dpc-3790	63	6	80.21	80.21	NUM
dpc-3790	63	7	%	%	NOUN
dpc-3790	63	8	(	(	PUNCT
dpc-3790	63	9	sd	sd	NOUN
dpc-3790	63	10	:	:	PUNCT
dpc-3790	63	11	24.09	24.09	NUM
dpc-3790	63	12	%	%	NOUN
dpc-3790	63	13	)	)	PUNCT
dpc-3790	63	14	and	and	CCONJ
dpc-3790	63	15	the	the	DET
dpc-3790	63	16	mean	mean	ADJ
dpc-3790	63	17	baseline	baseline	NOUN
dpc-3790	63	18	dlqi	dlqi	ADJ
dpc-3790	63	19	score	score	NOUN
dpc-3790	63	20	was	be	AUX
dpc-3790	63	21	12.59	12.59	NUM
dpc-3790	63	22	(	(	PUNCT
dpc-3790	63	23	sd	sd	NOUN
dpc-3790	63	24	:	:	PUNCT
dpc-3790	63	25	3.96	3.96	NUM
dpc-3790	63	26	)	)	PUNCT
dpc-3790	63	27	.	.	PUNCT
dpc-3790	64	1	statistically	statistically	ADV
dpc-3790	64	2	significant	significant	ADJ
dpc-3790	64	3	difference	difference	NOUN
dpc-3790	64	4	was	be	AUX
dpc-3790	64	5	recorded	record	VERB
dpc-3790	64	6	in	in	ADP
dpc-3790	64	7	mean	mean	PROPN
dpc-3790	64	8	baseline	baseline	PROPN
dpc-3790	64	9	dlqi	dlqi	ADJ
dpc-3790	64	10	score	score	NOUN
dpc-3790	64	11	between	between	ADP
dpc-3790	64	12	men	man	NOUN
dpc-3790	64	13	(	(	PUNCT
dpc-3790	64	14	11.15	11.15	NUM
dpc-3790	64	15	)	)	PUNCT
dpc-3790	64	16	and	and	CCONJ
dpc-3790	64	17	women	woman	NOUN
dpc-3790	64	18	(	(	PUNCT
dpc-3790	64	19	14.17	14.17	NUM
dpc-3790	64	20	,	,	PUNCT
dpc-3790	64	21	p	p	X
dpc-3790	64	22	=	=	NOUN
dpc-3790	64	23	0.04	0.04	NUM
dpc-3790	64	24	)	)	PUNCT
dpc-3790	64	25	,	,	PUNCT
dpc-3790	64	26	whilst	whilst	SCONJ
dpc-3790	64	27	no	no	DET
dpc-3790	64	28	statistically	statistically	ADV
dpc-3790	64	29	significant	significant	ADJ
dpc-3790	64	30	difference	difference	NOUN
dpc-3790	64	31	was	be	AUX
dpc-3790	64	32	observed	observe	VERB
dpc-3790	64	33	in	in	ADP
dpc-3790	64	34	the	the	DET
dpc-3790	64	35	corresponding	corresponding	ADJ
dpc-3790	64	36	mean	mean	ADJ
dpc-3790	64	37	salt	salt	NOUN
dpc-3790	64	38	scores	score	NOUN
dpc-3790	64	39	(	(	PUNCT
dpc-3790	64	40	mean	mean	INTJ
dpc-3790	64	41	baseline	baseline	NOUN
dpc-3790	64	42	salt	salt	NOUN
dpc-3790	64	43	for	for	ADP
dpc-3790	64	44	men	man	NOUN
dpc-3790	64	45	was	be	AUX
dpc-3790	64	46	78.38	78.38	NUM
dpc-3790	64	47	%	%	NOUN
dpc-3790	64	48	and	and	CCONJ
dpc-3790	64	49	89.11	89.11	NUM
dpc-3790	64	50	%	%	NOUN
dpc-3790	64	51	for	for	ADP
dpc-3790	64	52	women	woman	NOUN
dpc-3790	64	53	,	,	PUNCT
dpc-3790	64	54	p	p	X
dpc-3790	64	55	=	=	PROPN
dpc-3790	64	56	0.161	0.161	NUM
dpc-3790	64	57	)	)	PUNCT
dpc-3790	64	58	.	.	PUNCT
dpc-3790	65	1	the	the	DET
dpc-3790	65	2	latter	latter	ADJ
dpc-3790	65	3	observation	observation	NOUN
dpc-3790	65	4	indicates	indicate	VERB
dpc-3790	65	5	that	that	SCONJ
dpc-3790	65	6	aa	aa	PROPN
dpc-3790	65	7	has	have	VERB
dpc-3790	65	8	a	a	DET
dpc-3790	65	9	greater	great	ADJ
dpc-3790	65	10	impact	impact	NOUN
dpc-3790	65	11	on	on	ADP
dpc-3790	65	12	females	female	NOUN
dpc-3790	65	13	as	as	SCONJ
dpc-3790	65	14	compared	compare	VERB
dpc-3790	65	15	to	to	ADP
dpc-3790	65	16	males	male	NOUN
dpc-3790	65	17	.	.	PUNCT
dpc-3790	66	1	the	the	DET
dpc-3790	66	2	most	most	ADV
dpc-3790	66	3	frequent	frequent	ADJ
dpc-3790	66	4	clinical	clinical	ADJ
dpc-3790	66	5	type	type	NOUN
dpc-3790	66	6	of	of	ADP
dpc-3790	66	7	alopecia	alopecia	NOUN
dpc-3790	66	8	areata	areata	ADJ
dpc-3790	66	9	in	in	ADP
dpc-3790	66	10	this	this	DET
dpc-3790	66	11	cohort	cohort	NOUN
dpc-3790	66	12	was	be	AUX
dpc-3790	66	13	universalis	universali	NOUN
dpc-3790	66	14	(	(	PUNCT
dpc-3790	66	15	40.4	40.4	NUM
dpc-3790	66	16	%	%	NOUN
dpc-3790	66	17	)	)	PUNCT
dpc-3790	66	18	,	,	PUNCT
dpc-3790	66	19	followed	follow	VERB
dpc-3790	66	20	by	by	ADP
dpc-3790	66	21	plaque	plaque	NOUN
dpc-3790	66	22	type	type	NOUN
dpc-3790	66	23	aa	aa	NOUN
dpc-3790	66	24	covering	cover	VERB
dpc-3790	66	25	25	25	NUM
dpc-3790	66	26	-	-	SYM
dpc-3790	66	27	75	75	NUM
dpc-3790	66	28	%	%	NOUN
dpc-3790	66	29	of	of	ADP
dpc-3790	66	30	the	the	DET
dpc-3790	66	31	scalp	scalp	NOUN
dpc-3790	66	32	(	(	PUNCT
dpc-3790	66	33	16.6	16.6	NUM
dpc-3790	66	34	%	%	NOUN
dpc-3790	66	35	)	)	PUNCT
dpc-3790	66	36	and	and	CCONJ
dpc-3790	66	37	totalis	totali	NOUN
dpc-3790	66	38	seen	see	VERB
dpc-3790	66	39	in	in	ADP
dpc-3790	66	40	14.2	14.2	NUM
dpc-3790	66	41	%	%	NOUN
dpc-3790	66	42	.	.	PUNCT
dpc-3790	67	1	family	family	NOUN
dpc-3790	67	2	history	history	NOUN
dpc-3790	67	3	of	of	ADP
dpc-3790	67	4	aa	aa	PROPN
dpc-3790	67	5	was	be	AUX
dpc-3790	67	6	reported	report	VERB
dpc-3790	67	7	by	by	ADP
dpc-3790	67	8	26.1	26.1	NUM
dpc-3790	67	9	%	%	NOUN
dpc-3790	67	10	(	(	PUNCT
dpc-3790	67	11	11/42	11/42	NUM
dpc-3790	67	12	)	)	PUNCT
dpc-3790	67	13	of	of	ADP
dpc-3790	67	14	the	the	DET
dpc-3790	67	15	patients	patient	NOUN
dpc-3790	67	16	,	,	PUNCT
dpc-3790	67	17	while	while	SCONJ
dpc-3790	67	18	52.3	52.3	NUM
dpc-3790	67	19	%	%	NOUN
dpc-3790	67	20	(	(	PUNCT
dpc-3790	67	21	22/42	22/42	NUM
dpc-3790	67	22	)	)	PUNCT
dpc-3790	67	23	could	could	AUX
dpc-3790	67	24	not	not	PART
dpc-3790	67	25	recall	recall	VERB
dpc-3790	67	26	other	other	ADJ
dpc-3790	67	27	firstor	firstor	NOUN
dpc-3790	67	28	second	second	ADJ
dpc-3790	67	29	-	-	PUNCT
dpc-3790	67	30	degree	degree	NOUN
dpc-3790	67	31	relatives	relative	NOUN
dpc-3790	67	32	suffering	suffer	VERB
dpc-3790	67	33	from	from	ADP
dpc-3790	67	34	aa	aa	NOUN
dpc-3790	67	35	.	.	PUNCT
dpc-3790	68	1	from	from	ADP
dpc-3790	68	2	the	the	DET
dpc-3790	68	3	original	original	ADJ
dpc-3790	68	4	article	article	NOUN
dpc-3790	68	5	|	|	ADV
dpc-3790	68	6	dermatol	dermatol	ADJ
dpc-3790	68	7	pract	pract	NOUN
dpc-3790	68	8	concept	concept	NOUN
dpc-3790	68	9	.	.	PUNCT
dpc-3790	69	1	2024;14(2):e2024073	2024;14(2):e2024073	NUM
dpc-3790	69	2	3	3	NUM
dpc-3790	69	3	table	table	NOUN
dpc-3790	69	4	1	1	NUM
dpc-3790	69	5	.	.	NOUN
dpc-3790	69	6	epidemiologic	epidemiologic	ADJ
dpc-3790	69	7	and	and	CCONJ
dpc-3790	69	8	clinical	clinical	ADJ
dpc-3790	69	9	characteristics	characteristic	NOUN
dpc-3790	69	10	of	of	ADP
dpc-3790	69	11	the	the	DET
dpc-3790	69	12	patients	patient	NOUN
dpc-3790	69	13	included	include	VERB
dpc-3790	69	14	in	in	ADP
dpc-3790	69	15	the	the	DET
dpc-3790	69	16	study	study	NOUN
dpc-3790	69	17	variables	variable	VERB
dpc-3790	69	18	all	all	DET
dpc-3790	69	19	patients	patient	NOUN
dpc-3790	69	20	(	(	PUNCT
dpc-3790	69	21	n	n	NOUN
dpc-3790	69	22	=	=	SYM
dpc-3790	69	23	42	42	NUM
dpc-3790	69	24	)	)	PUNCT
dpc-3790	69	25	socio	socio	NOUN
dpc-3790	69	26	-	-	ADJ
dpc-3790	69	27	demographic	demographic	ADJ
dpc-3790	69	28	features	feature	NOUN
dpc-3790	69	29	age	age	NOUN
dpc-3790	69	30	,	,	PUNCT
dpc-3790	69	31	years	year	NOUN
dpc-3790	69	32	,	,	PUNCT
dpc-3790	69	33	mean	mean	INTJ
dpc-3790	69	34	(	(	PUNCT
dpc-3790	69	35	sd	sd	NOUN
dpc-3790	69	36	)	)	PUNCT
dpc-3790	69	37	39.52	39.52	NUM
dpc-3790	69	38	(	(	PUNCT
dpc-3790	69	39	14.48	14.48	NUM
dpc-3790	69	40	)	)	PUNCT
dpc-3790	69	41	time	time	NOUN
dpc-3790	69	42	since	since	SCONJ
dpc-3790	69	43	first	first	ADJ
dpc-3790	69	44	onset	onset	NOUN
dpc-3790	69	45	,	,	PUNCT
dpc-3790	69	46	years	year	NOUN
dpc-3790	69	47	mean	mean	VERB
dpc-3790	69	48	(	(	PUNCT
dpc-3790	69	49	sd	sd	NOUN
dpc-3790	69	50	)	)	PUNCT
dpc-3790	69	51	8.28	8.28	NUM
dpc-3790	69	52	(	(	PUNCT
dpc-3790	69	53	10.73	10.73	NUM
dpc-3790	69	54	)	)	PUNCT
dpc-3790	69	55	sex	sex	NOUN
dpc-3790	69	56	male	male	NOUN
dpc-3790	69	57	,	,	PUNCT
dpc-3790	69	58	%	%	NOUN
dpc-3790	69	59	(	(	PUNCT
dpc-3790	69	60	n	n	CCONJ
dpc-3790	69	61	)	)	PUNCT
dpc-3790	69	62	40.47	40.47	NUM
dpc-3790	69	63	%	%	NOUN
dpc-3790	69	64	(	(	PUNCT
dpc-3790	69	65	17/42	17/42	NUM
dpc-3790	69	66	)	)	PUNCT
dpc-3790	69	67	sex	sex	NOUN
dpc-3790	69	68	female	female	NOUN
dpc-3790	69	69	,	,	PUNCT
dpc-3790	69	70	%	%	NOUN
dpc-3790	69	71	(	(	PUNCT
dpc-3790	69	72	n	n	CCONJ
dpc-3790	69	73	)	)	PUNCT
dpc-3790	69	74	59.52	59.52	NUM
dpc-3790	69	75	%	%	NOUN
dpc-3790	69	76	(	(	PUNCT
dpc-3790	69	77	25/42	25/42	NUM
dpc-3790	69	78	)	)	PUNCT
dpc-3790	69	79	time	time	NOUN
dpc-3790	69	80	since	since	SCONJ
dpc-3790	69	81	last	last	ADJ
dpc-3790	69	82	episode	episode	NOUN
dpc-3790	69	83	of	of	ADP
dpc-3790	69	84	aa	aa	NOUN
dpc-3790	69	85	,	,	PUNCT
dpc-3790	69	86	years	year	NOUN
dpc-3790	69	87	,	,	PUNCT
dpc-3790	69	88	mean	mean	INTJ
dpc-3790	69	89	(	(	PUNCT
dpc-3790	69	90	sd	sd	NOUN
dpc-3790	69	91	)	)	PUNCT
dpc-3790	69	92	3.32	3.32	NUM
dpc-3790	69	93	(	(	PUNCT
dpc-3790	69	94	4.16	4.16	NUM
dpc-3790	69	95	)	)	PUNCT
dpc-3790	69	96	previous	previous	ADJ
dpc-3790	69	97	treatments	treatment	NOUN
dpc-3790	69	98	,	,	PUNCT
dpc-3790	69	99	%	%	INTJ
dpc-3790	69	100	(	(	PUNCT
dpc-3790	69	101	n	n	CCONJ
dpc-3790	69	102	)	)	PUNCT
dpc-3790	69	103	topical	topical	ADJ
dpc-3790	69	104	steroids	steroid	NOUN
dpc-3790	69	105	76	76	NUM
dpc-3790	69	106	%	%	NOUN
dpc-3790	69	107	(	(	PUNCT
dpc-3790	69	108	32/42	32/42	NUM
dpc-3790	69	109	)	)	PUNCT
dpc-3790	69	110	intralesional	intralesional	ADJ
dpc-3790	69	111	injections	injection	NOUN
dpc-3790	69	112	45.2	45.2	NUM
dpc-3790	69	113	%	%	NOUN
dpc-3790	69	114	(	(	PUNCT
dpc-3790	69	115	19/42	19/42	NUM
dpc-3790	69	116	)	)	PUNCT
dpc-3790	69	117	topical	topical	ADJ
dpc-3790	69	118	calcineurin	calcineurin	NOUN
dpc-3790	69	119	inhibitors	inhibitor	NOUN
dpc-3790	69	120	14.2	14.2	NUM
dpc-3790	69	121	%	%	NOUN
dpc-3790	69	122	(	(	PUNCT
dpc-3790	69	123	6/42	6/42	NUM
dpc-3790	69	124	)	)	PUNCT
dpc-3790	69	125	dpcp	dpcp	NOUN
dpc-3790	69	126	14.2	14.2	NUM
dpc-3790	69	127	%	%	NOUN
dpc-3790	69	128	(	(	PUNCT
dpc-3790	69	129	6/42	6/42	NUM
dpc-3790	69	130	)	)	PUNCT
dpc-3790	69	131	anthralin	anthralin	ADV
dpc-3790	69	132	9.5	9.5	NUM
dpc-3790	69	133	%	%	NOUN
dpc-3790	69	134	(	(	PUNCT
dpc-3790	69	135	4/42	4/42	NOUN
dpc-3790	69	136	)	)	PUNCT
dpc-3790	69	137	systemic	systemic	ADJ
dpc-3790	69	138	cortisone	cortisone	NOUN
dpc-3790	69	139	71	71	NUM
dpc-3790	69	140	%	%	NOUN
dpc-3790	69	141	(	(	PUNCT
dpc-3790	69	142	30/42	30/42	NUM
dpc-3790	69	143	)	)	PUNCT
dpc-3790	69	144	cyclosporine	cyclosporine	VERB
dpc-3790	69	145	52	52	NUM
dpc-3790	69	146	%	%	NOUN
dpc-3790	69	147	(	(	PUNCT
dpc-3790	69	148	22/42	22/42	NUM
dpc-3790	69	149	)	)	PUNCT
dpc-3790	69	150	jaki	jaki	PROPN
dpc-3790	69	151	4.7	4.7	NUM
dpc-3790	69	152	%	%	NOUN
dpc-3790	69	153	(	(	PUNCT
dpc-3790	69	154	2/42	2/42	NUM
dpc-3790	69	155	)	)	PUNCT
dpc-3790	69	156	prp	prp	NOUN
dpc-3790	69	157	9.5	9.5	NUM
dpc-3790	69	158	%	%	NOUN
dpc-3790	69	159	(	(	PUNCT
dpc-3790	69	160	4/42	4/42	PROPN
dpc-3790	69	161	)	)	PUNCT
dpc-3790	69	162	hydroxychloroquine	hydroxychloroquine	NOUN
dpc-3790	69	163	4.7	4.7	NUM
dpc-3790	69	164	%	%	NOUN
dpc-3790	69	165	(	(	PUNCT
dpc-3790	69	166	2/42	2/42	NUM
dpc-3790	69	167	)	)	PUNCT
dpc-3790	69	168	comorbidities	comorbiditie	NOUN
dpc-3790	69	169	,	,	PUNCT
dpc-3790	69	170	%	%	INTJ
dpc-3790	69	171	(	(	PUNCT
dpc-3790	69	172	n	n	CCONJ
dpc-3790	69	173	)	)	PUNCT
dpc-3790	69	174	thyroid	thyroid	NOUN
dpc-3790	69	175	disease	disease	NOUN
dpc-3790	69	176	38	38	NUM
dpc-3790	69	177	%	%	NOUN
dpc-3790	69	178	(	(	PUNCT
dpc-3790	69	179	16/42	16/42	NUM
dpc-3790	69	180	)	)	PUNCT
dpc-3790	69	181	myasthenia	myasthenia	NOUN
dpc-3790	69	182	gravis	gravis	NOUN
dpc-3790	69	183	4.7	4.7	NUM
dpc-3790	69	184	%	%	NOUN
dpc-3790	69	185	(	(	PUNCT
dpc-3790	69	186	2/42	2/42	NUM
dpc-3790	69	187	)	)	PUNCT
dpc-3790	69	188	diabetes	diabetes	NOUN
dpc-3790	69	189	mellitus	mellitus	NOUN
dpc-3790	69	190	4.7	4.7	NUM
dpc-3790	69	191	%	%	NOUN
dpc-3790	69	192	(	(	PUNCT
dpc-3790	69	193	2/42	2/42	NUM
dpc-3790	69	194	)	)	PUNCT
dpc-3790	69	195	vitiligo	vitiligo	VERB
dpc-3790	69	196	2	2	NUM
dpc-3790	69	197	%	%	NOUN
dpc-3790	69	198	(	(	PUNCT
dpc-3790	69	199	1/42	1/42	NUM
dpc-3790	69	200	)	)	PUNCT
dpc-3790	69	201	hypertension	hypertension	NOUN
dpc-3790	69	202	4.7	4.7	NUM
dpc-3790	69	203	%	%	NOUN
dpc-3790	69	204	(	(	PUNCT
dpc-3790	69	205	2/42	2/42	NUM
dpc-3790	69	206	)	)	PUNCT
dpc-3790	69	207	asthma	asthma	NOUN
dpc-3790	69	208	2	2	NUM
dpc-3790	69	209	%	%	NOUN
dpc-3790	69	210	(	(	PUNCT
dpc-3790	69	211	1/42	1/42	NUM
dpc-3790	69	212	)	)	PUNCT
dpc-3790	69	213	rheumatoid	rheumatoid	VERB
dpc-3790	69	214	arthritis	arthritis	NOUN
dpc-3790	69	215	2	2	NUM
dpc-3790	69	216	%	%	NOUN
dpc-3790	69	217	(	(	PUNCT
dpc-3790	69	218	1/42	1/42	NUM
dpc-3790	69	219	)	)	PUNCT
dpc-3790	69	220	severity	severity	NOUN
dpc-3790	69	221	of	of	ADP
dpc-3790	69	222	the	the	DET
dpc-3790	69	223	disease	disease	NOUN
dpc-3790	69	224	basal	basal	VERB
dpc-3790	69	225	salt	salt	NOUN
dpc-3790	69	226	score	score	NOUN
dpc-3790	69	227	mean	mean	NOUN
dpc-3790	69	228	(	(	PUNCT
dpc-3790	69	229	sd	sd	NOUN
dpc-3790	69	230	)	)	PUNCT
dpc-3790	69	231	80.21	80.21	NUM
dpc-3790	69	232	(	(	PUNCT
dpc-3790	69	233	24.09	24.09	NUM
dpc-3790	69	234	)	)	PUNCT
dpc-3790	69	235	current	current	ADJ
dpc-3790	69	236	salt	salt	NOUN
dpc-3790	69	237	score	score	NOUN
dpc-3790	69	238	mean	mean	NOUN
dpc-3790	69	239	(	(	PUNCT
dpc-3790	69	240	sd	sd	NOUN
dpc-3790	69	241	)	)	PUNCT
dpc-3790	69	242	43.27	43.27	NUM
dpc-3790	69	243	(	(	PUNCT
dpc-3790	69	244	39.44	39.44	NUM
dpc-3790	69	245	)	)	PUNCT
dpc-3790	69	246	treatment	treatment	NOUN
dpc-3790	69	247	characteristics	characteristic	NOUN
dpc-3790	69	248	baricitinib	baricitinib	NOUN
dpc-3790	69	249	tofacitinib	tofacitinib	NOUN
dpc-3790	69	250	mean	mean	VERB
dpc-3790	69	251	treatment	treatment	NOUN
dpc-3790	69	252	time	time	NOUN
dpc-3790	69	253	(	(	PUNCT
dpc-3790	69	254	months	month	NOUN
dpc-3790	69	255	)	)	PUNCT
dpc-3790	69	256	2.7	2.7	NUM
dpc-3790	69	257	11.7	11.7	NUM
dpc-3790	69	258	maintenance	maintenance	NOUN
dpc-3790	69	259	dose	dose	NOUN
dpc-3790	69	260	(	(	PUNCT
dpc-3790	69	261	mg	mg	PROPN
dpc-3790	69	262	/	/	SYM
dpc-3790	69	263	day	day	NOUN
dpc-3790	69	264	)	)	PUNCT
dpc-3790	69	265	4mg	4mg	ADJ
dpc-3790	69	266	/	/	SYM
dpc-3790	69	267	day	day	NOUN
dpc-3790	69	268	10mg	10mg	NUM
dpc-3790	69	269	/	/	SYM
dpc-3790	69	270	day	day	NOUN
dpc-3790	69	271	(	(	PUNCT
dpc-3790	69	272	17/22	17/22	NUM
dpc-3790	69	273	)	)	PUNCT
dpc-3790	69	274	20mg	20mg	NUM
dpc-3790	69	275	/	/	SYM
dpc-3790	69	276	day	day	NOUN
dpc-3790	69	277	(	(	PUNCT
dpc-3790	69	278	5/22	5/22	NUM
dpc-3790	69	279	)	)	PUNCT
dpc-3790	69	280	jaki	jaki	PROPN
dpc-3790	69	281	=	=	PROPN
dpc-3790	69	282	janus	janus	PROPN
dpc-3790	69	283	kinase	kinase	PROPN
dpc-3790	69	284	inhibitor	inhibitor	PROPN
dpc-3790	69	285	;	;	PUNCT
dpc-3790	69	286	prp	prp	NOUN
dpc-3790	69	287	=	=	NUM
dpc-3790	69	288	platelet	platelet	ADJ
dpc-3790	69	289	rich	rich	ADJ
dpc-3790	69	290	plasma	plasma	NOUN
dpc-3790	69	291	;	;	PUNCT
dpc-3790	69	292	salt	salt	NOUN
dpc-3790	69	293	=	=	SYM
dpc-3790	69	294	severity	severity	NOUN
dpc-3790	69	295	of	of	ADP
dpc-3790	69	296	alopecia	alopecia	NOUN
dpc-3790	69	297	tool	tool	NOUN
dpc-3790	69	298	;	;	PUNCT
dpc-3790	69	299	sd	sd	NOUN
dpc-3790	69	300	=	=	SYM
dpc-3790	69	301	standard	standard	ADJ
dpc-3790	69	302	deviation	deviation	NOUN
dpc-3790	69	303	;	;	PUNCT
dpc-3790	69	304	recorded	record	VERB
dpc-3790	69	305	comorbidities	comorbiditie	NOUN
dpc-3790	69	306	,	,	PUNCT
dpc-3790	69	307	thyroid	thyroid	NOUN
dpc-3790	69	308	disease	disease	NOUN
dpc-3790	69	309	was	be	AUX
dpc-3790	69	310	the	the	DET
dpc-3790	69	311	first	first	ADJ
dpc-3790	69	312	in	in	ADP
dpc-3790	69	313	the	the	DET
dpc-3790	69	314	list	list	NOUN
dpc-3790	69	315	,	,	PUNCT
dpc-3790	69	316	found	find	VERB
dpc-3790	69	317	in	in	ADP
dpc-3790	69	318	 	 	SPACE
dpc-3790	69	319	38	38	NUM
dpc-3790	69	320	%	%	NOUN
dpc-3790	69	321	(	(	PUNCT
dpc-3790	69	322	16/42	16/42	NUM
dpc-3790	69	323	)	)	PUNCT
dpc-3790	69	324	of	of	ADP
dpc-3790	69	325	the	the	DET
dpc-3790	69	326	participants	participant	NOUN
dpc-3790	69	327	.	.	PUNCT
dpc-3790	70	1	the	the	DET
dpc-3790	70	2	most	most	ADV
dpc-3790	70	3	common	common	ADJ
dpc-3790	70	4	previously	previously	ADV
dpc-3790	70	5	used	use	VERB
dpc-3790	70	6	treatments	treatment	NOUN
dpc-3790	70	7	were	be	AUX
dpc-3790	70	8	topical	topical	ADJ
dpc-3790	70	9	steroids	steroid	NOUN
dpc-3790	70	10	(	(	PUNCT
dpc-3790	70	11	32/42	32/42	NUM
dpc-3790	70	12	)	)	PUNCT
dpc-3790	70	13	,	,	PUNCT
dpc-3790	70	14	systemic	systemic	ADJ
dpc-3790	70	15	steroids	steroid	NOUN
dpc-3790	70	16	(	(	PUNCT
dpc-3790	70	17	30/42	30/42	NUM
dpc-3790	70	18	)	)	PUNCT
dpc-3790	70	19	,	,	PUNCT
dpc-3790	70	20	cyclosporine	cyclosporine	NOUN
dpc-3790	70	21	(	(	PUNCT
dpc-3790	70	22	22/42	22/42	NUM
dpc-3790	70	23	)	)	PUNCT
dpc-3790	70	24	,	,	PUNCT
dpc-3790	70	25	and	and	CCONJ
dpc-3790	70	26	intralesional	intralesional	ADJ
dpc-3790	70	27	steroids	steroid	NOUN
dpc-3790	70	28	(	(	PUNCT
dpc-3790	70	29	19/42	19/42	NUM
dpc-3790	70	30	)	)	PUNCT
dpc-3790	70	31	.	.	PUNCT
dpc-3790	71	1	adverse	adverse	ADJ
dpc-3790	71	2	events	event	NOUN
dpc-3790	71	3	to	to	ADP
dpc-3790	71	4	previous	previous	ADJ
dpc-3790	71	5	treatment	treatment	NOUN
dpc-3790	71	6	included	include	VERB
dpc-3790	71	7	hypertension	hypertension	NOUN
dpc-3790	71	8	(	(	PUNCT
dpc-3790	71	9	~41	~41	NOUN
dpc-3790	71	10	%	%	NOUN
dpc-3790	71	11	)	)	PUNCT
dpc-3790	71	12	,	,	PUNCT
dpc-3790	71	13	hypertrichosis	hypertrichosis	NOUN
dpc-3790	71	14	(	(	PUNCT
dpc-3790	71	15	~35	~35	ADJ
dpc-3790	71	16	%	%	NOUN
dpc-3790	71	17	)	)	PUNCT
dpc-3790	71	18	,	,	PUNCT
dpc-3790	71	19	cushing	cushe	VERB
dpc-3790	71	20	syndrome	syndrome	NOUN
dpc-3790	71	21	(	(	PUNCT
dpc-3790	71	22	~35	~35	NUM
dpc-3790	71	23	%	%	NOUN
dpc-3790	71	24	)	)	PUNCT
dpc-3790	71	25	and	and	CCONJ
dpc-3790	71	26	topical	topical	ADJ
dpc-3790	71	27	atrophy	atrophy	NOUN
dpc-3790	71	28	(	(	PUNCT
dpc-3790	71	29	~17	~17	NOUN
dpc-3790	71	30	%	%	NOUN
dpc-3790	71	31	)	)	PUNCT
dpc-3790	71	32	.	.	PUNCT
dpc-3790	72	1	in	in	ADP
dpc-3790	72	2	our	our	PRON
dpc-3790	72	3	cohort	cohort	NOUN
dpc-3790	72	4	,	,	PUNCT
dpc-3790	72	5	52.3	52.3	NUM
dpc-3790	72	6	%	%	NOUN
dpc-3790	72	7	(	(	PUNCT
dpc-3790	72	8	22/42	22/42	NUM
dpc-3790	72	9	)	)	PUNCT
dpc-3790	72	10	of	of	ADP
dpc-3790	72	11	the	the	DET
dpc-3790	72	12	patients	patient	NOUN
dpc-3790	72	13	were	be	AUX
dpc-3790	72	14	under	under	ADP
dpc-3790	72	15	tofacitinib	tofacitinib	NOUN
dpc-3790	72	16	and	and	CCONJ
dpc-3790	72	17	47.6	47.6	NUM
dpc-3790	72	18	%	%	NOUN
dpc-3790	72	19	(	(	PUNCT
dpc-3790	72	20	20/42	20/42	NUM
dpc-3790	72	21	)	)	PUNCT
dpc-3790	72	22	under	under	ADP
dpc-3790	72	23	baricitinib	baricitinib	NOUN
dpc-3790	72	24	and	and	CCONJ
dpc-3790	72	25	the	the	DET
dpc-3790	72	26	mean	mean	ADJ
dpc-3790	72	27	time	time	NOUN
dpc-3790	72	28	on	on	ADP
dpc-3790	72	29	current	current	ADJ
dpc-3790	72	30	treatment	treatment	NOUN
dpc-3790	72	31	was	be	AUX
dpc-3790	72	32	7.4	7.4	NUM
dpc-3790	72	33	months	month	NOUN
dpc-3790	72	34	(	(	PUNCT
dpc-3790	72	35	sd	sd	NOUN
dpc-3790	72	36	:	:	PUNCT
dpc-3790	72	37	6.46	6.46	NUM
dpc-3790	72	38	,	,	PUNCT
dpc-3790	72	39	range	range	NOUN
dpc-3790	72	40	:	:	PUNCT
dpc-3790	72	41	1	1	NUM
dpc-3790	72	42	-	-	SYM
dpc-3790	72	43	30	30	NUM
dpc-3790	72	44	months	month	NOUN
dpc-3790	72	45	)	)	PUNCT
dpc-3790	72	46	.	.	PUNCT
dpc-3790	73	1	table	table	NOUN
dpc-3790	73	2	1	1	NUM
dpc-3790	73	3	summarizes	summarize	NOUN
dpc-3790	73	4	patients	patient	NOUN
dpc-3790	73	5	epidemiological	epidemiological	ADJ
dpc-3790	73	6	and	and	CCONJ
dpc-3790	73	7	clinical	clinical	ADJ
dpc-3790	73	8	characteristics	characteristic	NOUN
dpc-3790	73	9	.	.	PUNCT
dpc-3790	74	1	clinical	clinical	ADJ
dpc-3790	74	2	outcomes	outcome	NOUN
dpc-3790	74	3	mean	mean	VERB
dpc-3790	74	4	time	time	NOUN
dpc-3790	74	5	on	on	ADP
dpc-3790	74	6	treatment	treatment	NOUN
dpc-3790	74	7	of	of	ADP
dpc-3790	74	8	all	all	DET
dpc-3790	74	9	participants	participant	NOUN
dpc-3790	74	10	was	be	AUX
dpc-3790	74	11	7.4	7.4	NUM
dpc-3790	74	12	months	month	NOUN
dpc-3790	74	13	(	(	PUNCT
dpc-3790	74	14	sd	sd	ADP
dpc-3790	74	15	6.46	6.46	NUM
dpc-3790	74	16	,	,	PUNCT
dpc-3790	74	17	1	1	NUM
dpc-3790	74	18	-	-	SYM
dpc-3790	74	19	30	30	NUM
dpc-3790	74	20	)	)	PUNCT
dpc-3790	74	21	,	,	PUNCT
dpc-3790	74	22	whilst	whilst	SCONJ
dpc-3790	74	23	mean	mean	VERB
dpc-3790	74	24	time	time	NOUN
dpc-3790	74	25	to	to	ADP
dpc-3790	74	26	first	first	ADJ
dpc-3790	74	27	signs	sign	NOUN
dpc-3790	74	28	of	of	ADP
dpc-3790	74	29	hair	hair	NOUN
dpc-3790	74	30	regrowth	regrowth	NOUN
dpc-3790	74	31	was	be	AUX
dpc-3790	74	32	2.66	2.66	NUM
dpc-3790	74	33	months	month	NOUN
dpc-3790	74	34	.	.	PUNCT
dpc-3790	75	1	all	all	DET
dpc-3790	75	2	patients	patient	NOUN
dpc-3790	75	3	on	on	ADP
dpc-3790	75	4	baricitinib	baricitinib	NOUN
dpc-3790	75	5	received	receive	VERB
dpc-3790	75	6	the	the	DET
dpc-3790	75	7	recommended	recommend	VERB
dpc-3790	75	8	dose	dose	NOUN
dpc-3790	75	9	of	of	ADP
dpc-3790	75	10	4	4	NUM
dpc-3790	75	11	mg	mg	NOUN
dpc-3790	75	12	per	per	ADP
dpc-3790	75	13	day	day	NOUN
dpc-3790	75	14	.	.	PUNCT
dpc-3790	76	1	in	in	ADP
dpc-3790	76	2	this	this	DET
dpc-3790	76	3	group	group	NOUN
dpc-3790	76	4	one	one	NUM
dpc-3790	76	5	patient	patient	NOUN
dpc-3790	76	6	switched	switch	VERB
dpc-3790	76	7	from	from	ADP
dpc-3790	76	8	tofacitinib	tofacitinib	NOUN
dpc-3790	76	9	due	due	ADP
dpc-3790	76	10	to	to	ADP
dpc-3790	76	11	treatment	treatment	NOUN
dpc-3790	76	12	failure	failure	NOUN
dpc-3790	76	13	(	(	PUNCT
dpc-3790	76	14	started	start	VERB
dpc-3790	76	15	with	with	ADP
dpc-3790	76	16	10mg	10mg	ADJ
dpc-3790	76	17	/	/	SYM
dpc-3790	76	18	day	day	NOUN
dpc-3790	76	19	for	for	ADP
dpc-3790	76	20	6	6	NUM
dpc-3790	76	21	months	month	NOUN
dpc-3790	76	22	and	and	CCONJ
dpc-3790	76	23	20	20	NUM
dpc-3790	76	24	mg	mg	NUM
dpc-3790	76	25	/	/	SYM
dpc-3790	76	26	day	day	NOUN
dpc-3790	76	27	for	for	ADP
dpc-3790	76	28	3	3	NUM
dpc-3790	76	29	 	 	SPACE
dpc-3790	76	30	months	month	NOUN
dpc-3790	76	31	with	with	ADP
dpc-3790	76	32	no	no	DET
dpc-3790	76	33	response	response	NOUN
dpc-3790	76	34	and	and	CCONJ
dpc-3790	76	35	continued	continue	VERB
dpc-3790	76	36	afterwards	afterwards	ADV
dpc-3790	76	37	with	with	ADP
dpc-3790	76	38	4	4	NUM
dpc-3790	76	39	original	original	ADJ
dpc-3790	76	40	article	article	NOUN
dpc-3790	76	41	|	|	ADV
dpc-3790	76	42	dermatol	dermatol	ADJ
dpc-3790	76	43	pract	pract	NOUN
dpc-3790	76	44	concept	concept	NOUN
dpc-3790	76	45	.	.	PUNCT
dpc-3790	77	1	2024;14(2):e2024073	2024;14(2):e2024073	NUM
dpc-3790	77	2	figure	figure	NOUN
dpc-3790	77	3	1	1	NUM
dpc-3790	77	4	.	.	PUNCT
dpc-3790	78	1	efficacy	efficacy	NOUN
dpc-3790	78	2	analysis	analysis	NOUN
dpc-3790	78	3	of	of	ADP
dpc-3790	78	4	30	30	NUM
dpc-3790	78	5	individuals	individual	NOUN
dpc-3790	78	6	that	that	PRON
dpc-3790	78	7	had	have	AUX
dpc-3790	78	8	completed	complete	VERB
dpc-3790	78	9	at	at	ADP
dpc-3790	78	10	least	least	ADV
dpc-3790	78	11	3	3	NUM
dpc-3790	78	12	months	month	NOUN
dpc-3790	78	13	on	on	ADP
dpc-3790	78	14	treatment	treatment	NOUN
dpc-3790	78	15	with	with	ADP
dpc-3790	78	16	janus	janus	PROPN
dpc-3790	78	17	kinase	kinase	PROPN
dpc-3790	78	18	inhibitors	inhibitor	NOUN
dpc-3790	78	19	revealed	reveal	VERB
dpc-3790	78	20	a	a	DET
dpc-3790	78	21	significant	significant	ADJ
dpc-3790	78	22	reduction	reduction	NOUN
dpc-3790	78	23	in	in	ADP
dpc-3790	78	24	mean	mean	ADJ
dpc-3790	78	25	severity	severity	NOUN
dpc-3790	78	26	of	of	ADP
dpc-3790	78	27	alopecia	alopecia	NOUN
dpc-3790	78	28	tool	tool	NOUN
dpc-3790	78	29	(	(	PUNCT
dpc-3790	78	30	salt	salt	NOUN
dpc-3790	78	31	)	)	PUNCT
dpc-3790	78	32	and	and	CCONJ
dpc-3790	78	33	dermatology	dermatology	NOUN
dpc-3790	78	34	life	life	NOUN
dpc-3790	78	35	quality	quality	NOUN
dpc-3790	78	36	index	index	NOUN
dpc-3790	78	37	(	(	PUNCT
dpc-3790	78	38	dlqi	dlqi	PROPN
dpc-3790	78	39	)	)	PUNCT
dpc-3790	78	40	scores	score	NOUN
dpc-3790	78	41	from	from	ADP
dpc-3790	78	42	baseline	baseline	NOUN
dpc-3790	78	43	to	to	ADP
dpc-3790	78	44	the	the	DET
dpc-3790	78	45	last	last	ADJ
dpc-3790	78	46	follow	follow	NOUN
dpc-3790	78	47	up	up	ADP
dpc-3790	78	48	visit	visit	NOUN
dpc-3790	78	49	(	(	PUNCT
dpc-3790	78	50	mean	mean	VERB
dpc-3790	78	51	treatment	treatment	NOUN
dpc-3790	78	52	time	time	NOUN
dpc-3790	78	53	10	10	NUM
dpc-3790	78	54	months	month	NOUN
dpc-3790	78	55	)	)	PUNCT
dpc-3790	78	56	.	.	PUNCT
dpc-3790	79	1	4	4	NUM
dpc-3790	79	2	mg	mg	NUM
dpc-3790	79	3	/	/	SYM
dpc-3790	79	4	day	day	NOUN
dpc-3790	79	5	baricitinib	baricitinib	NOUN
dpc-3790	79	6	)	)	PUNCT
dpc-3790	79	7	.	.	PUNCT
dpc-3790	80	1	the	the	DET
dpc-3790	80	2	maintenance	maintenance	NOUN
dpc-3790	80	3	dose	dose	VERB
dpc-3790	80	4	for	for	ADP
dpc-3790	80	5	all	all	DET
dpc-3790	80	6	the	the	DET
dpc-3790	80	7	20	20	NUM
dpc-3790	80	8	patients	patient	NOUN
dpc-3790	80	9	receiving	receive	VERB
dpc-3790	80	10	baricitinib	baricitinib	NOUN
dpc-3790	80	11	was	be	AUX
dpc-3790	80	12	4	4	NUM
dpc-3790	80	13	mg	mg	NUM
dpc-3790	80	14	/	/	SYM
dpc-3790	80	15	day	day	NOUN
dpc-3790	80	16	.	.	PUNCT
dpc-3790	81	1	in	in	ADP
dpc-3790	81	2	the	the	DET
dpc-3790	81	3	tofacitinib	tofacitinib	PROPN
dpc-3790	81	4	group	group	NOUN
dpc-3790	81	5	,	,	PUNCT
dpc-3790	81	6	21	21	NUM
dpc-3790	81	7	patients	patient	NOUN
dpc-3790	81	8	started	start	VERB
dpc-3790	81	9	with	with	ADP
dpc-3790	81	10	10	10	NUM
dpc-3790	81	11	mg	mg	NUM
dpc-3790	81	12	/	/	SYM
dpc-3790	81	13	day	day	NOUN
dpc-3790	81	14	,	,	PUNCT
dpc-3790	81	15	except	except	SCONJ
dpc-3790	81	16	from	from	ADP
dpc-3790	81	17	one	one	NUM
dpc-3790	81	18	patient	patient	NOUN
dpc-3790	81	19	who	who	PRON
dpc-3790	81	20	started	start	VERB
dpc-3790	81	21	with	with	ADP
dpc-3790	81	22	a	a	DET
dpc-3790	81	23	daily	daily	ADJ
dpc-3790	81	24	dose	dose	NOUN
dpc-3790	81	25	of	of	ADP
dpc-3790	81	26	5	5	NUM
dpc-3790	81	27	mg	mg	NOUN
dpc-3790	81	28	,	,	PUNCT
dpc-3790	81	29	due	due	ADP
dpc-3790	81	30	to	to	ADP
dpc-3790	81	31	history	history	NOUN
dpc-3790	81	32	of	of	ADP
dpc-3790	81	33	metabolic	metabolic	NOUN
dpc-3790	81	34	syndrome	syndrome	NOUN
dpc-3790	81	35	.	.	PUNCT
dpc-3790	82	1	this	this	DET
dpc-3790	82	2	individual	individual	NOUN
dpc-3790	82	3	had	have	AUX
dpc-3790	82	4	developed	develop	VERB
dpc-3790	82	5	cushing	cushe	VERB
dpc-3790	82	6	syndrome	syndrome	NOUN
dpc-3790	82	7	due	due	ADP
dpc-3790	82	8	to	to	ADP
dpc-3790	82	9	the	the	DET
dpc-3790	82	10	previous	previous	ADJ
dpc-3790	82	11	long	long	ADJ
dpc-3790	82	12	-	-	PUNCT
dpc-3790	82	13	term	term	NOUN
dpc-3790	82	14	use	use	NOUN
dpc-3790	82	15	of	of	ADP
dpc-3790	82	16	systemic	systemic	ADJ
dpc-3790	82	17	steroids	steroid	NOUN
dpc-3790	82	18	.	.	PUNCT
dpc-3790	83	1	after	after	ADP
dpc-3790	83	2	11	11	NUM
dpc-3790	83	3	months	month	NOUN
dpc-3790	83	4	of	of	ADP
dpc-3790	83	5	tofacitinib	tofacitinib	NOUN
dpc-3790	83	6	,	,	PUNCT
dpc-3790	83	7	he	he	PRON
dpc-3790	83	8	switched	switch	VERB
dpc-3790	83	9	to	to	ADP
dpc-3790	83	10	baricitinib	baricitinib	NOUN
dpc-3790	83	11	,	,	PUNCT
dpc-3790	83	12	due	due	ADP
dpc-3790	83	13	to	to	ADP
dpc-3790	83	14	lack	lack	NOUN
dpc-3790	83	15	of	of	ADP
dpc-3790	83	16	efficacy	efficacy	NOUN
dpc-3790	83	17	.	.	PUNCT
dpc-3790	84	1	five	five	NUM
dpc-3790	84	2	patients	patient	NOUN
dpc-3790	84	3	from	from	ADP
dpc-3790	84	4	the	the	DET
dpc-3790	84	5	tofacitinib	tofacitinib	PROPN
dpc-3790	84	6	group	group	NOUN
dpc-3790	84	7	received	receive	VERB
dpc-3790	84	8	a	a	DET
dpc-3790	84	9	maintenance	maintenance	NOUN
dpc-3790	84	10	dose	dose	NOUN
dpc-3790	84	11	of	of	ADP
dpc-3790	84	12	20	20	NUM
dpc-3790	84	13	mg	mg	NUM
dpc-3790	84	14	/	/	SYM
dpc-3790	84	15	day	day	NOUN
dpc-3790	84	16	,	,	PUNCT
dpc-3790	84	17	whilst	whilst	SCONJ
dpc-3790	84	18	17	17	NUM
dpc-3790	84	19	of	of	ADP
dpc-3790	84	20	them	they	PRON
dpc-3790	84	21	received	receive	VERB
dpc-3790	84	22	a	a	DET
dpc-3790	84	23	maintenance	maintenance	NOUN
dpc-3790	84	24	dose	dose	NOUN
dpc-3790	84	25	of	of	ADP
dpc-3790	84	26	10	10	NUM
dpc-3790	84	27	mg	mg	NUM
dpc-3790	84	28	/	/	SYM
dpc-3790	84	29	day	day	NOUN
dpc-3790	84	30	.	.	PUNCT
dpc-3790	85	1	for	for	ADP
dpc-3790	85	2	all	all	DET
dpc-3790	85	3	patients	patient	NOUN
dpc-3790	85	4	under	under	ADP
dpc-3790	85	5	tofacitinib	tofacitinib	PROPN
dpc-3790	85	6	the	the	DET
dpc-3790	85	7	maximum	maximum	PROPN
dpc-3790	85	8	dose	dose	NOUN
dpc-3790	85	9	was	be	AUX
dpc-3790	85	10	20	20	NUM
dpc-3790	85	11	mg	mg	NUM
dpc-3790	85	12	/	/	SYM
dpc-3790	85	13	day	day	NOUN
dpc-3790	85	14	for	for	ADP
dpc-3790	85	15	1	1	NUM
dpc-3790	85	16	-	-	SYM
dpc-3790	85	17	6	6	NUM
dpc-3790	85	18	months	month	NOUN
dpc-3790	85	19	,	,	PUNCT
dpc-3790	85	20	depending	depend	VERB
dpc-3790	85	21	on	on	ADP
dpc-3790	85	22	treatment	treatment	NOUN
dpc-3790	85	23	tolerance	tolerance	NOUN
dpc-3790	85	24	.	.	PUNCT
dpc-3790	86	1	the	the	DET
dpc-3790	86	2	maintenance	maintenance	NOUN
dpc-3790	86	3	dose	dose	NOUN
dpc-3790	86	4	was	be	AUX
dpc-3790	86	5	determined	determine	VERB
dpc-3790	86	6	by	by	ADP
dpc-3790	86	7	the	the	DET
dpc-3790	86	8	response	response	NOUN
dpc-3790	86	9	to	to	ADP
dpc-3790	86	10	treatment	treatment	NOUN
dpc-3790	86	11	and	and	CCONJ
dpc-3790	86	12	the	the	DET
dpc-3790	86	13	patient	patient	NOUN
dpc-3790	86	14	’s	’s	PART
dpc-3790	86	15	tolerance	tolerance	NOUN
dpc-3790	86	16	to	to	ADP
dpc-3790	86	17	the	the	DET
dpc-3790	86	18	drug	drug	NOUN
dpc-3790	86	19	.	.	PUNCT
dpc-3790	87	1	all	all	DET
dpc-3790	87	2	the	the	DET
dpc-3790	87	3	3	3	NUM
dpc-3790	87	4	adolescents	adolescent	NOUN
dpc-3790	87	5	that	that	PRON
dpc-3790	87	6	were	be	AUX
dpc-3790	87	7	treated	treat	VERB
dpc-3790	87	8	with	with	ADP
dpc-3790	87	9	tofacitinib	tofacitinib	NOUN
dpc-3790	87	10	,	,	PUNCT
dpc-3790	87	11	experienced	experience	VERB
dpc-3790	87	12	>	>	PUNCT
dpc-3790	87	13	90	90	NUM
dpc-3790	87	14	%	%	NOUN
dpc-3790	87	15	of	of	ADP
dpc-3790	87	16	hair	hair	NOUN
dpc-3790	87	17	regrowth	regrowth	NOUN
dpc-3790	87	18	.	.	PUNCT
dpc-3790	88	1	efficacy	efficacy	NOUN
dpc-3790	88	2	analysis	analysis	NOUN
dpc-3790	88	3	and	and	CCONJ
dpc-3790	88	4	correlations	correlation	NOUN
dpc-3790	88	5	efficacy	efficacy	NOUN
dpc-3790	88	6	analysis	analysis	NOUN
dpc-3790	88	7	was	be	AUX
dpc-3790	88	8	performed	perform	VERB
dpc-3790	88	9	on	on	ADP
dpc-3790	88	10	the	the	DET
dpc-3790	88	11	subgroup	subgroup	NOUN
dpc-3790	88	12	of	of	ADP
dpc-3790	88	13	30	30	NUM
dpc-3790	88	14	patients	patient	NOUN
dpc-3790	88	15	that	that	PRON
dpc-3790	88	16	had	have	AUX
dpc-3790	88	17	completed	complete	VERB
dpc-3790	88	18	at	at	ADP
dpc-3790	88	19	least	least	ADJ
dpc-3790	88	20	a	a	DET
dpc-3790	88	21	3	3	NUM
dpc-3790	88	22	-	-	PUNCT
dpc-3790	88	23	month	month	NOUN
dpc-3790	88	24	follow	follow	NOUN
dpc-3790	88	25	-	-	PUNCT
dpc-3790	88	26	up	up	NOUN
dpc-3790	88	27	on	on	ADP
dpc-3790	88	28	treatment	treatment	NOUN
dpc-3790	88	29	.	.	PUNCT
dpc-3790	89	1	the	the	DET
dpc-3790	89	2	rest	rest	NOUN
dpc-3790	89	3	twelve	twelve	NUM
dpc-3790	89	4	patients	patient	NOUN
dpc-3790	89	5	that	that	PRON
dpc-3790	89	6	had	have	AUX
dpc-3790	89	7	not	not	PART
dpc-3790	89	8	completed	complete	VERB
dpc-3790	89	9	the	the	DET
dpc-3790	89	10	first	first	ADJ
dpc-3790	89	11	3	3	NUM
dpc-3790	89	12	-	-	PUNCT
dpc-3790	89	13	month	month	NOUN
dpc-3790	89	14	follow	follow	NOUN
dpc-3790	89	15	-	-	PUNCT
dpc-3790	89	16	up	up	ADP
dpc-3790	89	17	visit	visit	NOUN
dpc-3790	89	18	were	be	AUX
dpc-3790	89	19	excluded	exclude	VERB
dpc-3790	89	20	,	,	PUNCT
dpc-3790	89	21	due	due	ADP
dpc-3790	89	22	to	to	ADP
dpc-3790	89	23	lack	lack	NOUN
dpc-3790	89	24	of	of	ADP
dpc-3790	89	25	efficacy	efficacy	NOUN
dpc-3790	89	26	data	datum	NOUN
dpc-3790	89	27	at	at	ADP
dpc-3790	89	28	this	this	DET
dpc-3790	89	29	time	time	NOUN
dpc-3790	89	30	point	point	NOUN
dpc-3790	89	31	.	.	PUNCT
dpc-3790	90	1	in	in	ADP
dpc-3790	90	2	the	the	DET
dpc-3790	90	3	30	30	NUM
dpc-3790	90	4	individuals	individual	NOUN
dpc-3790	90	5	analyzed	analyze	VERB
dpc-3790	90	6	,	,	PUNCT
dpc-3790	90	7	the	the	DET
dpc-3790	90	8	mean	mean	ADJ
dpc-3790	90	9	time	time	NOUN
dpc-3790	90	10	on	on	ADP
dpc-3790	90	11	treatment	treatment	NOUN
dpc-3790	90	12	was	be	AUX
dpc-3790	90	13	10	10	NUM
dpc-3790	90	14	months	month	NOUN
dpc-3790	90	15	.	.	PUNCT
dpc-3790	91	1	their	their	PRON
dpc-3790	91	2	mean	mean	ADJ
dpc-3790	91	3	salt	salt	NOUN
dpc-3790	91	4	and	and	CCONJ
dpc-3790	91	5	mean	mean	VERB
dpc-3790	91	6	dlqi	dlqi	PROPN
dpc-3790	91	7	scores	score	NOUN
dpc-3790	91	8	decreased	decrease	VERB
dpc-3790	91	9	from	from	ADP
dpc-3790	91	10	84.46	84.46	NUM
dpc-3790	91	11	%	%	NOUN
dpc-3790	91	12	and	and	CCONJ
dpc-3790	91	13	12.86	12.86	NUM
dpc-3790	91	14	at	at	ADP
dpc-3790	91	15	baseline	baseline	NOUN
dpc-3790	91	16	,	,	PUNCT
dpc-3790	91	17	to	to	ADP
dpc-3790	91	18	43.26	43.26	NUM
dpc-3790	91	19	%	%	NOUN
dpc-3790	91	20	and	and	CCONJ
dpc-3790	91	21	6.63	6.63	NUM
dpc-3790	91	22	,	,	PUNCT
dpc-3790	91	23	respectively	respectively	ADV
dpc-3790	91	24	.	.	PUNCT
dpc-3790	92	1	cr	cr	PROPN
dpc-3790	92	2	was	be	AUX
dpc-3790	92	3	recorded	record	VERB
dpc-3790	92	4	in	in	ADP
dpc-3790	92	5	4	4	NUM
dpc-3790	92	6	patients	patient	NOUN
dpc-3790	92	7	(	(	PUNCT
dpc-3790	92	8	13.33	13.33	NUM
dpc-3790	92	9	%	%	NOUN
dpc-3790	92	10	)	)	PUNCT
dpc-3790	92	11	,	,	PUNCT
dpc-3790	92	12	pr	pr	X
dpc-3790	92	13	in	in	ADP
dpc-3790	92	14	12	12	NUM
dpc-3790	92	15	patients	patient	NOUN
dpc-3790	92	16	(	(	PUNCT
dpc-3790	92	17	40	40	NUM
dpc-3790	92	18	%	%	NOUN
dpc-3790	92	19	)	)	PUNCT
dpc-3790	92	20	and	and	CCONJ
dpc-3790	92	21	no	no	DET
dpc-3790	92	22	response	response	NOUN
dpc-3790	92	23	in	in	ADP
dpc-3790	92	24	14	14	NUM
dpc-3790	92	25	patients	patient	NOUN
dpc-3790	92	26	(	(	PUNCT
dpc-3790	92	27	46.66	46.66	NUM
dpc-3790	92	28	%	%	NOUN
dpc-3790	92	29	)	)	PUNCT
dpc-3790	92	30	patients	patient	NOUN
dpc-3790	92	31	.	.	PUNCT
dpc-3790	92	32	  	  	SPACE
dpc-3790	93	1	figure	figure	NOUN
dpc-3790	93	2	1	1	NUM
dpc-3790	93	3	illustrates	illustrate	VERB
dpc-3790	93	4	clinical	clinical	ADJ
dpc-3790	93	5	examples	example	NOUN
dpc-3790	93	6	of	of	ADP
dpc-3790	93	7	the	the	DET
dpc-3790	93	8	three	three	NUM
dpc-3790	93	9	groups	group	NOUN
dpc-3790	93	10	.	.	PUNCT
dpc-3790	94	1	there	there	PRON
dpc-3790	94	2	was	be	VERB
dpc-3790	94	3	statistically	statistically	ADV
dpc-3790	94	4	significant	significant	ADJ
dpc-3790	94	5	difference	difference	NOUN
dpc-3790	94	6	in	in	ADP
dpc-3790	94	7	the	the	DET
dpc-3790	94	8	treatment	treatment	NOUN
dpc-3790	94	9	duration	duration	NOUN
dpc-3790	94	10	among	among	ADP
dpc-3790	94	11	the	the	DET
dpc-3790	94	12	3	3	NUM
dpc-3790	94	13	response	response	NOUN
dpc-3790	94	14	subgroups	subgroup	NOUN
dpc-3790	94	15	  	  	SPACE
dpc-3790	94	16	(	(	PUNCT
dpc-3790	94	17	p=	p=	NOUN
dpc-3790	94	18	0.002	0.002	NUM
dpc-3790	94	19	)	)	PUNCT
dpc-3790	94	20	.	.	PUNCT
dpc-3790	95	1	the	the	DET
dpc-3790	95	2	majority	majority	NOUN
dpc-3790	95	3	of	of	ADP
dpc-3790	95	4	non	non	PROPN
dpc-3790	95	5	responders	responder	NOUN
dpc-3790	95	6	(	(	PUNCT
dpc-3790	95	7	64.2	64.2	NUM
dpc-3790	95	8	%	%	NOUN
dpc-3790	95	9	)	)	PUNCT
dpc-3790	95	10	belonged	belong	VERB
dpc-3790	95	11	to	to	ADP
dpc-3790	95	12	the	the	DET
dpc-3790	95	13	group	group	NOUN
dpc-3790	95	14	of	of	ADP
dpc-3790	95	15	au	au	PROPN
dpc-3790	95	16	.	.	PUNCT
dpc-3790	96	1	no	no	DET
dpc-3790	96	2	statistically	statistically	ADV
dpc-3790	96	3	significant	significant	ADJ
dpc-3790	96	4	differences	difference	NOUN
dpc-3790	96	5	were	be	AUX
dpc-3790	96	6	observed	observe	VERB
dpc-3790	96	7	between	between	ADP
dpc-3790	96	8	sex	sex	NOUN
dpc-3790	96	9	and	and	CCONJ
dpc-3790	96	10	 	 	SPACE
dpc-3790	96	11	δsalt	δsalt	ADJ
dpc-3790	96	12	score	score	NOUN
dpc-3790	96	13	and	and	CCONJ
dpc-3790	96	14	thus	thus	ADV
dpc-3790	96	15	effectiveness	effectiveness	NOUN
dpc-3790	96	16	does	do	AUX
dpc-3790	96	17	not	not	PART
dpc-3790	96	18	appear	appear	VERB
dpc-3790	96	19	to	to	PART
dpc-3790	96	20	be	be	AUX
dpc-3790	96	21	related	relate	VERB
dpc-3790	96	22	to	to	ADP
dpc-3790	96	23	sex	sex	NOUN
dpc-3790	96	24	(	(	PUNCT
dpc-3790	96	25	p	p	X
dpc-3790	96	26	=	=	NOUN
dpc-3790	96	27	0.323	0.323	NUM
dpc-3790	96	28	,	,	PUNCT
dpc-3790	96	29	two	two	NUM
dpc-3790	96	30	-	-	PUNCT
dpc-3790	96	31	sided	sided	ADJ
dpc-3790	96	32	test	test	NOUN
dpc-3790	96	33	)	)	PUNCT
dpc-3790	96	34	.	.	PUNCT
dpc-3790	97	1	we	we	PRON
dpc-3790	97	2	divided	divide	VERB
dpc-3790	97	3	the	the	DET
dpc-3790	97	4	patients	patient	NOUN
dpc-3790	97	5	into	into	ADP
dpc-3790	97	6	three	three	NUM
dpc-3790	97	7	age	age	NOUN
dpc-3790	97	8	groups	group	NOUN
dpc-3790	97	9	(	(	PUNCT
dpc-3790	97	10	<	<	X
dpc-3790	97	11	25	25	NUM
dpc-3790	97	12	years	year	NOUN
dpc-3790	97	13	,	,	PUNCT
dpc-3790	97	14	25	25	NUM
dpc-3790	97	15	-	-	SYM
dpc-3790	97	16	50	50	NUM
dpc-3790	97	17	years	year	NOUN
dpc-3790	97	18	and	and	CCONJ
dpc-3790	97	19	>	>	X
dpc-3790	97	20	50	50	NUM
dpc-3790	97	21	years	year	NOUN
dpc-3790	97	22	)	)	PUNCT
dpc-3790	97	23	and	and	CCONJ
dpc-3790	97	24	we	we	PRON
dpc-3790	97	25	found	find	VERB
dpc-3790	97	26	no	no	DET
dpc-3790	97	27	statistical	statistical	ADJ
dpc-3790	97	28	correlation	correlation	NOUN
dpc-3790	97	29	between	between	ADP
dpc-3790	97	30	 	 	SPACE
dpc-3790	97	31	δsalt	δsalt	ADJ
dpc-3790	97	32	score	score	NOUN
dpc-3790	97	33	and	and	CCONJ
dpc-3790	97	34	age	age	NOUN
dpc-3790	97	35	(	(	PUNCT
dpc-3790	97	36	p=0.693	p=0.693	X
dpc-3790	97	37	)	)	PUNCT
dpc-3790	97	38	.	.	PUNCT
dpc-3790	97	39	 	 	SPACE
dpc-3790	98	1	δsalt	δsalt	ADJ
dpc-3790	98	2	score	score	NOUN
dpc-3790	98	3	did	do	AUX
dpc-3790	98	4	not	not	PART
dpc-3790	98	5	significantly	significantly	ADV
dpc-3790	98	6	differ	differ	VERB
dpc-3790	98	7	among	among	ADP
dpc-3790	98	8	the	the	DET
dpc-3790	98	9	7	7	NUM
dpc-3790	98	10	clinical	clinical	ADJ
dpc-3790	98	11	types	type	NOUN
dpc-3790	98	12	of	of	ADP
dpc-3790	98	13	alopecia	alopecia	NOUN
dpc-3790	98	14	areata	areata	ADJ
dpc-3790	98	15	(	(	PUNCT
dpc-3790	98	16	p	p	X
dpc-3790	98	17	=	=	NOUN
dpc-3790	98	18	0.207	0.207	NUM
dpc-3790	98	19	,	,	PUNCT
dpc-3790	98	20	the	the	DET
dpc-3790	98	21	significance	significance	NOUN
dpc-3790	98	22	level	level	NOUN
dpc-3790	98	23	is	be	AUX
dpc-3790	98	24	0.05	0.05	NUM
dpc-3790	98	25	)	)	PUNCT
dpc-3790	98	26	and	and	CCONJ
dpc-3790	98	27	was	be	AUX
dpc-3790	98	28	not	not	PART
dpc-3790	98	29	affected	affect	VERB
dpc-3790	98	30	by	by	ADP
dpc-3790	98	31	time	time	NOUN
dpc-3790	98	32	since	since	SCONJ
dpc-3790	98	33	the	the	DET
dpc-3790	98	34	last	last	ADJ
dpc-3790	98	35	episode	episode	NOUN
dpc-3790	98	36	of	of	ADP
dpc-3790	98	37	aa	aa	NOUN
dpc-3790	98	38	(	(	PUNCT
dpc-3790	98	39	rs	rs	NOUN
dpc-3790	98	40	:	:	PUNCT
dpc-3790	98	41	0.373	0.373	NUM
dpc-3790	98	42	,	,	PUNCT
dpc-3790	98	43	p	p	X
dpc-3790	98	44	>	>	X
dpc-3790	98	45	0.05	0.05	NUM
dpc-3790	98	46	)	)	PUNCT
dpc-3790	98	47	.	.	PUNCT
dpc-3790	99	1	all	all	DET
dpc-3790	99	2	performed	perform	VERB
dpc-3790	99	3	correlations	correlation	NOUN
dpc-3790	99	4	are	be	AUX
dpc-3790	99	5	presented	present	VERB
dpc-3790	99	6	in	in	ADP
dpc-3790	99	7	table	table	NOUN
dpc-3790	99	8	2	2	NUM
dpc-3790	99	9	.	.	PUNCT
dpc-3790	99	10	table	table	NOUN
dpc-3790	99	11	2	2	NUM
dpc-3790	99	12	.	.	PUNCT
dpc-3790	99	13	correlations	correlation	NOUN
dpc-3790	99	14	and	and	CCONJ
dpc-3790	99	15	non	non	ADJ
dpc-3790	99	16	-	-	ADJ
dpc-3790	99	17	parametric	parametric	ADJ
dpc-3790	99	18	tests	test	NOUN
dpc-3790	99	19	correlations	correlation	VERB
dpc-3790	99	20	p	p	NOUN
dpc-3790	99	21	-	-	PUNCT
dpc-3790	99	22	value	value	NOUN
dpc-3790	99	23	δsalt	δsalt	NOUN
dpc-3790	99	24	score	score	NOUN
dpc-3790	99	25	and	and	CCONJ
dpc-3790	99	26	patient	patient	ADJ
dpc-3790	99	27	age	age	NOUN
dpc-3790	99	28	rs	rs	NOUN
dpc-3790	99	29	:	:	PUNCT
dpc-3790	99	30	0.596	0.596	NUM
dpc-3790	99	31	,	,	PUNCT
dpc-3790	99	32	p>0.05	p>0.05	NOUN
dpc-3790	99	33	δsalt	δsalt	ADJ
dpc-3790	99	34	score	score	NOUN
dpc-3790	99	35	and	and	CCONJ
dpc-3790	99	36	patient	patient	ADJ
dpc-3790	99	37	age	age	NOUN
dpc-3790	99	38	(	(	PUNCT
dpc-3790	99	39	among	among	ADP
dpc-3790	99	40	the	the	DET
dpc-3790	99	41	3	3	NUM
dpc-3790	99	42	age	age	NOUN
dpc-3790	99	43	groups	group	NOUN
dpc-3790	99	44	)	)	PUNCT
dpc-3790	100	1	p	p	X
dpc-3790	100	2	=	=	PUNCT
dpc-3790	100	3	0.693	0.693	NUM
dpc-3790	100	4	δsalt	δsalt	NOUN
dpc-3790	100	5	score	score	NOUN
dpc-3790	100	6	and	and	CCONJ
dpc-3790	100	7	clinical	clinical	ADJ
dpc-3790	100	8	types	type	NOUN
dpc-3790	100	9	of	of	ADP
dpc-3790	100	10	aa	aa	NOUN
dpc-3790	100	11	p	p	NOUN
dpc-3790	100	12	=	=	PROPN
dpc-3790	100	13	0.207	0.207	NUM
dpc-3790	100	14	δsalt	δsalt	ADJ
dpc-3790	100	15	score	score	NOUN
dpc-3790	100	16	and	and	CCONJ
dpc-3790	100	17	time	time	NOUN
dpc-3790	100	18	since	since	SCONJ
dpc-3790	100	19	last	last	ADJ
dpc-3790	100	20	episode	episode	NOUN
dpc-3790	100	21	of	of	ADP
dpc-3790	100	22	aa	aa	PROPN
dpc-3790	100	23	rs	rs	NOUN
dpc-3790	100	24	:	:	PUNCT
dpc-3790	100	25	0.373	0.373	NUM
dpc-3790	100	26	,	,	PUNCT
dpc-3790	100	27	p>0.05	p>0.05	ADJ
dpc-3790	100	28	clinical	clinical	ADJ
dpc-3790	100	29	response	response	NOUN
dpc-3790	100	30	and	and	CCONJ
dpc-3790	100	31	treatment	treatment	NOUN
dpc-3790	100	32	duration	duration	NOUN
dpc-3790	100	33	p	p	X
dpc-3790	100	34	=	=	NOUN
dpc-3790	100	35	0.002	0.002	NUM
dpc-3790	100	36	aa	aa	NOUN
dpc-3790	100	37	=	=	ADJ
dpc-3790	100	38	aa	aa	NOUN
dpc-3790	100	39	:	:	PUNCT
dpc-3790	100	40	alopecia	alopecia	NOUN
dpc-3790	100	41	areata	areata	NOUN
dpc-3790	100	42	;	;	PUNCT
dpc-3790	100	43	salt	salt	NOUN
dpc-3790	100	44	=	=	SYM
dpc-3790	100	45	severity	severity	NOUN
dpc-3790	100	46	of	of	ADP
dpc-3790	100	47	alopecia	alopecia	NOUN
dpc-3790	100	48	tool	tool	NOUN
dpc-3790	100	49	.	.	PUNCT
dpc-3790	101	1	original	original	ADJ
dpc-3790	101	2	article	article	NOUN
dpc-3790	101	3	|	|	ADV
dpc-3790	101	4	dermatol	dermatol	ADJ
dpc-3790	101	5	pract	pract	NOUN
dpc-3790	101	6	concept	concept	NOUN
dpc-3790	101	7	.	.	PUNCT
dpc-3790	102	1	2024;14(2):e2024073	2024;14(2):e2024073	NUM
dpc-3790	102	2	5	5	NUM
dpc-3790	102	3	table	table	NOUN
dpc-3790	102	4	3	3	NUM
dpc-3790	102	5	.	.	PUNCT
dpc-3790	103	1	the	the	DET
dpc-3790	103	2	most	most	ADV
dpc-3790	103	3	common	common	ADJ
dpc-3790	103	4	adverse	adverse	ADJ
dpc-3790	103	5	events	event	NOUN
dpc-3790	103	6	in	in	ADP
dpc-3790	103	7	patients	patient	NOUN
dpc-3790	103	8	with	with	ADP
dpc-3790	103	9	alopecia	alopecia	NOUN
dpc-3790	103	10	areata	areata	PROPN
dpc-3790	103	11	treated	treat	VERB
dpc-3790	103	12	with	with	ADP
dpc-3790	103	13	baricitinib	baricitinib	NOUN
dpc-3790	103	14	and	and	CCONJ
dpc-3790	103	15	tofacitinib	tofacitinib	NOUN
dpc-3790	103	16	in	in	ADP
dpc-3790	103	17	our	our	PRON
dpc-3790	103	18	cohort	cohort	NOUN
dpc-3790	103	19	type	type	NOUN
dpc-3790	103	20	of	of	ADP
dpc-3790	103	21	adverse	adverse	ADJ
dpc-3790	103	22	event	event	NOUN
dpc-3790	103	23	percentage	percentage	NOUN
dpc-3790	103	24	(	(	PUNCT
dpc-3790	103	25	%	%	NOUN
dpc-3790	103	26	)	)	PUNCT
dpc-3790	103	27	elevated	elevated	ADJ
dpc-3790	103	28	liver	liver	NOUN
dpc-3790	103	29	enzymes	enzyme	NOUN
dpc-3790	103	30	and	and	CCONJ
dpc-3790	103	31	lipid	lipid	NOUN
dpc-3790	103	32	elevation	elevation	NOUN
dpc-3790	103	33	4.7	4.7	NUM
dpc-3790	103	34	lipid	lipid	NOUN
dpc-3790	103	35	elevation	elevation	NOUN
dpc-3790	103	36	9.5	9.5	NUM
dpc-3790	103	37	covid-19	covid-19	PROPN
dpc-3790	103	38	infection	infection	NOUN
dpc-3790	103	39	•	•	NOUN
dpc-3790	103	40	mild	mild	ADJ
dpc-3790	103	41	symptoms	symptom	NOUN
dpc-3790	103	42	•	•	ADP
dpc-3790	103	43	moderate	moderate	ADJ
dpc-3790	103	44	symptoms	symptom	NOUN
dpc-3790	103	45	•	•	VERB
dpc-3790	103	46	serious	serious	ADJ
dpc-3790	103	47	symptoms	symptom	NOUN
dpc-3790	103	48	•	•	ADV
dpc-3790	103	49	asymptomatic	asymptomatic	ADJ
dpc-3790	103	50	35.7	35.7	NUM
dpc-3790	103	51	19.0	19.0	NUM
dpc-3790	103	52	9.5	9.5	NUM
dpc-3790	103	53	2.3	2.3	NUM
dpc-3790	103	54	4.7	4.7	NUM
dpc-3790	103	55	herpes	herpe	NOUN
dpc-3790	103	56	zoster	zoster	NOUN
dpc-3790	103	57	and	and	CCONJ
dpc-3790	103	58	herpes	herpe	NOUN
dpc-3790	103	59	simplex	simplex	NOUN
dpc-3790	103	60	2.3	2.3	NUM
dpc-3790	103	61	none	none	NOUN
dpc-3790	103	62	59.5	59.5	NUM
dpc-3790	103	63	safety	safety	NOUN
dpc-3790	103	64	outcomes	outcome	NOUN
dpc-3790	103	65	twenty	twenty	NUM
dpc-3790	103	66	five	five	NUM
dpc-3790	103	67	out	out	ADP
dpc-3790	103	68	of	of	ADP
dpc-3790	103	69	42	42	NUM
dpc-3790	103	70	(	(	PUNCT
dpc-3790	103	71	59.5	59.5	NUM
dpc-3790	103	72	%	%	NOUN
dpc-3790	103	73	)	)	PUNCT
dpc-3790	103	74	individuals	individual	NOUN
dpc-3790	103	75	experienced	experience	VERB
dpc-3790	103	76	no	no	DET
dpc-3790	103	77	adverse	adverse	ADJ
dpc-3790	103	78	events	event	NOUN
dpc-3790	103	79	(	(	PUNCT
dpc-3790	103	80	ae	ae	PROPN
dpc-3790	103	81	)	)	PUNCT
dpc-3790	103	82	,	,	PUNCT
dpc-3790	103	83	whilst	whilst	SCONJ
dpc-3790	103	84	17/42	17/42	NUM
dpc-3790	103	85	(	(	PUNCT
dpc-3790	103	86	40.5	40.5	NUM
dpc-3790	103	87	%	%	NOUN
dpc-3790	103	88	)	)	PUNCT
dpc-3790	103	89	reported	report	VERB
dpc-3790	103	90	at	at	ADP
dpc-3790	103	91	least	least	ADV
dpc-3790	103	92	1	1	NUM
dpc-3790	103	93	ae	ae	PROPN
dpc-3790	103	94	,	,	PUNCT
dpc-3790	103	95	during	during	ADP
dpc-3790	103	96	jaki	jaki	PROPN
dpc-3790	103	97	treatment	treatment	PROPN
dpc-3790	103	98	.	.	PUNCT
dpc-3790	104	1	thirteen	thirteen	NUM
dpc-3790	104	2	patients	patient	NOUN
dpc-3790	104	3	(	(	PUNCT
dpc-3790	104	4	30.9	30.9	NUM
dpc-3790	104	5	%	%	NOUN
dpc-3790	104	6	)	)	PUNCT
dpc-3790	104	7	presented	present	VERB
dpc-3790	104	8	with	with	ADP
dpc-3790	104	9	one	one	NUM
dpc-3790	104	10	ae	ae	PROPN
dpc-3790	104	11	,	,	PUNCT
dpc-3790	104	12	7.1	7.1	NUM
dpc-3790	104	13	%	%	NOUN
dpc-3790	104	14	(	(	PUNCT
dpc-3790	104	15	3/42	3/42	NUM
dpc-3790	104	16	)	)	PUNCT
dpc-3790	104	17	presented	present	VERB
dpc-3790	104	18	with	with	ADP
dpc-3790	104	19	two	two	NUM
dpc-3790	104	20	and	and	CCONJ
dpc-3790	104	21	2.3	2.3	NUM
dpc-3790	104	22	%	%	NOUN
dpc-3790	104	23	(	(	PUNCT
dpc-3790	104	24	1/42	1/42	NUM
dpc-3790	104	25	)	)	PUNCT
dpc-3790	104	26	presented	present	VERB
dpc-3790	104	27	with	with	ADP
dpc-3790	104	28	three	three	NUM
dpc-3790	104	29	ae	ae	PROPN
dpc-3790	104	30	.	.	PUNCT
dpc-3790	105	1	no	no	DET
dpc-3790	105	2	patient	patient	NOUN
dpc-3790	105	3	required	require	VERB
dpc-3790	105	4	hospitalization	hospitalization	NOUN
dpc-3790	105	5	for	for	ADP
dpc-3790	105	6	jaki	jaki	NOUN
dpc-3790	105	7	-	-	PUNCT
dpc-3790	105	8	related	relate	VERB
dpc-3790	105	9	ae	ae	PROPN
dpc-3790	105	10	.	.	PUNCT
dpc-3790	106	1	fifteen	fifteen	NUM
dpc-3790	106	2	patients	patient	NOUN
dpc-3790	106	3	(	(	PUNCT
dpc-3790	106	4	35.7	35.7	NUM
dpc-3790	106	5	%	%	NOUN
dpc-3790	106	6	)	)	PUNCT
dpc-3790	106	7	got	get	VERB
dpc-3790	106	8	covid-19	covid-19	PROPN
dpc-3790	106	9	infection	infection	NOUN
dpc-3790	106	10	during	during	ADP
dpc-3790	106	11	treatment	treatment	NOUN
dpc-3790	106	12	.	.	PUNCT
dpc-3790	107	1	among	among	ADP
dpc-3790	107	2	them	they	PRON
dpc-3790	107	3	,	,	PUNCT
dpc-3790	107	4	two	two	NUM
dpc-3790	107	5	out	out	ADP
dpc-3790	107	6	of	of	ADP
dpc-3790	107	7	42	42	NUM
dpc-3790	107	8	(	(	PUNCT
dpc-3790	107	9	4.7	4.7	NUM
dpc-3790	107	10	%	%	NOUN
dpc-3790	107	11	)	)	PUNCT
dpc-3790	107	12	individuals	individual	NOUN
dpc-3790	107	13	were	be	AUX
dpc-3790	107	14	totally	totally	ADV
dpc-3790	107	15	asymptomatic	asymptomatic	ADJ
dpc-3790	107	16	,	,	PUNCT
dpc-3790	107	17	8/42	8/42	NUM
dpc-3790	107	18	(	(	PUNCT
dpc-3790	107	19	19	19	NUM
dpc-3790	107	20	%	%	NOUN
dpc-3790	107	21	)	)	PUNCT
dpc-3790	107	22	presented	present	VERB
dpc-3790	107	23	with	with	ADP
dpc-3790	107	24	mild	mild	ADJ
dpc-3790	107	25	infection	infection	NOUN
dpc-3790	107	26	(	(	PUNCT
dpc-3790	107	27	fever	fever	NOUN
dpc-3790	107	28	up	up	ADP
dpc-3790	107	29	to	to	ADP
dpc-3790	107	30	37.5oc	37.5oc	NUM
dpc-3790	107	31	,	,	PUNCT
dpc-3790	107	32	myalgia	myalgia	NOUN
dpc-3790	107	33	,	,	PUNCT
dpc-3790	107	34	weakness	weakness	NOUN
dpc-3790	107	35	and	and	CCONJ
dpc-3790	107	36	cough	cough	NOUN
dpc-3790	107	37	)	)	PUNCT
dpc-3790	107	38	and	and	CCONJ
dpc-3790	107	39	4/42	4/42	NUM
dpc-3790	107	40	(	(	PUNCT
dpc-3790	107	41	9.5	9.5	NUM
dpc-3790	107	42	%	%	NOUN
dpc-3790	107	43	)	)	PUNCT
dpc-3790	107	44	presented	present	VERB
dpc-3790	107	45	with	with	ADP
dpc-3790	107	46	moderate	moderate	ADJ
dpc-3790	107	47	symptom	symptom	NOUN
dpc-3790	107	48	(	(	PUNCT
dpc-3790	107	49	fever	fever	NOUN
dpc-3790	107	50	up	up	ADP
dpc-3790	107	51	to	to	ADP
dpc-3790	107	52	38.5oc	38.5oc	NUM
dpc-3790	107	53	for	for	ADP
dpc-3790	107	54	2	2	NUM
dpc-3790	107	55	days	day	NOUN
dpc-3790	107	56	,	,	PUNCT
dpc-3790	107	57	weakness	weakness	NOUN
dpc-3790	107	58	and	and	CCONJ
dpc-3790	107	59	sore	sore	ADJ
dpc-3790	107	60	throat	throat	NOUN
dpc-3790	107	61	)	)	PUNCT
dpc-3790	107	62	.	.	PUNCT
dpc-3790	108	1	one	one	NUM
dpc-3790	108	2	individual	individual	NOUN
dpc-3790	108	3	(	(	PUNCT
dpc-3790	108	4	2.3	2.3	NUM
dpc-3790	108	5	%	%	NOUN
dpc-3790	108	6	)	)	PUNCT
dpc-3790	108	7	suffered	suffer	VERB
dpc-3790	108	8	from	from	ADP
dpc-3790	108	9	serious	serious	ADJ
dpc-3790	108	10	covid-19	covid-19	PROPN
dpc-3790	108	11	disease	disease	NOUN
dpc-3790	108	12	(	(	PUNCT
dpc-3790	108	13	fever	fever	NOUN
dpc-3790	108	14	up	up	ADP
dpc-3790	108	15	to	to	ADP
dpc-3790	108	16	40oc	40oc	PROPN
dpc-3790	108	17	for	for	ADP
dpc-3790	108	18	3	3	NUM
dpc-3790	108	19	days	day	NOUN
dpc-3790	108	20	,	,	PUNCT
dpc-3790	108	21	headache	headache	NOUN
dpc-3790	108	22	,	,	PUNCT
dpc-3790	108	23	cough	cough	NOUN
dpc-3790	108	24	,	,	PUNCT
dpc-3790	108	25	weakness	weakness	NOUN
dpc-3790	108	26	)	)	PUNCT
dpc-3790	108	27	.	.	PUNCT
dpc-3790	109	1	it	it	PRON
dpc-3790	109	2	is	be	AUX
dpc-3790	109	3	of	of	ADP
dpc-3790	109	4	particular	particular	ADJ
dpc-3790	109	5	importance	importance	NOUN
dpc-3790	109	6	to	to	PART
dpc-3790	109	7	report	report	VERB
dpc-3790	109	8	that	that	SCONJ
dpc-3790	109	9	the	the	DET
dpc-3790	109	10	3	3	NUM
dpc-3790	109	11	adolescent	adolescent	ADJ
dpc-3790	109	12	patients	patient	NOUN
dpc-3790	109	13	did	do	AUX
dpc-3790	109	14	not	not	PART
dpc-3790	109	15	experience	experience	VERB
dpc-3790	109	16	any	any	DET
dpc-3790	109	17	kind	kind	NOUN
dpc-3790	109	18	of	of	ADP
dpc-3790	109	19	ae	ae	PROPN
dpc-3790	109	20	or	or	CCONJ
dpc-3790	109	21	laboratory	laboratory	NOUN
dpc-3790	109	22	abnormalities	abnormality	NOUN
dpc-3790	109	23	,	,	PUNCT
dpc-3790	109	24	except	except	SCONJ
dpc-3790	109	25	of	of	ADP
dpc-3790	109	26	persistent	persistent	ADJ
dpc-3790	109	27	common	common	ADJ
dpc-3790	109	28	warts	wart	NOUN
dpc-3790	109	29	in	in	ADP
dpc-3790	109	30	one	one	NUM
dpc-3790	109	31	of	of	ADP
dpc-3790	109	32	them	they	PRON
dpc-3790	109	33	.	.	PUNCT
dpc-3790	110	1	table	table	NOUN
dpc-3790	110	2	3	3	NUM
dpc-3790	110	3	summarizes	summarize	NOUN
dpc-3790	110	4	the	the	DET
dpc-3790	110	5	aes	aes	NOUN
dpc-3790	110	6	observed	observe	VERB
dpc-3790	110	7	in	in	ADP
dpc-3790	110	8	our	our	PRON
dpc-3790	110	9	cohort	cohort	NOUN
dpc-3790	110	10	.	.	PUNCT
dpc-3790	111	1	conclusions	conclusion	NOUN
dpc-3790	111	2	severe	severe	ADJ
dpc-3790	111	3	aa	aa	NOUN
dpc-3790	111	4	is	be	AUX
dpc-3790	111	5	a	a	DET
dpc-3790	111	6	challenging	challenging	ADJ
dpc-3790	111	7	-	-	PUNCT
dpc-3790	111	8	to	to	ADP
dpc-3790	111	9	-	-	PUNCT
dpc-3790	111	10	treat	treat	VERB
dpc-3790	111	11	immune	immune	ADJ
dpc-3790	111	12	mediated	mediate	VERB
dpc-3790	111	13	disorder	disorder	NOUN
dpc-3790	111	14	,	,	PUNCT
dpc-3790	111	15	characterized	characterize	VERB
dpc-3790	111	16	by	by	ADP
dpc-3790	111	17	treatment	treatment	NOUN
dpc-3790	111	18	resistance	resistance	NOUN
dpc-3790	111	19	and	and	CCONJ
dpc-3790	111	20	high	high	ADJ
dpc-3790	111	21	recurrence	recurrence	NOUN
dpc-3790	111	22	rate	rate	NOUN
dpc-3790	111	23	.	.	PUNCT
dpc-3790	112	1	until	until	ADP
dpc-3790	112	2	recently	recently	ADV
dpc-3790	112	3	,	,	PUNCT
dpc-3790	112	4	there	there	PRON
dpc-3790	112	5	were	be	VERB
dpc-3790	112	6	no	no	DET
dpc-3790	112	7	safe	safe	ADJ
dpc-3790	112	8	and	and	CCONJ
dpc-3790	112	9	effective	effective	ADJ
dpc-3790	112	10	treatments	treatment	NOUN
dpc-3790	112	11	for	for	ADP
dpc-3790	112	12	aa	aa	NOUN
dpc-3790	112	13	that	that	PRON
dpc-3790	112	14	could	could	AUX
dpc-3790	112	15	offer	offer	VERB
dpc-3790	112	16	consistent	consistent	ADJ
dpc-3790	112	17	and	and	CCONJ
dpc-3790	112	18	long	long	ADV
dpc-3790	112	19	lasting	last	VERB
dpc-3790	112	20	results	result	NOUN
dpc-3790	112	21	.	.	PUNCT
dpc-3790	113	1	topical	topical	ADJ
dpc-3790	113	2	,	,	PUNCT
dpc-3790	113	3	intralesional	intralesional	ADJ
dpc-3790	113	4	and	and	CCONJ
dpc-3790	113	5	systemic	systemic	ADJ
dpc-3790	113	6	treatment	treatment	NOUN
dpc-3790	113	7	with	with	ADP
dpc-3790	113	8	corticosteroids	corticosteroid	NOUN
dpc-3790	113	9	,	,	PUNCT
dpc-3790	113	10	contact	contact	NOUN
dpc-3790	113	11	immunotherapy	immunotherapy	NOUN
dpc-3790	113	12	,	,	PUNCT
dpc-3790	113	13	and	and	CCONJ
dpc-3790	113	14	systemic	systemic	ADJ
dpc-3790	113	15	immunomodulating	immunomodulating	ADJ
dpc-3790	113	16	drugs	drug	NOUN
dpc-3790	113	17	as	as	ADP
dpc-3790	113	18	cyclosporine	cyclosporine	NOUN
dpc-3790	113	19	,	,	PUNCT
dpc-3790	113	20	methotrexate	methotrexate	NOUN
dpc-3790	113	21	and	and	CCONJ
dpc-3790	113	22	azathioprine	azathioprine	PROPN
dpc-3790	113	23	have	have	AUX
dpc-3790	113	24	been	be	AUX
dpc-3790	113	25	administered	administer	VERB
dpc-3790	113	26	with	with	ADP
dpc-3790	113	27	variable	variable	ADJ
dpc-3790	113	28	efficacy	efficacy	NOUN
dpc-3790	113	29	outcomes	outcome	NOUN
dpc-3790	113	30	,	,	PUNCT
dpc-3790	113	31	although	although	SCONJ
dpc-3790	113	32	the	the	DET
dpc-3790	113	33	abovementioned	abovementione	VERB
dpc-3790	113	34	agents	agent	NOUN
dpc-3790	113	35	are	be	AUX
dpc-3790	113	36	used	use	VERB
dpc-3790	113	37	as	as	ADP
dpc-3790	113	38	off	off	ADP
dpc-3790	113	39	label	label	NOUN
dpc-3790	113	40	treatments	treatment	NOUN
dpc-3790	113	41	in	in	ADP
dpc-3790	113	42	cases	case	NOUN
dpc-3790	113	43	of	of	ADP
dpc-3790	113	44	aa	aa	NOUN
dpc-3790	114	1	[	[	X
dpc-3790	114	2	6	6	NUM
dpc-3790	114	3	]	]	PUNCT
dpc-3790	114	4	.	.	PUNCT
dpc-3790	115	1	in	in	ADP
dpc-3790	115	2	the	the	DET
dpc-3790	115	3	last	last	ADJ
dpc-3790	115	4	years	year	NOUN
dpc-3790	115	5	,	,	PUNCT
dpc-3790	115	6	several	several	ADJ
dpc-3790	115	7	studies	study	NOUN
dpc-3790	115	8	on	on	ADP
dpc-3790	115	9	  	  	SPACE
dpc-3790	115	10	tofacitinib	tofacitinib	NOUN
dpc-3790	115	11	,	,	PUNCT
dpc-3790	115	12	baricitinib	baricitinib	NOUN
dpc-3790	115	13	and	and	CCONJ
dpc-3790	115	14	other	other	ADJ
dpc-3790	115	15	jak	jak	PROPN
dpc-3790	115	16	inhibitors	inhibitor	NOUN
dpc-3790	115	17	have	have	AUX
dpc-3790	115	18	demonstrated	demonstrate	VERB
dpc-3790	115	19	encouraging	encourage	VERB
dpc-3790	115	20	outcomes	outcome	NOUN
dpc-3790	115	21	[	[	X
dpc-3790	115	22	7	7	NUM
dpc-3790	115	23	]	]	PUNCT
dpc-3790	115	24	.	.	PUNCT
dpc-3790	115	25	 	 	SPACE
dpc-3790	115	26	tofacitinib	tofacitinib	NOUN
dpc-3790	115	27	and	and	CCONJ
dpc-3790	115	28	baricitinib	baricitinib	NOUN
dpc-3790	115	29	showed	show	VERB
dpc-3790	115	30	to	to	PART
dpc-3790	115	31	be	be	AUX
dpc-3790	115	32	effective	effective	ADJ
dpc-3790	115	33	and	and	CCONJ
dpc-3790	115	34	well	well	ADV
dpc-3790	115	35	-	-	PUNCT
dpc-3790	115	36	tolerated	tolerate	VERB
dpc-3790	115	37	also	also	ADV
dpc-3790	115	38	in	in	ADP
dpc-3790	115	39	our	our	PRON
dpc-3790	115	40	cases	case	NOUN
dpc-3790	115	41	of	of	ADP
dpc-3790	115	42	aa	aa	NOUN
dpc-3790	115	43	,	,	PUNCT
dpc-3790	115	44	achieving	achieve	VERB
dpc-3790	115	45	almost	almost	ADV
dpc-3790	115	46	50	50	NUM
dpc-3790	115	47	%	%	NOUN
dpc-3790	115	48	reduction	reduction	NOUN
dpc-3790	115	49	in	in	ADP
dpc-3790	115	50	the	the	DET
dpc-3790	115	51	mean	mean	ADJ
dpc-3790	115	52	salt	salt	NOUN
dpc-3790	115	53	score	score	NOUN
dpc-3790	115	54	.	.	PUNCT
dpc-3790	116	1	furthermore	furthermore	ADV
dpc-3790	116	2	,	,	PUNCT
dpc-3790	116	3	16/30	16/30	NUM
dpc-3790	116	4	patients	patient	NOUN
dpc-3790	116	5	responded	respond	VERB
dpc-3790	116	6	to	to	ADP
dpc-3790	116	7	treatment	treatment	NOUN
dpc-3790	116	8	,	,	PUNCT
dpc-3790	116	9	and	and	CCONJ
dpc-3790	116	10	13.33	13.33	NUM
dpc-3790	116	11	%	%	NOUN
dpc-3790	116	12	achieved	achieve	VERB
dpc-3790	116	13	an	an	DET
dpc-3790	116	14	improvement	improvement	NOUN
dpc-3790	116	15	in	in	ADP
dpc-3790	116	16	the	the	DET
dpc-3790	116	17	salt	salt	NOUN
dpc-3790	116	18	score	score	NOUN
dpc-3790	116	19	of	of	ADP
dpc-3790	116	20	>	>	PROPN
dpc-3790	116	21	90	90	NUM
dpc-3790	116	22	%	%	NOUN
dpc-3790	116	23	.	.	PUNCT
dpc-3790	117	1	similar	similar	ADJ
dpc-3790	117	2	results	result	NOUN
dpc-3790	117	3	were	be	AUX
dpc-3790	117	4	recorded	record	VERB
dpc-3790	117	5	by	by	ADP
dpc-3790	117	6	kenedy	kenedy	PROPN
dpc-3790	117	7	crispin	crispin	PROPN
dpc-3790	117	8	et	et	PROPN
dpc-3790	117	9	al	al	PROPN
dpc-3790	117	10	in	in	ADP
dpc-3790	117	11	an	an	DET
dpc-3790	117	12	openlabel	openlabel	NOUN
dpc-3790	117	13	study	study	NOUN
dpc-3790	117	14	,	,	PUNCT
dpc-3790	117	15	evaluating	evaluate	VERB
dpc-3790	117	16	the	the	DET
dpc-3790	117	17	use	use	NOUN
dpc-3790	117	18	of	of	ADP
dpc-3790	117	19	oral	oral	ADJ
dpc-3790	117	20	tofacitinib	tofacitinib	NOUN
dpc-3790	117	21	and	and	CCONJ
dpc-3790	117	22	reporting	report	VERB
dpc-3790	117	23	64	64	NUM
dpc-3790	117	24	%	%	NOUN
dpc-3790	117	25	of	of	ADP
dpc-3790	117	26	patients	patient	NOUN
dpc-3790	117	27	responding	respond	VERB
dpc-3790	117	28	to	to	ADP
dpc-3790	117	29	the	the	DET
dpc-3790	117	30	therapy	therapy	NOUN
dpc-3790	117	31	and	and	CCONJ
dpc-3790	117	32	32	32	NUM
dpc-3790	117	33	%	%	NOUN
dpc-3790	117	34	of	of	ADP
dpc-3790	117	35	them	they	PRON
dpc-3790	117	36	achieving	achieve	VERB
dpc-3790	117	37	a	a	DET
dpc-3790	117	38	salt	salt	NOUN
dpc-3790	117	39	score	score	NOUN
dpc-3790	117	40	reduction	reduction	NOUN
dpc-3790	117	41	>	>	PUNCT
dpc-3790	117	42	50	50	NUM
dpc-3790	117	43	%	%	NOUN
dpc-3790	117	44	.	.	PUNCT
dpc-3790	118	1	accordingly	accordingly	ADV
dpc-3790	118	2	,	,	PUNCT
dpc-3790	118	3	liu	liu	PROPN
dpc-3790	118	4	et	et	PROPN
dpc-3790	118	5	  	  	SPACE
dpc-3790	118	6	al	al	PROPN
dpc-3790	118	7	report	report	PROPN
dpc-3790	118	8	>	>	PUNCT
dpc-3790	118	9	50	50	NUM
dpc-3790	118	10	%	%	NOUN
dpc-3790	118	11	improvement	improvement	NOUN
dpc-3790	118	12	in	in	ADP
dpc-3790	118	13	salt	salt	NOUN
dpc-3790	118	14	score	score	NOUN
dpc-3790	118	15	in	in	ADP
dpc-3790	118	16	42	42	NUM
dpc-3790	118	17	%	%	NOUN
dpc-3790	118	18	of	of	ADP
dpc-3790	118	19	their	their	PRON
dpc-3790	118	20	patients	patient	NOUN
dpc-3790	118	21	[	[	X
dpc-3790	118	22	8	8	NUM
dpc-3790	118	23	]	]	PUNCT
dpc-3790	118	24	.	.	PUNCT
dpc-3790	119	1	similar	similar	ADJ
dpc-3790	119	2	,	,	PUNCT
dpc-3790	119	3	were	be	AUX
dpc-3790	119	4	the	the	DET
dpc-3790	119	5	results	result	NOUN
dpc-3790	119	6	from	from	ADP
dpc-3790	119	7	the	the	DET
dpc-3790	119	8	brave	brave	ADJ
dpc-3790	119	9	-	-	PUNCT
dpc-3790	119	10	aa1	aa1	PROPN
dpc-3790	119	11	and	and	CCONJ
dpc-3790	119	12	brave	brave	ADJ
dpc-3790	119	13	-	-	PUNCT
dpc-3790	119	14	aa2	aa2	NOUN
dpc-3790	119	15	clinical	clinical	ADJ
dpc-3790	119	16	trials	trial	NOUN
dpc-3790	119	17	where	where	SCONJ
dpc-3790	119	18	19.7	19.7	NUM
dpc-3790	119	19	%	%	NOUN
dpc-3790	119	20	and	and	CCONJ
dpc-3790	119	21	34	34	NUM
dpc-3790	119	22	%	%	NOUN
dpc-3790	119	23	of	of	ADP
dpc-3790	119	24	patients	patient	NOUN
dpc-3790	119	25	achieving	achieve	VERB
dpc-3790	119	26	salt≤20	salt≤20	SCONJ
dpc-3790	119	27	in	in	ADP
dpc-3790	119	28	the	the	DET
dpc-3790	119	29	2	2	NUM
dpc-3790	119	30	and	and	CCONJ
dpc-3790	119	31	4	4	NUM
dpc-3790	119	32	mg	mg	NOUN
dpc-3790	119	33	baricitinib	baricitinib	NOUN
dpc-3790	119	34	arms	arm	NOUN
dpc-3790	119	35	,	,	PUNCT
dpc-3790	119	36	respectively	respectively	ADV
dpc-3790	119	37	[	[	X
dpc-3790	119	38	9,10	9,10	NUM
dpc-3790	119	39	]	]	X
dpc-3790	119	40	.	.	PUNCT
dpc-3790	120	1	a	a	DET
dpc-3790	120	2	recent	recent	ADJ
dpc-3790	120	3	meta	meta	ADJ
dpc-3790	120	4	-	-	PUNCT
dpc-3790	120	5	analysis	analysis	NOUN
dpc-3790	120	6	of	of	ADP
dpc-3790	120	7	jaki	jaki	PROPN
dpc-3790	120	8	in	in	ADP
dpc-3790	120	9	the	the	DET
dpc-3790	120	10	treatment	treatment	NOUN
dpc-3790	120	11	of	of	ADP
dpc-3790	120	12	aa	aa	NOUN
dpc-3790	120	13	,	,	PUNCT
dpc-3790	120	14	reported	report	VERB
dpc-3790	120	15	that	that	SCONJ
dpc-3790	120	16	from	from	ADP
dpc-3790	120	17	289	289	NUM
dpc-3790	120	18	patients	patient	NOUN
dpc-3790	120	19	,	,	PUNCT
dpc-3790	120	20	there	there	PRON
dpc-3790	120	21	were	be	VERB
dpc-3790	120	22	45.7	45.7	NUM
dpc-3790	120	23	%	%	NOUN
dpc-3790	120	24	good	good	ADJ
dpc-3790	120	25	responders	responder	NOUN
dpc-3790	120	26	,	,	PUNCT
dpc-3790	120	27	and	and	CCONJ
dpc-3790	120	28	21.4	21.4	NUM
dpc-3790	120	29	%	%	NOUN
dpc-3790	120	30	partial	partial	ADJ
dpc-3790	120	31	responders	responder	NOUN
dpc-3790	120	32	.	.	PUNCT
dpc-3790	121	1	interestingly	interestingly	ADV
dpc-3790	121	2	,	,	PUNCT
dpc-3790	121	3	the	the	DET
dpc-3790	121	4	researchers	researcher	NOUN
dpc-3790	121	5	found	find	VERB
dpc-3790	121	6	no	no	DET
dpc-3790	121	7	difference	difference	NOUN
dpc-3790	121	8	in	in	ADP
dpc-3790	121	9	the	the	DET
dpc-3790	121	10	response	response	NOUN
dpc-3790	121	11	rates	rate	NOUN
dpc-3790	121	12	between	between	ADP
dpc-3790	121	13	tofacitinib	tofacitinib	NOUN
dpc-3790	121	14	,	,	PUNCT
dpc-3790	121	15	baricitinib	baricitinib	NOUN
dpc-3790	121	16	,	,	PUNCT
dpc-3790	121	17	and	and	CCONJ
dpc-3790	121	18	ruxolitinib	ruxolitinib	NOUN
dpc-3790	121	19	[	[	X
dpc-3790	121	20	11	11	NUM
dpc-3790	121	21	]	]	PUNCT
dpc-3790	121	22	.	.	PUNCT
dpc-3790	122	1	our	our	PRON
dpc-3790	122	2	treatment	treatment	NOUN
dpc-3790	122	3	response	response	NOUN
dpc-3790	122	4	rates	rate	NOUN
dpc-3790	122	5	comply	comply	VERB
dpc-3790	122	6	with	with	ADP
dpc-3790	122	7	that	that	PRON
dpc-3790	122	8	from	from	ADP
dpc-3790	122	9	other	other	ADJ
dpc-3790	122	10	trials	trial	NOUN
dpc-3790	122	11	and	and	CCONJ
dpc-3790	122	12	we	we	PRON
dpc-3790	122	13	confirm	confirm	VERB
dpc-3790	122	14	the	the	DET
dpc-3790	122	15	efficacy	efficacy	NOUN
dpc-3790	122	16	of	of	ADP
dpc-3790	122	17	these	these	DET
dpc-3790	122	18	new	new	ADJ
dpc-3790	122	19	drugs	drug	NOUN
dpc-3790	122	20	in	in	ADP
dpc-3790	122	21	treating	treat	VERB
dpc-3790	122	22	aa	aa	NOUN
dpc-3790	122	23	at	at	ADP
dpc-3790	122	24	a	a	DET
dpc-3790	122	25	real	real	ADJ
dpc-3790	122	26	world	world	NOUN
dpc-3790	122	27	setting	setting	NOUN
dpc-3790	122	28	.	.	PUNCT
dpc-3790	123	1	except	except	SCONJ
dpc-3790	123	2	of	of	ADP
dpc-3790	123	3	tofacitinib	tofacitinib	NOUN
dpc-3790	123	4	and	and	CCONJ
dpc-3790	123	5	baricitinib	baricitinib	NOUN
dpc-3790	123	6	,	,	PUNCT
dpc-3790	123	7	efficacy	efficacy	NOUN
dpc-3790	123	8	of	of	ADP
dpc-3790	123	9	upatacitinib	upatacitinib	NOUN
dpc-3790	123	10	in	in	ADP
dpc-3790	123	11	aa	aa	NOUN
dpc-3790	123	12	has	have	AUX
dpc-3790	123	13	been	be	AUX
dpc-3790	123	14	evaluated	evaluate	VERB
dpc-3790	123	15	in	in	ADP
dpc-3790	123	16	a	a	DET
dpc-3790	123	17	study	study	NOUN
dpc-3790	123	18	including	include	VERB
dpc-3790	123	19	patients	patient	NOUN
dpc-3790	123	20	concomitantly	concomitantly	ADV
dpc-3790	123	21	suffering	suffer	VERB
dpc-3790	123	22	from	from	ADP
dpc-3790	123	23	both	both	PRON
dpc-3790	123	24	,	,	PUNCT
dpc-3790	123	25	atopic	atopic	NOUN
dpc-3790	123	26	dermatitis	dermatitis	NOUN
dpc-3790	123	27	and	and	CCONJ
dpc-3790	123	28	aa	aa	NOUN
dpc-3790	123	29	.	.	PUNCT
dpc-3790	124	1	the	the	DET
dpc-3790	124	2	investigators	investigator	NOUN
dpc-3790	124	3	recorded	record	VERB
dpc-3790	124	4	a	a	DET
dpc-3790	124	5	significant	significant	ADJ
dpc-3790	124	6	reduction	reduction	NOUN
dpc-3790	124	7	of	of	ADP
dpc-3790	124	8	the	the	DET
dpc-3790	124	9	mean	mean	ADJ
dpc-3790	124	10	salt	salt	NOUN
dpc-3790	124	11	score	score	NOUN
dpc-3790	124	12	from	from	ADP
dpc-3790	124	13	baseline	baseline	PROPN
dpc-3790	124	14	(	(	PUNCT
dpc-3790	124	15	95.1	95.1	NUM
dpc-3790	124	16	±9	±9	VERB
dpc-3790	124	17	.6	.6	NUM
dpc-3790	124	18	)	)	PUNCT
dpc-3790	124	19	to	to	ADP
dpc-3790	124	20	the	the	DET
dpc-3790	124	21	4th	4th	ADJ
dpc-3790	124	22	week	week	NOUN
dpc-3790	124	23	of	of	ADP
dpc-3790	124	24	treatment	treatment	NOUN
dpc-3790	124	25	(	(	PUNCT
dpc-3790	124	26	77.6	77.6	NUM
dpc-3790	124	27	±	±	NUM
dpc-3790	124	28	28.2	28.2	NUM
dpc-3790	124	29	,	,	PUNCT
dpc-3790	124	30	p	p	X
dpc-3790	124	31	=	=	NOUN
dpc-3790	124	32	0.0087	0.0087	NUM
dpc-3790	124	33	)	)	PUNCT
dpc-3790	124	34	,	,	PUNCT
dpc-3790	124	35	highlighting	highlight	VERB
dpc-3790	124	36	that	that	SCONJ
dpc-3790	124	37	the	the	DET
dpc-3790	124	38	group	group	NOUN
dpc-3790	124	39	of	of	ADP
dpc-3790	124	40	jaki	jaki	PROPN
dpc-3790	124	41	opens	open	VERB
dpc-3790	124	42	a	a	DET
dpc-3790	124	43	new	new	ADJ
dpc-3790	124	44	horizon	horizon	NOUN
dpc-3790	124	45	in	in	ADP
dpc-3790	124	46	the	the	DET
dpc-3790	124	47	treatment	treatment	NOUN
dpc-3790	124	48	of	of	ADP
dpc-3790	124	49	aa	aa	NOUN
dpc-3790	125	1	[	[	X
dpc-3790	125	2	12	12	NUM
dpc-3790	125	3	]	]	PUNCT
dpc-3790	125	4	.	.	PUNCT
dpc-3790	126	1	in	in	ADP
dpc-3790	126	2	our	our	PRON
dpc-3790	126	3	studied	studied	ADJ
dpc-3790	126	4	population	population	NOUN
dpc-3790	126	5	we	we	PRON
dpc-3790	126	6	included	include	VERB
dpc-3790	126	7	3	3	NUM
dpc-3790	126	8	adolescents	adolescent	NOUN
dpc-3790	126	9	and	and	CCONJ
dpc-3790	126	10	no	no	DET
dpc-3790	126	11	statistical	statistical	ADJ
dpc-3790	126	12	correlation	correlation	NOUN
dpc-3790	126	13	was	be	AUX
dpc-3790	126	14	identified	identify	VERB
dpc-3790	126	15	regarding	regard	VERB
dpc-3790	126	16	the	the	DET
dpc-3790	126	17	efficacy	efficacy	NOUN
dpc-3790	126	18	outcome	outcome	NOUN
dpc-3790	126	19	and	and	CCONJ
dpc-3790	126	20	the	the	DET
dpc-3790	126	21	age	age	NOUN
dpc-3790	126	22	of	of	ADP
dpc-3790	126	23	the	the	DET
dpc-3790	126	24	patient	patient	NOUN
dpc-3790	126	25	.	.	PUNCT
dpc-3790	127	1	in	in	ADP
dpc-3790	127	2	this	this	DET
dpc-3790	127	3	specific	specific	ADJ
dpc-3790	127	4	age	age	NOUN
dpc-3790	127	5	group	group	NOUN
dpc-3790	127	6	,	,	PUNCT
dpc-3790	127	7	no	no	DET
dpc-3790	127	8	differences	difference	NOUN
dpc-3790	127	9	were	be	AUX
dpc-3790	127	10	identified	identify	VERB
dpc-3790	127	11	regarding	regard	VERB
dpc-3790	127	12	the	the	DET
dpc-3790	127	13	adverse	adverse	ADJ
dpc-3790	127	14	events	event	NOUN
dpc-3790	127	15	recordings	recording	NOUN
dpc-3790	127	16	.	.	PUNCT
dpc-3790	128	1	similarly	similarly	ADV
dpc-3790	128	2	low	low	ADJ
dpc-3790	128	3	is	be	AUX
dpc-3790	128	4	the	the	DET
dpc-3790	128	5	adverse	adverse	ADJ
dpc-3790	128	6	event	event	NOUN
dpc-3790	128	7	rate	rate	NOUN
dpc-3790	128	8	from	from	ADP
dpc-3790	128	9	analogous	analogous	ADJ
dpc-3790	128	10	studies	study	NOUN
dpc-3790	128	11	[	[	X
dpc-3790	128	12	13	13	NUM
dpc-3790	128	13	-	-	SYM
dpc-3790	128	14	15	15	NUM
dpc-3790	128	15	]	]	PUNCT
dpc-3790	128	16	.	.	PUNCT
dpc-3790	129	1	our	our	PRON
dpc-3790	129	2	observations	observation	NOUN
dpc-3790	129	3	also	also	ADV
dpc-3790	129	4	pose	pose	VERB
dpc-3790	129	5	a	a	DET
dpc-3790	129	6	few	few	ADJ
dpc-3790	129	7	questions	question	NOUN
dpc-3790	129	8	regarding	regard	VERB
dpc-3790	129	9	treatment	treatment	NOUN
dpc-3790	129	10	handling	handling	NOUN
dpc-3790	129	11	during	during	ADP
dpc-3790	129	12	infections	infection	NOUN
dpc-3790	129	13	[	[	X
dpc-3790	129	14	16,17	16,17	NUM
dpc-3790	129	15	]	]	PUNCT
dpc-3790	129	16	.	.	PUNCT
dpc-3790	130	1	from	from	ADP
dpc-3790	130	2	the	the	DET
dpc-3790	130	3	meta	meta	ADJ
dpc-3790	130	4	-	-	PUNCT
dpc-3790	130	5	analysis	analysis	NOUN
dpc-3790	130	6	report	report	NOUN
dpc-3790	130	7	,	,	PUNCT
dpc-3790	130	8	the	the	DET
dpc-3790	130	9	most	most	ADV
dpc-3790	130	10	common	common	ADJ
dpc-3790	130	11	adverse	adverse	ADJ
dpc-3790	130	12	events	event	NOUN
dpc-3790	130	13	observed	observe	VERB
dpc-3790	130	14	are	be	AUX
dpc-3790	130	15	upper	upper	ADJ
dpc-3790	130	16	respiratory	respiratory	NOUN
dpc-3790	130	17	(	(	PUNCT
dpc-3790	130	18	18.2	18.2	NUM
dpc-3790	130	19	%	%	NOUN
dpc-3790	130	20	)	)	PUNCT
dpc-3790	130	21	,	,	PUNCT
dpc-3790	130	22	urinary	urinary	ADJ
dpc-3790	130	23	tract	tract	NOUN
dpc-3790	130	24	infections	infection	NOUN
dpc-3790	130	25	(	(	PUNCT
dpc-3790	130	26	2.2	2.2	NUM
dpc-3790	130	27	%	%	NOUN
dpc-3790	130	28	)	)	PUNCT
dpc-3790	130	29	and	and	CCONJ
dpc-3790	130	30	total	total	ADJ
dpc-3790	130	31	infections	infection	NOUN
dpc-3790	130	32	(	(	PUNCT
dpc-3790	130	33	24.6	24.6	NUM
dpc-3790	130	34	%	%	NOUN
dpc-3790	130	35	)	)	PUNCT
dpc-3790	131	1	[	[	X
dpc-3790	131	2	11	11	NUM
dpc-3790	131	3	]	]	PUNCT
dpc-3790	131	4	.	.	PUNCT
dpc-3790	132	1	the	the	DET
dpc-3790	132	2	observation	observation	NOUN
dpc-3790	132	3	period	period	NOUN
dpc-3790	132	4	of	of	ADP
dpc-3790	132	5	our	our	PRON
dpc-3790	132	6	study	study	NOUN
dpc-3790	132	7	included	include	VERB
dpc-3790	132	8	the	the	DET
dpc-3790	132	9	covid-19	covid-19	PROPN
dpc-3790	132	10	pandemic	pandemic	ADJ
dpc-3790	132	11	period	period	NOUN
dpc-3790	132	12	and	and	CCONJ
dpc-3790	132	13	maybe	maybe	ADV
dpc-3790	132	14	this	this	PRON
dpc-3790	132	15	is	be	AUX
dpc-3790	132	16	the	the	DET
dpc-3790	132	17	reason	reason	NOUN
dpc-3790	132	18	for	for	SCONJ
dpc-3790	132	19	the	the	DET
dpc-3790	132	20	high	high	ADJ
dpc-3790	132	21	incidence	incidence	NOUN
dpc-3790	132	22	of	of	ADP
dpc-3790	132	23	covid-19	covid-19	PROPN
dpc-3790	132	24	infection	infection	NOUN
dpc-3790	132	25	rates	rate	NOUN
dpc-3790	132	26	recorded	record	VERB
dpc-3790	132	27	.	.	PUNCT
dpc-3790	133	1	whether	whether	SCONJ
dpc-3790	133	2	treatment	treatment	NOUN
dpc-3790	133	3	with	with	ADP
dpc-3790	133	4	jaki	jaki	PROPN
dpc-3790	133	5	should	should	AUX
dpc-3790	133	6	be	be	AUX
dpc-3790	133	7	discontinued	discontinue	VERB
dpc-3790	133	8	,	,	PUNCT
dpc-3790	133	9	as	as	SCONJ
dpc-3790	133	10	advised	advise	VERB
dpc-3790	133	11	in	in	ADP
dpc-3790	133	12	cases	case	NOUN
dpc-3790	133	13	of	of	ADP
dpc-3790	133	14	other	other	ADJ
dpc-3790	133	15	chronic	chronic	ADJ
dpc-3790	133	16	inflammatory	inflammatory	ADJ
dpc-3790	133	17	diseases	disease	NOUN
dpc-3790	133	18	,	,	PUNCT
dpc-3790	133	19	is	be	AUX
dpc-3790	133	20	under	under	ADP
dpc-3790	133	21	discussion	discussion	NOUN
dpc-3790	133	22	.	.	PUNCT
dpc-3790	134	1	considering	consider	VERB
dpc-3790	134	2	covid-19	covid-19	PROPN
dpc-3790	134	3	disease	disease	NOUN
dpc-3790	134	4	,	,	PUNCT
dpc-3790	134	5	our	our	PRON
dpc-3790	134	6	results	result	NOUN
dpc-3790	134	7	indicate	indicate	VERB
dpc-3790	134	8	that	that	PRON
dpc-3790	134	9	jaki	jaki	PROPN
dpc-3790	134	10	have	have	VERB
dpc-3790	134	11	a	a	DET
dpc-3790	134	12	satisfactory	satisfactory	ADJ
dpc-3790	134	13	safety	safety	NOUN
dpc-3790	134	14	profile	profile	NOUN
dpc-3790	134	15	,	,	PUNCT
dpc-3790	134	16	as	as	ADV
dpc-3790	134	17	long	long	ADV
dpc-3790	134	18	as	as	SCONJ
dpc-3790	134	19	patients	patient	NOUN
dpc-3790	134	20	are	be	AUX
dpc-3790	134	21	compliant	compliant	ADJ
dpc-3790	134	22	and	and	CCONJ
dpc-3790	134	23	discontinue	discontinue	VERB
dpc-3790	134	24	treatment	treatment	NOUN
dpc-3790	134	25	during	during	ADP
dpc-3790	134	26	infection	infection	NOUN
dpc-3790	134	27	[	[	X
dpc-3790	134	28	18	18	NUM
dpc-3790	134	29	]	]	PUNCT
dpc-3790	134	30	.	.	PUNCT
dpc-3790	135	1	although	although	SCONJ
dpc-3790	135	2	there	there	PRON
dpc-3790	135	3	are	be	VERB
dpc-3790	135	4	reports	report	NOUN
dpc-3790	135	5	proposing	propose	VERB
dpc-3790	135	6	jaki	jaki	PROPN
dpc-3790	135	7	as	as	ADP
dpc-3790	135	8	a	a	DET
dpc-3790	135	9	potential	potential	ADJ
dpc-3790	135	10	treatment	treatment	NOUN
dpc-3790	135	11	for	for	ADP
dpc-3790	135	12	covid-19	covid-19	PROPN
dpc-3790	135	13	,	,	PUNCT
dpc-3790	135	14	we	we	PRON
dpc-3790	135	15	recommend	recommend	VERB
dpc-3790	135	16	jaki	jaki	PROPN
dpc-3790	135	17	discontinuation	discontinuation	PROPN
dpc-3790	135	18	,	,	PUNCT
dpc-3790	135	19	especially	especially	ADV
dpc-3790	135	20	in	in	ADP
dpc-3790	135	21	symptomatic	symptomatic	ADJ
dpc-3790	135	22	patients	patient	NOUN
dpc-3790	135	23	.	.	PUNCT
dpc-3790	136	1	overall	overall	ADJ
dpc-3790	136	2	,	,	PUNCT
dpc-3790	136	3	complication	complication	NOUN
dpc-3790	136	4	rates	rate	NOUN
dpc-3790	136	5	and	and	CCONJ
dpc-3790	136	6	adverse	adverse	ADJ
dpc-3790	136	7	events	event	NOUN
dpc-3790	136	8	during	during	ADP
dpc-3790	136	9	treatment	treatment	NOUN
dpc-3790	136	10	with	with	ADP
dpc-3790	136	11	jaki	jaki	PROPN
dpc-3790	136	12	are	be	AUX
dpc-3790	136	13	low	low	ADJ
dpc-3790	136	14	,	,	PUNCT
dpc-3790	136	15	and	and	CCONJ
dpc-3790	136	16	so	so	ADV
dpc-3790	136	17	far	far	ADV
dpc-3790	136	18	,	,	PUNCT
dpc-3790	136	19	no	no	DET
dpc-3790	136	20	hospitalization	hospitalization	NOUN
dpc-3790	136	21	6	6	NUM
dpc-3790	136	22	original	original	ADJ
dpc-3790	136	23	article	article	NOUN
dpc-3790	136	24	|	|	ADV
dpc-3790	136	25	dermatol	dermatol	ADJ
dpc-3790	136	26	pract	pract	NOUN
dpc-3790	136	27	concept	concept	NOUN
dpc-3790	136	28	.	.	PUNCT
dpc-3790	137	1	2024;14(2):e2024073	2024;14(2):e2024073	NUM
dpc-3790	137	2	figure	figure	NOUN
dpc-3790	137	3	2	2	NUM
dpc-3790	137	4	.	.	PUNCT
dpc-3790	138	1	(	(	PUNCT
dpc-3790	138	2	a	a	DET
dpc-3790	138	3	,	,	PUNCT
dpc-3790	138	4	d	d	NOUN
dpc-3790	138	5	)	)	PUNCT
dpc-3790	138	6	clinical	clinical	ADJ
dpc-3790	138	7	picture	picture	NOUN
dpc-3790	138	8	of	of	ADP
dpc-3790	138	9	a	a	DET
dpc-3790	138	10	patient	patient	NOUN
dpc-3790	138	11	at	at	ADP
dpc-3790	138	12	baseline	baseline	NOUN
dpc-3790	138	13	(	(	PUNCT
dpc-3790	138	14	a	a	X
dpc-3790	138	15	)	)	PUNCT
dpc-3790	138	16	who	who	PRON
dpc-3790	138	17	achieved	achieve	VERB
dpc-3790	138	18	complete	complete	ADJ
dpc-3790	138	19	response	response	NOUN
dpc-3790	138	20	after	after	ADP
dpc-3790	138	21	9	9	NUM
dpc-3790	138	22	months	month	NOUN
dpc-3790	138	23	of	of	ADP
dpc-3790	138	24	treatment	treatment	NOUN
dpc-3790	138	25	(	(	PUNCT
dpc-3790	138	26	d	d	NOUN
dpc-3790	138	27	)	)	PUNCT
dpc-3790	138	28	.	.	PUNCT
dpc-3790	139	1	(	(	PUNCT
dpc-3790	139	2	b	b	X
dpc-3790	139	3	,	,	PUNCT
dpc-3790	139	4	e	e	NOUN
dpc-3790	139	5	)	)	PUNCT
dpc-3790	139	6	clinical	clinical	ADJ
dpc-3790	139	7	picture	picture	NOUN
dpc-3790	139	8	of	of	ADP
dpc-3790	139	9	a	a	DET
dpc-3790	139	10	patient	patient	NOUN
dpc-3790	139	11	at	at	ADP
dpc-3790	139	12	baseline	baseline	ADJ
dpc-3790	139	13	partial	partial	ADJ
dpc-3790	139	14	(	(	PUNCT
dpc-3790	139	15	b	b	NOUN
dpc-3790	139	16	)	)	PUNCT
dpc-3790	139	17	who	who	PRON
dpc-3790	139	18	achieved	achieve	VERB
dpc-3790	139	19	partial	partial	ADJ
dpc-3790	139	20	response	response	NOUN
dpc-3790	139	21	after	after	ADP
dpc-3790	139	22	6	6	NUM
dpc-3790	139	23	months	month	NOUN
dpc-3790	139	24	of	of	ADP
dpc-3790	139	25	treatment	treatment	NOUN
dpc-3790	139	26	(	(	PUNCT
dpc-3790	139	27	c	c	NOUN
dpc-3790	139	28	)	)	PUNCT
dpc-3790	139	29	.	.	PUNCT
dpc-3790	140	1	(	(	PUNCT
dpc-3790	140	2	c	c	X
dpc-3790	140	3	,	,	PUNCT
dpc-3790	140	4	f	f	X
dpc-3790	140	5	)	)	PUNCT
dpc-3790	140	6	clinical	clinical	ADJ
dpc-3790	140	7	picture	picture	NOUN
dpc-3790	140	8	of	of	ADP
dpc-3790	140	9	a	a	DET
dpc-3790	140	10	patient	patient	NOUN
dpc-3790	140	11	at	at	ADP
dpc-3790	140	12	baseline	baseline	ADJ
dpc-3790	140	13	partial	partial	ADJ
dpc-3790	140	14	(	(	PUNCT
dpc-3790	140	15	c	c	NOUN
dpc-3790	140	16	)	)	PUNCT
dpc-3790	140	17	who	who	PRON
dpc-3790	140	18	failed	fail	VERB
dpc-3790	140	19	to	to	PART
dpc-3790	140	20	respond	respond	VERB
dpc-3790	140	21	after	after	ADP
dpc-3790	140	22	9	9	NUM
dpc-3790	140	23	months	month	NOUN
dpc-3790	140	24	of	of	ADP
dpc-3790	140	25	treatment	treatment	NOUN
dpc-3790	140	26	(	(	PUNCT
dpc-3790	140	27	f	f	NOUN
dpc-3790	140	28	)	)	PUNCT
dpc-3790	140	29	.	.	PUNCT
dpc-3790	141	1	for	for	ADP
dpc-3790	141	2	jak	jak	PROPN
dpc-3790	141	3	inhibitor	inhibitor	NOUN
dpc-3790	141	4	-	-	PUNCT
dpc-3790	141	5	related	relate	VERB
dpc-3790	141	6	adverse	adverse	ADJ
dpc-3790	141	7	events	event	NOUN
dpc-3790	141	8	is	be	AUX
dpc-3790	141	9	reported	report	VERB
dpc-3790	141	10	in	in	ADP
dpc-3790	141	11	the	the	DET
dpc-3790	141	12	literature	literature	NOUN
dpc-3790	141	13	.	.	PUNCT
dpc-3790	142	1	addressing	address	VERB
dpc-3790	142	2	safety	safety	NOUN
dpc-3790	142	3	and	and	CCONJ
dpc-3790	142	4	efficacy	efficacy	NOUN
dpc-3790	142	5	of	of	ADP
dpc-3790	142	6	sars	sar	NOUN
dpc-3790	142	7	-	-	PUNCT
dpc-3790	142	8	cov-2	cov-2	PART
dpc-3790	142	9	vaccination	vaccination	NOUN
dpc-3790	142	10	in	in	ADP
dpc-3790	142	11	patients	patient	NOUN
dpc-3790	142	12	receiving	receive	VERB
dpc-3790	142	13	immunotherapeutics	immunotherapeutic	NOUN
dpc-3790	142	14	,	,	PUNCT
dpc-3790	142	15	gresham	gresham	PROPN
dpc-3790	142	16	et	et	PROPN
dpc-3790	142	17	 	 	SPACE
dpc-3790	142	18	al	al	PROPN
dpc-3790	142	19	outlines	outline	VERB
dpc-3790	142	20	that	that	SCONJ
dpc-3790	142	21	there	there	PRON
dpc-3790	142	22	is	be	VERB
dpc-3790	142	23	a	a	DET
dpc-3790	142	24	possibility	possibility	NOUN
dpc-3790	142	25	of	of	ADP
dpc-3790	142	26	decreased	decrease	VERB
dpc-3790	142	27	immune	immune	ADJ
dpc-3790	142	28	response	response	NOUN
dpc-3790	142	29	and	and	CCONJ
dpc-3790	142	30	vaccine	vaccine	NOUN
dpc-3790	142	31	immunogenicity	immunogenicity	NOUN
dpc-3790	142	32	in	in	ADP
dpc-3790	142	33	patients	patient	NOUN
dpc-3790	142	34	on	on	ADP
dpc-3790	142	35	systemic	systemic	ADJ
dpc-3790	142	36	immunotherapies	immunotherapy	NOUN
dpc-3790	142	37	,	,	PUNCT
dpc-3790	142	38	particularly	particularly	ADV
dpc-3790	142	39	in	in	ADP
dpc-3790	142	40	patients	patient	NOUN
dpc-3790	142	41	receiving	receive	VERB
dpc-3790	142	42	azathioprine	azathioprine	NOUN
dpc-3790	142	43	,	,	PUNCT
dpc-3790	142	44	cyclosporine	cyclosporine	NOUN
dpc-3790	142	45	,	,	PUNCT
dpc-3790	142	46	methotrexate	methotrexate	NOUN
dpc-3790	142	47	,	,	PUNCT
dpc-3790	142	48	or	or	CCONJ
dpc-3790	142	49	jakis	jakis	PROPN
dpc-3790	143	1	[	[	X
dpc-3790	143	2	19	19	NUM
dpc-3790	143	3	]	]	PUNCT
dpc-3790	143	4	.	.	PUNCT
dpc-3790	144	1	additionally	additionally	ADV
dpc-3790	144	2	,	,	PUNCT
dpc-3790	144	3	seror	seror	NOUN
dpc-3790	144	4	et	et	NOUN
dpc-3790	144	5	al	al	PROPN
dpc-3790	144	6	conducted	conduct	VERB
dpc-3790	144	7	a	a	DET
dpc-3790	144	8	study	study	NOUN
dpc-3790	144	9	in	in	ADP
dpc-3790	144	10	order	order	NOUN
dpc-3790	144	11	to	to	PART
dpc-3790	144	12	investigate	investigate	VERB
dpc-3790	144	13	the	the	DET
dpc-3790	144	14	immune	immune	ADJ
dpc-3790	144	15	response	response	NOUN
dpc-3790	144	16	to	to	ADP
dpc-3790	144	17	covid-19	covid-19	PROPN
dpc-3790	144	18	vaccination	vaccination	NOUN
dpc-3790	144	19	in	in	ADP
dpc-3790	144	20	patients	patient	NOUN
dpc-3790	144	21	treated	treat	VERB
dpc-3790	144	22	with	with	ADP
dpc-3790	144	23	jakis	jakis	PROPN
dpc-3790	144	24	.	.	PUNCT
dpc-3790	145	1	113	113	NUM
dpc-3790	145	2	patients	patient	NOUN
dpc-3790	145	3	with	with	ADP
dpc-3790	145	4	rheumatoid	rheumatoid	VERB
dpc-3790	145	5	arthritis	arthritis	NOUN
dpc-3790	145	6	or	or	CCONJ
dpc-3790	145	7	psoriatic	psoriatic	ADJ
dpc-3790	145	8	arthritis	arthritis	NOUN
dpc-3790	145	9	receiving	receiving	NOUN
dpc-3790	145	10	baricitinib	baricitinib	NOUN
dpc-3790	145	11	(	(	PUNCT
dpc-3790	145	12	56/113	56/113	NUM
dpc-3790	145	13	,	,	PUNCT
dpc-3790	145	14	50	50	NUM
dpc-3790	145	15	%	%	NOUN
dpc-3790	145	16	)	)	PUNCT
dpc-3790	145	17	,	,	PUNCT
dpc-3790	145	18	tofacitinib	tofacitinib	PROPN
dpc-3790	145	19	(	(	PUNCT
dpc-3790	145	20	30/113	30/113	NUM
dpc-3790	145	21	,	,	PUNCT
dpc-3790	145	22	27	27	NUM
dpc-3790	145	23	%	%	NOUN
dpc-3790	145	24	)	)	PUNCT
dpc-3790	145	25	or	or	CCONJ
dpc-3790	145	26	upadacitinib	upadacitinib	NOUN
dpc-3790	145	27	(	(	PUNCT
dpc-3790	145	28	27/113	27/113	NUM
dpc-3790	145	29	,	,	PUNCT
dpc-3790	145	30	24	24	NUM
dpc-3790	145	31	%	%	NOUN
dpc-3790	145	32	)	)	PUNCT
dpc-3790	145	33	were	be	AUX
dpc-3790	145	34	included	include	VERB
dpc-3790	145	35	and	and	CCONJ
dpc-3790	145	36	their	their	PRON
dpc-3790	145	37	immune	immune	ADJ
dpc-3790	145	38	response	response	NOUN
dpc-3790	145	39	to	to	ADP
dpc-3790	145	40	covid-19	covid-19	PROPN
dpc-3790	145	41	vaccination	vaccination	NOUN
dpc-3790	145	42	was	be	AUX
dpc-3790	145	43	evaluated	evaluate	VERB
dpc-3790	145	44	.	.	PUNCT
dpc-3790	146	1	the	the	DET
dpc-3790	146	2	overall	overall	ADJ
dpc-3790	146	3	response	response	NOUN
dpc-3790	146	4	rate	rate	NOUN
dpc-3790	146	5	to	to	ADP
dpc-3790	146	6	the	the	DET
dpc-3790	146	7	vaccination	vaccination	NOUN
dpc-3790	146	8	in	in	ADP
dpc-3790	146	9	patients	patient	NOUN
dpc-3790	146	10	treated	treat	VERB
dpc-3790	146	11	with	with	ADP
dpc-3790	146	12	jakis	jakis	PROPN
dpc-3790	146	13	remained	remain	VERB
dpc-3790	146	14	high	high	ADJ
dpc-3790	146	15	.	.	PUNCT
dpc-3790	147	1	nonresponders	nonresponder	NOUN
dpc-3790	147	2	were	be	AUX
dpc-3790	147	3	mostly	mostly	ADV
dpc-3790	147	4	older	old	ADJ
dpc-3790	147	5	patients	patient	NOUN
dpc-3790	147	6	,	,	PUNCT
dpc-3790	147	7	and	and	CCONJ
dpc-3790	147	8	patients	patient	NOUN
dpc-3790	147	9	receiving	receive	VERB
dpc-3790	147	10	upadacitinib	upadacitinib	NOUN
dpc-3790	147	11	.	.	PUNCT
dpc-3790	148	1	serological	serological	ADJ
dpc-3790	148	2	assessment	assessment	NOUN
dpc-3790	148	3	2	2	NUM
dpc-3790	148	4	weeks	week	NOUN
dpc-3790	148	5	after	after	SCONJ
dpc-3790	148	6	vaccination	vaccination	NOUN
dpc-3790	148	7	should	should	AUX
dpc-3790	148	8	be	be	AUX
dpc-3790	148	9	recommended	recommend	VERB
dpc-3790	148	10	for	for	ADP
dpc-3790	148	11	patients	patient	NOUN
dpc-3790	148	12	aged	age	VERB
dpc-3790	148	13	65	65	NUM
dpc-3790	148	14	 	 	SPACE
dpc-3790	148	15	years	year	NOUN
dpc-3790	148	16	and	and	CCONJ
dpc-3790	148	17	older	old	ADJ
dpc-3790	148	18	or	or	CCONJ
dpc-3790	148	19	treated	treat	VERB
dpc-3790	148	20	with	with	ADP
dpc-3790	148	21	upadacitinib	upadacitinib	NOUN
dpc-3790	148	22	to	to	PART
dpc-3790	148	23	secure	secure	VERB
dpc-3790	148	24	a	a	DET
dpc-3790	148	25	high	high	ADJ
dpc-3790	148	26	safety	safety	NOUN
dpc-3790	148	27	profile	profile	NOUN
dpc-3790	148	28	[	[	X
dpc-3790	148	29	20	20	NUM
dpc-3790	148	30	]	]	PUNCT
dpc-3790	148	31	.	.	PUNCT
dpc-3790	149	1	in	in	ADP
dpc-3790	149	2	conclusion	conclusion	NOUN
dpc-3790	149	3	,	,	PUNCT
dpc-3790	149	4	our	our	PRON
dpc-3790	149	5	results	result	NOUN
dpc-3790	149	6	demonstrate	demonstrate	VERB
dpc-3790	149	7	that	that	SCONJ
dpc-3790	149	8	tofacitinib	tofacitinib	NOUN
dpc-3790	149	9	and	and	CCONJ
dpc-3790	149	10	baricitinib	baricitinib	NOUN
dpc-3790	149	11	are	be	AUX
dpc-3790	149	12	effective	effective	ADJ
dpc-3790	149	13	and	and	CCONJ
dpc-3790	149	14	safe	safe	ADJ
dpc-3790	149	15	therapeutic	therapeutic	ADJ
dpc-3790	149	16	modalities	modality	NOUN
dpc-3790	149	17	for	for	ADP
dpc-3790	149	18	aa	aa	NOUN
dpc-3790	149	19	in	in	ADP
dpc-3790	149	20	real	real	ADJ
dpc-3790	149	21	-	-	PUNCT
dpc-3790	149	22	world	world	NOUN
dpc-3790	149	23	settings	setting	NOUN
dpc-3790	149	24	.	.	PUNCT
dpc-3790	150	1	currently	currently	ADV
dpc-3790	150	2	,	,	PUNCT
dpc-3790	150	3	only	only	ADV
dpc-3790	150	4	baricitinib	baricitinib	NOUN
dpc-3790	150	5	is	be	AUX
dpc-3790	150	6	officially	officially	ADV
dpc-3790	150	7	indicated	indicate	VERB
dpc-3790	150	8	for	for	ADP
dpc-3790	150	9	aa	aa	NOUN
dpc-3790	150	10	.	.	PUNCT
dpc-3790	151	1	limitation	limitation	NOUN
dpc-3790	151	2	of	of	ADP
dpc-3790	151	3	our	our	PRON
dpc-3790	151	4	study	study	NOUN
dpc-3790	151	5	is	be	AUX
dpc-3790	151	6	the	the	DET
dpc-3790	151	7	short	short	ADJ
dpc-3790	151	8	follow	follow	NOUN
dpc-3790	151	9	up	up	ADP
dpc-3790	151	10	on	on	ADP
dpc-3790	151	11	treatment	treatment	NOUN
dpc-3790	151	12	and	and	CCONJ
dpc-3790	151	13	the	the	DET
dpc-3790	151	14	small	small	ADJ
dpc-3790	151	15	number	number	NOUN
dpc-3790	151	16	of	of	ADP
dpc-3790	151	17	participants	participant	NOUN
dpc-3790	151	18	.	.	PUNCT
dpc-3790	152	1	references	reference	NOUN
dpc-3790	152	2	1	1	NUM
dpc-3790	152	3	.	.	PUNCT
dpc-3790	153	1	triyangkulsri	triyangkulsri	ADJ
dpc-3790	153	2	k	k	NOUN
dpc-3790	153	3	,	,	PUNCT
dpc-3790	153	4	suchonwanit	suchonwanit	NOUN
dpc-3790	153	5	p.	p.	NOUN
dpc-3790	153	6	role	role	NOUN
dpc-3790	153	7	of	of	ADP
dpc-3790	153	8	janus	janus	PROPN
dpc-3790	153	9	kinase	kinase	PROPN
dpc-3790	153	10	inhibitors	inhibitor	NOUN
dpc-3790	153	11	in	in	ADP
dpc-3790	153	12	the	the	DET
dpc-3790	153	13	treatment	treatment	NOUN
dpc-3790	153	14	of	of	ADP
dpc-3790	153	15	alopecia	alopecia	NOUN
dpc-3790	153	16	areata	areata	ADJ
dpc-3790	153	17	.	.	PUNCT
dpc-3790	154	1	drug	drug	NOUN
dpc-3790	154	2	des	des	PROPN
dpc-3790	154	3	devel	devel	NOUN
dpc-3790	154	4	ther	ther	ADV
dpc-3790	154	5	.	.	PUNCT
dpc-3790	155	1	2018;12:2323	2018;12:2323	NUM
dpc-3790	155	2	-	-	SYM
dpc-3790	155	3	2335	2335	NUM
dpc-3790	155	4	.	.	PUNCT
dpc-3790	156	1	doi	doi	NOUN
dpc-3790	156	2	:	:	PUNCT
dpc-3790	156	3	10.2147	10.2147	NUM
dpc-3790	156	4	/	/	SYM
dpc-3790	156	5	dddt.s172638	dddt.s172638	NOUN
dpc-3790	156	6	.	.	PUNCT
dpc-3790	157	1	pmid	pmid	NOUN
dpc-3790	157	2	:	:	PUNCT
dpc-3790	157	3	30100707	30100707	NUM
dpc-3790	157	4	.	.	PUNCT
dpc-3790	158	1	pmcid	pmcid	NOUN
dpc-3790	158	2	:	:	PUNCT
dpc-3790	158	3	pmc6067625	pmc6067625	ADJ
dpc-3790	158	4	.	.	PUNCT
dpc-3790	159	1	2	2	X
dpc-3790	159	2	.	.	X
dpc-3790	159	3	husein	husein	NOUN
dpc-3790	159	4	-	-	PUNCT
dpc-3790	159	5	elahmed	elahme	VERB
dpc-3790	159	6	h	h	NOUN
dpc-3790	159	7	,	,	PUNCT
dpc-3790	159	8	abdulla	abdulla	PROPN
dpc-3790	159	9	n	n	PROPN
dpc-3790	159	10	,	,	PUNCT
dpc-3790	159	11	al	al	PROPN
dpc-3790	159	12	-	-	PROPN
dpc-3790	159	13	obaidli	obaidli	PROPN
dpc-3790	159	14	a	a	PRON
dpc-3790	159	15	,	,	PUNCT
dpc-3790	159	16	ali	ali	PROPN
dpc-3790	159	17	-	-	PUNCT
dpc-3790	159	18	alam	alam	PROPN
dpc-3790	159	19	m	m	PROPN
dpc-3790	159	20	,	,	PUNCT
dpc-3790	159	21	steinhoff	steinhoff	PROPN
dpc-3790	159	22	m.	m.	NOUN
dpc-3790	159	23	real	real	ADJ
dpc-3790	159	24	-	-	PUNCT
dpc-3790	159	25	world	world	NOUN
dpc-3790	159	26	experience	experience	NOUN
dpc-3790	159	27	and	and	CCONJ
dpc-3790	159	28	long	long	ADJ
dpc-3790	159	29	-	-	PUNCT
dpc-3790	159	30	term	term	NOUN
dpc-3790	159	31	evaluation	evaluation	NOUN
dpc-3790	159	32	of	of	ADP
dpc-3790	159	33	tofacitinib	tofacitinib	NOUN
dpc-3790	159	34	in	in	ADP
dpc-3790	159	35	refractory	refractory	NOUN
dpc-3790	159	36	alopecia	alopecia	NOUN
dpc-3790	159	37	areata	areata	NOUN
dpc-3790	159	38	:	:	PUNCT
dpc-3790	159	39	a	a	DET
dpc-3790	159	40	prospective	prospective	ADJ
dpc-3790	159	41	,	,	PUNCT
dpc-3790	159	42	openlabel	openlabel	ADJ
dpc-3790	159	43	,	,	PUNCT
dpc-3790	159	44	single	single	ADJ
dpc-3790	159	45	-	-	PUNCT
dpc-3790	159	46	center	center	NOUN
dpc-3790	159	47	study	study	NOUN
dpc-3790	159	48	in	in	ADP
dpc-3790	159	49	asian	asian	ADJ
dpc-3790	159	50	arab	arab	ADJ
dpc-3790	159	51	population	population	NOUN
dpc-3790	159	52	.	.	PUNCT
dpc-3790	160	1	dermatol	dermatol	NOUN
dpc-3790	160	2	ther	ther	ADV
dpc-3790	160	3	.	.	PUNCT
dpc-3790	161	1	2022;35(12):e15871	2022;35(12):e15871	X
dpc-3790	161	2	.	.	PUNCT
dpc-3790	161	3	  	  	SPACE
dpc-3790	162	1	doi	doi	NOUN
dpc-3790	162	2	:	:	PUNCT
dpc-3790	162	3	10.1111	10.1111	NUM
dpc-3790	162	4	/	/	SYM
dpc-3790	162	5	dth.15871	dth.15871	PROPN
dpc-3790	162	6	.	.	PUNCT
dpc-3790	163	1	pmid	pmid	NOUN
dpc-3790	163	2	:	:	PUNCT
dpc-3790	163	3	36177791	36177791	NUM
dpc-3790	163	4	.	.	PUNCT
dpc-3790	164	1	3	3	X
dpc-3790	164	2	.	.	X
dpc-3790	164	3	zhan	zhan	PROPN
dpc-3790	164	4	j	j	PROPN
dpc-3790	164	5	,	,	PUNCT
dpc-3790	164	6	cao	cao	PROPN
dpc-3790	164	7	j	j	PROPN
dpc-3790	164	8	,	,	PUNCT
dpc-3790	164	9	chen	chen	PROPN
dpc-3790	164	10	f	f	PROPN
dpc-3790	164	11	,	,	PUNCT
dpc-3790	164	12	jin	jin	PROPN
dpc-3790	164	13	y	y	PROPN
dpc-3790	164	14	,	,	PUNCT
dpc-3790	164	15	huang	huang	PROPN
dpc-3790	164	16	c.	c.	PROPN
dpc-3790	164	17	real	real	PROPN
dpc-3790	164	18	-	-	PUNCT
dpc-3790	164	19	data	data	NOUN
dpc-3790	164	20	on	on	ADP
dpc-3790	164	21	the	the	DET
dpc-3790	164	22	use	use	NOUN
dpc-3790	164	23	of	of	ADP
dpc-3790	164	24	baricitinib	baricitinib	NOUN
dpc-3790	164	25	in	in	ADP
dpc-3790	164	26	adolescents	adolescent	NOUN
dpc-3790	164	27	with	with	ADP
dpc-3790	164	28	severe	severe	ADJ
dpc-3790	164	29	alopecia	alopecia	NOUN
dpc-3790	164	30	areata	areata	NOUN
dpc-3790	164	31	.	.	PUNCT
dpc-3790	165	1	j	j	PROPN
dpc-3790	165	2	eur	eur	PROPN
dpc-3790	165	3	acad	acad	PROPN
dpc-3790	165	4	dermatol	dermatol	NOUN
dpc-3790	165	5	venereol	venereol	NOUN
dpc-3790	165	6	.	.	PUNCT
dpc-3790	166	1	2023	2023	NUM
dpc-3790	166	2	apr	apr	NOUN
dpc-3790	166	3	17	17	NUM
dpc-3790	166	4	.	.	PUNCT
dpc-3790	167	1	doi	doi	NOUN
dpc-3790	167	2	:	:	PUNCT
dpc-3790	167	3	10.1111	10.1111	NUM
dpc-3790	167	4	/	/	SYM
dpc-3790	167	5	jdv.19121	jdv.19121	NUM
dpc-3790	167	6	.	.	PUNCT
dpc-3790	168	1	pmid	pmid	NOUN
dpc-3790	168	2	:	:	PUNCT
dpc-3790	168	3	37066986	37066986	NUM
dpc-3790	168	4	.	.	PUNCT
dpc-3790	169	1	4	4	X
dpc-3790	169	2	.	.	X
dpc-3790	169	3	hernandez	hernandez	PROPN
dpc-3790	169	4	-	-	PUNCT
dpc-3790	169	5	montoya	montoya	PROPN
dpc-3790	169	6	c	c	PROPN
dpc-3790	169	7	,	,	PUNCT
dpc-3790	169	8	ruiz	ruiz	NOUN
dpc-3790	169	9	-	-	PUNCT
dpc-3790	169	10	villaverde	villaverde	NOUN
dpc-3790	169	11	r.	r.	NOUN
dpc-3790	169	12	the	the	DET
dpc-3790	169	13	role	role	NOUN
dpc-3790	169	14	of	of	ADP
dpc-3790	169	15	tofacitinib	tofacitinib	NOUN
dpc-3790	169	16	in	in	ADP
dpc-3790	169	17	the	the	DET
dpc-3790	169	18	management	management	NOUN
dpc-3790	169	19	of	of	ADP
dpc-3790	169	20	alopecia	alopecia	NOUN
dpc-3790	169	21	 	 	SPACE
dpc-3790	169	22	totalis	totalis	PROPN
dpc-3790	169	23	.	.	PUNCT
dpc-3790	170	1	sultan	sultan	PROPN
dpc-3790	170	2	qaboos	qaboos	PROPN
dpc-3790	170	3	univ	univ	PROPN
dpc-3790	170	4	med	med	PROPN
dpc-3790	170	5	j.	j.	PROPN
dpc-3790	170	6	2019;19(1):e77	2019;19(1):e77	PROPN
dpc-3790	170	7	-	-	PUNCT
dpc-3790	170	8	e78	e78	NOUN
dpc-3790	170	9	.	.	PUNCT
dpc-3790	171	1	doi	doi	NOUN
dpc-3790	171	2	:	:	PUNCT
dpc-3790	171	3	10.18295	10.18295	NUM
dpc-3790	171	4	/	/	SYM
dpc-3790	171	5	squmj.2019.19.01.015	squmj.2019.19.01.015	PROPN
dpc-3790	171	6	.	.	PUNCT
dpc-3790	172	1	pmid	pmid	NOUN
dpc-3790	172	2	:	:	PUNCT
dpc-3790	172	3	31198601	31198601	NUM
dpc-3790	172	4	.	.	PUNCT
dpc-3790	173	1	pmcid	pmcid	NOUN
dpc-3790	173	2	:	:	PUNCT
dpc-3790	173	3	pmc6544057	pmc6544057	NOUN
dpc-3790	173	4	.	.	PUNCT
dpc-3790	174	1	5	5	X
dpc-3790	174	2	.	.	X
dpc-3790	174	3	sanchez	sanchez	PROPN
dpc-3790	174	4	-	-	PUNCT
dpc-3790	174	5	diaz	diaz	PROPN
dpc-3790	174	6	m	m	PROPN
dpc-3790	174	7	,	,	PUNCT
dpc-3790	174	8	diaz	diaz	PROPN
dpc-3790	174	9	-	-	PUNCT
dpc-3790	174	10	calvillo	calvillo	PROPN
dpc-3790	174	11	p	p	NOUN
dpc-3790	174	12	,	,	PUNCT
dpc-3790	174	13	rodriguez	rodriguez	PROPN
dpc-3790	174	14	-	-	PUNCT
dpc-3790	174	15	pozo	pozo	PROPN
dpc-3790	174	16	ja	ja	PROPN
dpc-3790	174	17	,	,	PUNCT
dpc-3790	174	18	tercedor	tercedor	PROPN
dpc-3790	174	19	-	-	PUNCT
dpc-3790	174	20	sánchez	sánchez	PROPN
dpc-3790	174	21	j	j	PROPN
dpc-3790	174	22	,	,	PUNCT
dpc-3790	174	23	cantudo	cantudo	PROPN
dpc-3790	174	24	-	-	PROPN
dpc-3790	174	25	cuenca	cuenca	NOUN
dpc-3790	174	26	mr	mr	PROPN
dpc-3790	174	27	,	,	PUNCT
dpc-3790	174	28	molina	molina	PROPN
dpc-3790	174	29	-	-	PUNCT
dpc-3790	174	30	leyva	leyva	PROPN
dpc-3790	174	31	a	a	NOUN
dpc-3790	174	32	,	,	PUNCT
dpc-3790	174	33	arias	arias	PROPN
dpc-3790	174	34	-	-	PUNCT
dpc-3790	174	35	santiago	santiago	PROPN
dpc-3790	174	36	s.	s.	PROPN
dpc-3790	174	37	tofacitinib	tofacitinib	PROPN
dpc-3790	174	38	for	for	ADP
dpc-3790	174	39	treatment	treatment	NOUN
dpc-3790	174	40	of	of	ADP
dpc-3790	174	41	alopecia	alopecia	NOUN
dpc-3790	174	42	areata	areata	NOUN
dpc-3790	174	43	:	:	PUNCT
dpc-3790	174	44	real	real	ADJ
dpc-3790	174	45	-	-	PUNCT
dpc-3790	174	46	world	world	NOUN
dpc-3790	174	47	evidence	evidence	NOUN
dpc-3790	174	48	and	and	CCONJ
dpc-3790	174	49	factors	factor	NOUN
dpc-3790	174	50	associated	associate	VERB
dpc-3790	174	51	with	with	ADP
dpc-3790	174	52	therapeutic	therapeutic	ADJ
dpc-3790	174	53	response	response	NOUN
dpc-3790	174	54	.	.	PUNCT
dpc-3790	175	1	acta	acta	PROPN
dpc-3790	175	2	derm	derm	PROPN
dpc-3790	175	3	venereol	venereol	NOUN
dpc-3790	175	4	.	.	PUNCT
dpc-3790	176	1	2022;102	2022;102	NUM
dpc-3790	176	2	:	:	PUNCT
dpc-3790	176	3	adv00736	adv00736	PROPN
dpc-3790	176	4	.	.	PUNCT
dpc-3790	177	1	s	s	PART
dpc-3790	177	2	doi	doi	NOUN
dpc-3790	177	3	:	:	PUNCT
dpc-3790	177	4	10.2340	10.2340	NUM
dpc-3790	177	5	/	/	SYM
dpc-3790	177	6	actadv.v102.2036	actadv.v102.2036	NOUN
dpc-3790	177	7	.	.	PUNCT
dpc-3790	178	1	pmid	pmid	NOUN
dpc-3790	178	2	:	:	PUNCT
dpc-3790	178	3	35578820	35578820	NUM
dpc-3790	178	4	.	.	PUNCT
dpc-3790	179	1	pmcid	pmcid	NOUN
dpc-3790	179	2	:	:	PUNCT
dpc-3790	179	3	pmc9574676	pmc9574676	PROPN
dpc-3790	179	4	.	.	PUNCT
dpc-3790	180	1	6	6	NUM
dpc-3790	180	2	.	.	X
dpc-3790	180	3	meah	meah	PROPN
dpc-3790	180	4	n	n	CCONJ
dpc-3790	180	5	,	,	PUNCT
dpc-3790	180	6	wall	wall	PROPN
dpc-3790	180	7	d	d	PROPN
dpc-3790	180	8	,	,	PUNCT
dpc-3790	180	9	york	york	PROPN
dpc-3790	180	10	k	k	PROPN
dpc-3790	180	11	,	,	PUNCT
dpc-3790	180	12	et	et	PROPN
dpc-3790	180	13	al	al	PROPN
dpc-3790	180	14	.	.	PUNCT
dpc-3790	181	1	the	the	DET
dpc-3790	181	2	alopecia	alopecia	NOUN
dpc-3790	181	3	areata	areata	ADJ
dpc-3790	181	4	consensus	consensus	NOUN
dpc-3790	181	5	of	of	ADP
dpc-3790	181	6	experts	expert	NOUN
dpc-3790	181	7	(	(	PUNCT
dpc-3790	181	8	ace	ace	NOUN
dpc-3790	181	9	)	)	PUNCT
dpc-3790	181	10	study	study	NOUN
dpc-3790	181	11	:	:	PUNCT
dpc-3790	181	12	results	result	NOUN
dpc-3790	181	13	of	of	ADP
dpc-3790	181	14	an	an	DET
dpc-3790	181	15	international	international	ADJ
dpc-3790	181	16	expert	expert	NOUN
dpc-3790	181	17	opinion	opinion	NOUN
dpc-3790	181	18	on	on	ADP
dpc-3790	181	19	treatments	treatment	NOUN
dpc-3790	181	20	for	for	ADP
dpc-3790	181	21	alopecia	alopecia	NOUN
dpc-3790	181	22	areata	areata	ADJ
dpc-3790	181	23	.	.	PUNCT
dpc-3790	182	1	j	j	PROPN
dpc-3790	182	2	am	be	AUX
dpc-3790	182	3	acad	acad	ADJ
dpc-3790	182	4	dermatol	dermatol	NOUN
dpc-3790	182	5	.	.	PUNCT
dpc-3790	183	1	2020;83(1):123	2020;83(1):123	NUM
dpc-3790	183	2	-	-	PUNCT
dpc-3790	183	3	130	130	NUM
dpc-3790	183	4	.	.	PUNCT
dpc-3790	184	1	doi	doi	NOUN
dpc-3790	184	2	:	:	PUNCT
dpc-3790	184	3	10.1016	10.1016	NUM
dpc-3790	184	4	/	/	SYM
dpc-3790	184	5	j.jaad.2020.03.004	j.jaad.2020.03.004	PROPN
dpc-3790	184	6	.	.	PUNCT
dpc-3790	185	1	pmid	pmid	NOUN
dpc-3790	185	2	:	:	PUNCT
dpc-3790	185	3	32165196	32165196	NUM
dpc-3790	185	4	.	.	PUNCT
dpc-3790	186	1	original	original	ADJ
dpc-3790	186	2	article	article	NOUN
dpc-3790	186	3	|	|	ADV
dpc-3790	186	4	dermatol	dermatol	ADJ
dpc-3790	186	5	pract	pract	NOUN
dpc-3790	186	6	concept	concept	NOUN
dpc-3790	186	7	.	.	PUNCT
dpc-3790	187	1	2024;14(2):e2024073	2024;14(2):e2024073	NUM
dpc-3790	187	2	7	7	NUM
dpc-3790	187	3	15	15	NUM
dpc-3790	187	4	.	.	PUNCT
dpc-3790	188	1	moussa	moussa	PROPN
dpc-3790	188	2	a	a	PROPN
dpc-3790	188	3	,	,	PUNCT
dpc-3790	188	4	eisman	eisman	NOUN
dpc-3790	188	5	s	s	PROPN
dpc-3790	188	6	,	,	PUNCT
dpc-3790	188	7	kazmi	kazmi	PROPN
dpc-3790	188	8	a	a	PROPN
dpc-3790	188	9	,	,	PUNCT
dpc-3790	188	10	et	et	PROPN
dpc-3790	188	11	al	al	PROPN
dpc-3790	188	12	.	.	PROPN
dpc-3790	188	13	treatment	treatment	NOUN
dpc-3790	188	14	of	of	ADP
dpc-3790	188	15	moderate	moderate	ADJ
dpc-3790	188	16	to	to	PART
dpc-3790	188	17	-	-	PUNCT
dpc-3790	188	18	severe	severe	ADJ
dpc-3790	188	19	alopecia	alopecia	NOUN
dpc-3790	188	20	areata	areata	ADJ
dpc-3790	188	21	in	in	ADP
dpc-3790	188	22	adolescents	adolescent	NOUN
dpc-3790	188	23	with	with	ADP
dpc-3790	188	24	baricitinib	baricitinib	NOUN
dpc-3790	188	25	:	:	PUNCT
dpc-3790	188	26	a	a	DET
dpc-3790	188	27	retrospective	retrospective	ADJ
dpc-3790	188	28	review	review	NOUN
dpc-3790	188	29	of	of	ADP
dpc-3790	188	30	29	29	NUM
dpc-3790	188	31	patients	patient	NOUN
dpc-3790	188	32	.	.	PUNCT
dpc-3790	189	1	j	j	PROPN
dpc-3790	189	2	am	be	AUX
dpc-3790	189	3	acad	acad	ADJ
dpc-3790	189	4	dermatol	dermatol	NOUN
dpc-3790	189	5	.	.	PUNCT
dpc-3790	190	1	2023;88(5):1194	2023;88(5):1194	NUM
dpc-3790	190	2	-	-	SYM
dpc-3790	190	3	1196	1196	NUM
dpc-3790	190	4	.	.	PUNCT
dpc-3790	191	1	doi	doi	NOUN
dpc-3790	191	2	:	:	PUNCT
dpc-3790	191	3	10.1016	10.1016	NUM
dpc-3790	191	4	/	/	SYM
dpc-3790	191	5	j.jaad.2022.12.033	j.jaad.2022.12.033	PROPN
dpc-3790	191	6	.	.	PUNCT
dpc-3790	192	1	pmid	pmid	NOUN
dpc-3790	192	2	:	:	PUNCT
dpc-3790	192	3	36623557	36623557	NUM
dpc-3790	192	4	.	.	PUNCT
dpc-3790	193	1	16	16	NUM
dpc-3790	193	2	.	.	PUNCT
dpc-3790	194	1	ghazawi	ghazawi	PROPN
dpc-3790	194	2	fm	fm	PROPN
dpc-3790	194	3	,	,	PUNCT
dpc-3790	194	4	lim	lim	PROPN
dpc-3790	194	5	m	m	PROPN
dpc-3790	194	6	,	,	PUNCT
dpc-3790	194	7	dutz	dutz	ADJ
dpc-3790	194	8	jp	jp	NOUN
dpc-3790	194	9	,	,	PUNCT
dpc-3790	194	10	kirchhof	kirchhof	PROPN
dpc-3790	194	11	mg	mg	PROPN
dpc-3790	194	12	.	.	PUNCT
dpc-3790	195	1	infection	infection	NOUN
dpc-3790	195	2	risk	risk	NOUN
dpc-3790	195	3	of	of	ADP
dpc-3790	195	4	dermatologic	dermatologic	ADJ
dpc-3790	195	5	therapeutics	therapeutic	NOUN
dpc-3790	195	6	during	during	ADP
dpc-3790	195	7	the	the	DET
dpc-3790	195	8	covid-19	covid-19	PROPN
dpc-3790	195	9	pandemic	pandemic	NOUN
dpc-3790	195	10	:	:	PUNCT
dpc-3790	195	11	an	an	DET
dpc-3790	195	12	evidence	evidence	NOUN
dpc-3790	195	13	-	-	PUNCT
dpc-3790	195	14	based	base	VERB
dpc-3790	195	15	recalibration	recalibration	NOUN
dpc-3790	195	16	.	.	PUNCT
dpc-3790	196	1	int	int	NOUN
dpc-3790	196	2	j	j	PROPN
dpc-3790	196	3	dermatol	dermatol	NOUN
dpc-3790	196	4	.	.	PUNCT
dpc-3790	197	1	2020;59(9):10431056	2020;59(9):10431056	NUM
dpc-3790	197	2	.	.	PUNCT
dpc-3790	198	1	doi	doi	NOUN
dpc-3790	198	2	:	:	PUNCT
dpc-3790	198	3	10.1111	10.1111	NUM
dpc-3790	198	4	/	/	SYM
dpc-3790	198	5	ijd.15028	ijd.15028	PROPN
dpc-3790	198	6	.	.	PUNCT
dpc-3790	199	1	pmid	pmid	NOUN
dpc-3790	199	2	:	:	PUNCT
dpc-3790	199	3	32621284	32621284	NUM
dpc-3790	199	4	;	;	PUNCT
dpc-3790	199	5	pmcid	pmcid	ADJ
dpc-3790	199	6	:	:	PUNCT
dpc-3790	199	7	pmc7361427	pmc7361427	NOUN
dpc-3790	199	8	.	.	PUNCT
dpc-3790	200	1	17	17	NUM
dpc-3790	200	2	.	.	PUNCT
dpc-3790	200	3	zazahedi	zazahedi	PROPN
dpc-3790	200	4	niaki	niaki	PROPN
dpc-3790	201	1	o	o	PROPN
dpc-3790	201	2	,	,	PUNCT
dpc-3790	201	3	anadkat	anadkat	PROPN
dpc-3790	201	4	mj	mj	PROPN
dpc-3790	201	5	,	,	PUNCT
dpc-3790	201	6	chen	chen	PROPN
dpc-3790	201	7	st	st	PROPN
dpc-3790	201	8	,	,	PUNCT
dpc-3790	201	9	et	et	PROPN
dpc-3790	201	10	al	al	PROPN
dpc-3790	201	11	.	.	PUNCT
dpc-3790	202	1	navigating	navigate	VERB
dpc-3790	202	2	immunosuppression	immunosuppression	NOUN
dpc-3790	202	3	in	in	ADP
dpc-3790	202	4	a	a	DET
dpc-3790	202	5	pandemic	pandemic	NOUN
dpc-3790	202	6	:	:	PUNCT
dpc-3790	202	7	a	a	DET
dpc-3790	202	8	guide	guide	NOUN
dpc-3790	202	9	for	for	ADP
dpc-3790	202	10	the	the	DET
dpc-3790	202	11	dermatologist	dermatologist	NOUN
dpc-3790	202	12	from	from	ADP
dpc-3790	202	13	the	the	DET
dpc-3790	202	14	covid	covid	PROPN
dpc-3790	202	15	task	task	PROPN
dpc-3790	202	16	force	force	NOUN
dpc-3790	202	17	of	of	ADP
dpc-3790	202	18	the	the	DET
dpc-3790	202	19	medical	medical	ADJ
dpc-3790	202	20	dermatology	dermatology	NOUN
dpc-3790	202	21	society	society	NOUN
dpc-3790	202	22	and	and	CCONJ
dpc-3790	202	23	society	society	NOUN
dpc-3790	202	24	of	of	ADP
dpc-3790	202	25	dermatology	dermatology	NOUN
dpc-3790	202	26	hospitalists	hospitalist	NOUN
dpc-3790	202	27	.	.	PUNCT
dpc-3790	203	1	j	j	PROPN
dpc-3790	203	2	am	be	AUX
dpc-3790	203	3	acad	acad	ADJ
dpc-3790	203	4	dermatol	dermatol	NOUN
dpc-3790	203	5	.	.	PUNCT
dpc-3790	204	1	2020;83(4):1150	2020;83(4):1150	NUM
dpc-3790	204	2	-	-	PUNCT
dpc-3790	204	3	1159	1159	NUM
dpc-3790	204	4	.	.	PUNCT
dpc-3790	205	1	doi	doi	NOUN
dpc-3790	205	2	:	:	PUNCT
dpc-3790	205	3	10.1016	10.1016	NUM
dpc-3790	205	4	/	/	SYM
dpc-3790	205	5	j.jaad.2020.06.051	j.jaad.2020.06.051	PROPN
dpc-3790	205	6	.	.	PUNCT
dpc-3790	206	1	pmid	pmid	NOUN
dpc-3790	206	2	:	:	PUNCT
dpc-3790	206	3	32569797	32569797	NUM
dpc-3790	206	4	.	.	PUNCT
dpc-3790	207	1	pmcid	pmcid	NOUN
dpc-3790	207	2	:	:	PUNCT
dpc-3790	207	3	pmc7303642	pmc7303642	PROPN
dpc-3790	207	4	.	.	PUNCT
dpc-3790	208	1	18	18	NUM
dpc-3790	208	2	.	.	X
dpc-3790	208	3	guimarães	guimarães	PROPN
dpc-3790	208	4	po	po	PROPN
dpc-3790	208	5	,	,	PUNCT
dpc-3790	208	6	quirk	quirk	PROPN
dpc-3790	208	7	d	d	PROPN
dpc-3790	208	8	,	,	PUNCT
dpc-3790	208	9	furtado	furtado	PROPN
dpc-3790	208	10	rh	rh	PROPN
dpc-3790	208	11	,	,	PUNCT
dpc-3790	208	12	et	et	PROPN
dpc-3790	208	13	al	al	PROPN
dpc-3790	208	14	.	.	PROPN
dpc-3790	208	15	tofacitinib	tofacitinib	PROPN
dpc-3790	208	16	in	in	ADP
dpc-3790	208	17	patients	patient	NOUN
dpc-3790	208	18	hospitalized	hospitalize	VERB
dpc-3790	208	19	with	with	ADP
dpc-3790	208	20	covid-19	covid-19	PROPN
dpc-3790	208	21	pneumonia	pneumonia	NOUN
dpc-3790	208	22	.	.	PUNCT
dpc-3790	209	1	n	n	PROPN
dpc-3790	209	2	engl	engl	PROPN
dpc-3790	209	3	j	j	PROPN
dpc-3790	209	4	med	med	PROPN
dpc-3790	209	5	.	.	PUNCT
dpc-3790	210	1	2021;385(5):406	2021;385(5):406	VERB
dpc-3790	210	2	-	-	SYM
dpc-3790	210	3	415	415	NUM
dpc-3790	210	4	.	.	PUNCT
dpc-3790	211	1	doi	doi	NOUN
dpc-3790	211	2	:	:	PUNCT
dpc-3790	211	3	10.1056	10.1056	NUM
dpc-3790	211	4	/	/	SYM
dpc-3790	211	5	nejmoa2101643	nejmoa2101643	PROPN
dpc-3790	211	6	.	.	PUNCT
dpc-3790	212	1	pmid	pmid	NOUN
dpc-3790	212	2	:	:	PUNCT
dpc-3790	212	3	34133856	34133856	NUM
dpc-3790	212	4	.	.	PUNCT
dpc-3790	213	1	pmcid	pmcid	NOUN
dpc-3790	213	2	:	:	PUNCT
dpc-3790	213	3	pmc8220898	pmc8220898	NOUN
dpc-3790	213	4	.	.	PUNCT
dpc-3790	214	1	19	19	NUM
dpc-3790	214	2	.	.	X
dpc-3790	214	3	gresham	gresham	PROPN
dpc-3790	214	4	lm	lm	PROPN
dpc-3790	214	5	,	,	PUNCT
dpc-3790	214	6	marzario	marzario	PROPN
dpc-3790	214	7	b	b	PROPN
dpc-3790	214	8	,	,	PUNCT
dpc-3790	214	9	dutz	dutz	PROPN
dpc-3790	214	10	j	j	PROPN
dpc-3790	214	11	,	,	PUNCT
dpc-3790	214	12	kirchhof	kirchhof	NOUN
dpc-3790	214	13	mg	mg	PROPN
dpc-3790	214	14	.	.	PUNCT
dpc-3790	215	1	an	an	DET
dpc-3790	215	2	evidence	evidence	NOUN
dpc-3790	215	3	-	-	PUNCT
dpc-3790	215	4	based	base	VERB
dpc-3790	215	5	guide	guide	NOUN
dpc-3790	215	6	to	to	ADP
dpc-3790	215	7	sars	sar	NOUN
dpc-3790	215	8	-	-	PUNCT
dpc-3790	215	9	cov-2	cov-2	PART
dpc-3790	215	10	vaccination	vaccination	NOUN
dpc-3790	215	11	of	of	ADP
dpc-3790	215	12	patients	patient	NOUN
dpc-3790	215	13	on	on	ADP
dpc-3790	215	14	immunotherapies	immunotherapy	NOUN
dpc-3790	215	15	in	in	ADP
dpc-3790	215	16	dermatology	dermatology	NOUN
dpc-3790	215	17	.	.	PUNCT
dpc-3790	216	1	j	j	PROPN
dpc-3790	216	2	am	be	AUX
dpc-3790	216	3	acad	acad	ADJ
dpc-3790	216	4	dermatol	dermatol	NOUN
dpc-3790	216	5	.	.	PUNCT
dpc-3790	217	1	2021;84(6):1652	2021;84(6):1652	NUM
dpc-3790	217	2	-	-	PUNCT
dpc-3790	217	3	1666	1666	NUM
dpc-3790	217	4	.	.	PUNCT
dpc-3790	218	1	doi	doi	NOUN
dpc-3790	218	2	:	:	PUNCT
dpc-3790	218	3	10.1016	10.1016	NUM
dpc-3790	218	4	/	/	SYM
dpc-3790	218	5	j.jaad.2021.01.047	j.jaad.2021.01.047	PROPN
dpc-3790	218	6	.	.	PUNCT
dpc-3790	219	1	pmid	pmid	NOUN
dpc-3790	219	2	:	:	PUNCT
dpc-3790	219	3	33482251	33482251	NUM
dpc-3790	219	4	.	.	PUNCT
dpc-3790	220	1	pmcid	pmcid	NOUN
dpc-3790	220	2	:	:	PUNCT
dpc-3790	220	3	pmc7816618	pmc7816618	NOUN
dpc-3790	220	4	.	.	PUNCT
dpc-3790	221	1	20	20	NUM
dpc-3790	221	2	.	.	PUNCT
dpc-3790	221	3	seror	seror	NOUN
dpc-3790	221	4	r	r	NOUN
dpc-3790	221	5	,	,	PUNCT
dpc-3790	221	6	camus	camus	PROPN
dpc-3790	221	7	m	m	PROPN
dpc-3790	221	8	,	,	PUNCT
dpc-3790	221	9	salmon	salmon	PROPN
dpc-3790	221	10	jh	jh	PROPN
dpc-3790	221	11	,	,	PUNCT
dpc-3790	221	12	et	et	PROPN
dpc-3790	221	13	al	al	PROPN
dpc-3790	221	14	.	.	PROPN
dpc-3790	222	1	do	do	AUX
dpc-3790	222	2	jak	jak	PROPN
dpc-3790	222	3	inhibitors	inhibitor	NOUN
dpc-3790	222	4	affect	affect	VERB
dpc-3790	222	5	immune	immune	ADJ
dpc-3790	222	6	response	response	NOUN
dpc-3790	222	7	to	to	ADP
dpc-3790	222	8	covid-19	covid-19	PROPN
dpc-3790	222	9	vaccination	vaccination	NOUN
dpc-3790	222	10	?	?	PUNCT
dpc-3790	223	1	data	datum	NOUN
dpc-3790	223	2	from	from	ADP
dpc-3790	223	3	the	the	DET
dpc-3790	223	4	majik	majik	PROPN
dpc-3790	223	5	-	-	PUNCT
dpc-3790	223	6	sfr	sfr	PROPN
dpc-3790	223	7	registry	registry	NOUN
dpc-3790	223	8	.	.	PUNCT
dpc-3790	224	1	lancet	lancet	PROPN
dpc-3790	224	2	rheumatol	rheumatol	NOUN
dpc-3790	224	3	.	.	PUNCT
dpc-3790	225	1	2022;4(1):e8	2022;4(1):e8	NUM
dpc-3790	225	2	-	-	PUNCT
dpc-3790	225	3	e11	e11	NOUN
dpc-3790	225	4	.	.	PUNCT
dpc-3790	226	1	doi	doi	NOUN
dpc-3790	226	2	:	:	PUNCT
dpc-3790	226	3	10.1016	10.1016	NUM
dpc-3790	226	4	/	/	SYM
dpc-3790	226	5	s2665	s2665	NUM
dpc-3790	226	6	-	-	PUNCT
dpc-3790	226	7	9913(21)00314	9913(21)00314	NUM
dpc-3790	226	8	-	-	PUNCT
dpc-3790	226	9	3	3	NUM
dpc-3790	226	10	.	.	PUNCT
dpc-3790	227	1	pmid	pmid	NOUN
dpc-3790	227	2	:	:	PUNCT
dpc-3790	227	3	34642669	34642669	NUM
dpc-3790	227	4	.	.	PUNCT
dpc-3790	228	1	pmcid	pmcid	ADJ
dpc-3790	228	2	:	:	PUNCT
dpc-3790	228	3	pmc8494471	pmc8494471	NOUN
dpc-3790	228	4	.	.	PUNCT
dpc-3790	229	1	7	7	X
dpc-3790	229	2	.	.	X
dpc-3790	229	3	kennedy	kennedy	PROPN
dpc-3790	229	4	crispin	crispin	PROPN
dpc-3790	229	5	m	m	PROPN
dpc-3790	229	6	,	,	PUNCT
dpc-3790	229	7	ko	ko	PROPN
dpc-3790	229	8	jm	jm	PROPN
dpc-3790	229	9	,	,	PUNCT
dpc-3790	229	10	cet	cet	PROPN
dpc-3790	229	11	al	al	PROPN
dpc-3790	229	12	.	.	PROPN
dpc-3790	229	13	safety	safety	PROPN
dpc-3790	229	14	and	and	CCONJ
dpc-3790	229	15	efficacy	efficacy	NOUN
dpc-3790	229	16	of	of	ADP
dpc-3790	229	17	the	the	DET
dpc-3790	229	18	jak	jak	PROPN
dpc-3790	229	19	inhibitor	inhibitor	PROPN
dpc-3790	229	20	tofacitinib	tofacitinib	PROPN
dpc-3790	229	21	citrate	citrate	VERB
dpc-3790	229	22	in	in	ADP
dpc-3790	229	23	patients	patient	NOUN
dpc-3790	229	24	with	with	ADP
dpc-3790	229	25	alopecia	alopecia	NOUN
dpc-3790	229	26	areata	areata	NOUN
dpc-3790	229	27	.	.	PUNCT
dpc-3790	230	1	jci	jci	PROPN
dpc-3790	230	2	insight	insight	PROPN
dpc-3790	230	3	.	.	PUNCT
dpc-3790	231	1	2016;1(15):e89776	2016;1(15):e89776	PROPN
dpc-3790	231	2	.	.	PUNCT
dpc-3790	231	3	doi	doi	NOUN
dpc-3790	231	4	:	:	PUNCT
dpc-3790	231	5	10.1172	10.1172	NUM
dpc-3790	231	6	/	/	SYM
dpc-3790	231	7	jci.insight.89776	jci.insight.89776	PROPN
dpc-3790	231	8	.	.	PUNCT
dpc-3790	232	1	pmid	pmid	NOUN
dpc-3790	232	2	:	:	PUNCT
dpc-3790	232	3	27699252	27699252	NUM
dpc-3790	232	4	.	.	PUNCT
dpc-3790	233	1	pmcid	pmcid	ADJ
dpc-3790	233	2	:	:	PUNCT
dpc-3790	233	3	pmc5033755	pmc5033755	X
dpc-3790	233	4	.	.	PUNCT
dpc-3790	234	1	8	8	X
dpc-3790	234	2	.	.	X
dpc-3790	235	1	liu	liu	PROPN
dpc-3790	235	2	ly	ly	PROPN
dpc-3790	235	3	,	,	PUNCT
dpc-3790	235	4	craiglow	craiglow	NOUN
dpc-3790	235	5	bg	bg	PROPN
dpc-3790	235	6	,	,	PUNCT
dpc-3790	235	7	dai	dai	PROPN
dpc-3790	235	8	f	f	PROPN
dpc-3790	235	9	,	,	PUNCT
dpc-3790	235	10	king	king	PROPN
dpc-3790	235	11	ba	ba	PROPN
dpc-3790	235	12	.	.	PROPN
dpc-3790	235	13	tofacitinib	tofacitinib	PROPN
dpc-3790	235	14	for	for	ADP
dpc-3790	235	15	the	the	DET
dpc-3790	235	16	treatment	treatment	NOUN
dpc-3790	235	17	of	of	ADP
dpc-3790	235	18	severe	severe	ADJ
dpc-3790	235	19	alopecia	alopecia	NOUN
dpc-3790	235	20	areata	areata	NOUN
dpc-3790	235	21	and	and	CCONJ
dpc-3790	235	22	variants	variant	NOUN
dpc-3790	235	23	:	:	PUNCT
dpc-3790	235	24	a	a	DET
dpc-3790	235	25	study	study	NOUN
dpc-3790	235	26	of	of	ADP
dpc-3790	235	27	90	90	NUM
dpc-3790	235	28	patients	patient	NOUN
dpc-3790	235	29	.	.	PUNCT
dpc-3790	236	1	j	j	PROPN
dpc-3790	236	2	am	be	AUX
dpc-3790	236	3	acad	acad	ADJ
dpc-3790	236	4	dermatol	dermatol	NOUN
dpc-3790	236	5	.	.	PUNCT
dpc-3790	237	1	2017;76(1):22	2017;76(1):22	NUM
dpc-3790	237	2	-	-	PUNCT
dpc-3790	237	3	28	28	NUM
dpc-3790	237	4	.	.	PUNCT
dpc-3790	238	1	doi	doi	NOUN
dpc-3790	238	2	:	:	PUNCT
dpc-3790	238	3	10.1016	10.1016	NUM
dpc-3790	238	4	/	/	SYM
dpc-3790	238	5	j	j	PROPN
dpc-3790	238	6	.jaad.2016.09.007	.jaad.2016.09.007	X
dpc-3790	238	7	.	.	PUNCT
dpc-3790	239	1	pmid	pmid	NOUN
dpc-3790	239	2	:	:	PUNCT
dpc-3790	239	3	27816293	27816293	NUM
dpc-3790	239	4	.	.	PUNCT
dpc-3790	240	1	9	9	X
dpc-3790	240	2	.	.	X
dpc-3790	240	3	king	king	PROPN
dpc-3790	240	4	b	b	PROPN
dpc-3790	240	5	,	,	PUNCT
dpc-3790	240	6	ko	ko	PROPN
dpc-3790	240	7	j	j	PROPN
dpc-3790	240	8	,	,	PUNCT
dpc-3790	240	9	forman	forman	PROPN
dpc-3790	240	10	s	s	PROPN
dpc-3790	240	11	,	,	PUNCT
dpc-3790	240	12	et	et	PROPN
dpc-3790	240	13	al	al	PROPN
dpc-3790	240	14	.	.	PROPN
dpc-3790	240	15	efficacy	efficacy	NOUN
dpc-3790	240	16	and	and	CCONJ
dpc-3790	240	17	safety	safety	NOUN
dpc-3790	240	18	of	of	ADP
dpc-3790	240	19	the	the	DET
dpc-3790	240	20	oral	oral	ADJ
dpc-3790	240	21	janus	janus	PROPN
dpc-3790	240	22	kinase	kinase	PROPN
dpc-3790	240	23	inhibitor	inhibitor	NOUN
dpc-3790	240	24	baricitinib	baricitinib	NOUN
dpc-3790	240	25	in	in	ADP
dpc-3790	240	26	the	the	DET
dpc-3790	240	27	treatment	treatment	NOUN
dpc-3790	240	28	of	of	ADP
dpc-3790	240	29	adults	adult	NOUN
dpc-3790	240	30	with	with	ADP
dpc-3790	240	31	alopecia	alopecia	NOUN
dpc-3790	240	32	areata	areata	NOUN
dpc-3790	240	33	:	:	PUNCT
dpc-3790	240	34	phase	phase	NOUN
dpc-3790	240	35	2	2	NUM
dpc-3790	240	36	results	result	NOUN
dpc-3790	240	37	from	from	ADP
dpc-3790	240	38	a	a	DET
dpc-3790	240	39	randomized	randomized	ADJ
dpc-3790	240	40	controlled	control	VERB
dpc-3790	240	41	study	study	NOUN
dpc-3790	240	42	.	.	PUNCT
dpc-3790	241	1	j	j	PROPN
dpc-3790	241	2	am	be	AUX
dpc-3790	241	3	acad	acad	ADJ
dpc-3790	241	4	dermatol	dermatol	NOUN
dpc-3790	241	5	.	.	PUNCT
dpc-3790	242	1	2021;85(4):847	2021;85(4):847	NUM
dpc-3790	242	2	-	-	PUNCT
dpc-3790	242	3	853	853	NUM
dpc-3790	242	4	.	.	PUNCT
dpc-3790	243	1	doi	doi	NOUN
dpc-3790	243	2	:	:	PUNCT
dpc-3790	243	3	10.1016	10.1016	NUM
dpc-3790	243	4	/	/	SYM
dpc-3790	243	5	j.jaad.2021.05.050	j.jaad.2021.05.050	PROPN
dpc-3790	243	6	.	.	PUNCT
dpc-3790	244	1	pmid	pmid	NOUN
dpc-3790	244	2	:	:	PUNCT
dpc-3790	244	3	34090959	34090959	NUM
dpc-3790	244	4	.	.	PUNCT
dpc-3790	245	1	10	10	NUM
dpc-3790	245	2	.	.	PUNCT
dpc-3790	245	3	king	king	PROPN
dpc-3790	245	4	b	b	PROPN
dpc-3790	245	5	,	,	PUNCT
dpc-3790	245	6	ohyama	ohyama	PROPN
dpc-3790	245	7	m	m	PROPN
dpc-3790	245	8	,	,	PUNCT
dpc-3790	245	9	kwon	kwon	VERB
dpc-3790	245	10	o	o	PROPN
dpc-3790	245	11	,	,	PUNCT
dpc-3790	245	12	zet	zet	PROPN
dpc-3790	245	13	al	al	PROPN
dpc-3790	245	14	.	.	PROPN
dpc-3790	246	1	two	two	NUM
dpc-3790	246	2	phase	phase	NOUN
dpc-3790	246	3	3	3	NUM
dpc-3790	246	4	trials	trial	NOUN
dpc-3790	246	5	of	of	ADP
dpc-3790	246	6	baricitinib	baricitinib	NOUN
dpc-3790	246	7	for	for	ADP
dpc-3790	246	8	alopecia	alopecia	NOUN
dpc-3790	246	9	areata	areata	ADJ
dpc-3790	246	10	.	.	PUNCT
dpc-3790	247	1	n	n	PROPN
dpc-3790	247	2	engl	engl	PROPN
dpc-3790	247	3	j	j	PROPN
dpc-3790	247	4	med	med	PROPN
dpc-3790	247	5	.	.	PUNCT
dpc-3790	248	1	2022;386(18):16871699	2022;386(18):16871699	NUM
dpc-3790	248	2	.	.	PUNCT
dpc-3790	248	3	  	  	SPACE
dpc-3790	248	4	doi	doi	NOUN
dpc-3790	248	5	:	:	PUNCT
dpc-3790	248	6	10.1056	10.1056	NUM
dpc-3790	248	7	/	/	SYM
dpc-3790	248	8	nejmoa2110343	nejmoa2110343	PROPN
dpc-3790	248	9	.	.	PUNCT
dpc-3790	249	1	pmid	pmid	NOUN
dpc-3790	249	2	:	:	PUNCT
dpc-3790	249	3	35334197	35334197	NUM
dpc-3790	249	4	.	.	PUNCT
dpc-3790	250	1	11	11	NUM
dpc-3790	250	2	.	.	PUNCT
dpc-3790	251	1	phan	phan	PROPN
dpc-3790	251	2	k	k	PROPN
dpc-3790	251	3	,	,	PUNCT
dpc-3790	251	4	sebaratnam	sebaratnam	PROPN
dpc-3790	251	5	df	df	PROPN
dpc-3790	251	6	.	.	PUNCT
dpc-3790	251	7	jak	jak	PROPN
dpc-3790	251	8	inhibitors	inhibitor	NOUN
dpc-3790	251	9	for	for	ADP
dpc-3790	251	10	alopecia	alopecia	NOUN
dpc-3790	251	11	areata	areata	NOUN
dpc-3790	251	12	:	:	PUNCT
dpc-3790	251	13	a	a	DET
dpc-3790	251	14	systematic	systematic	ADJ
dpc-3790	251	15	review	review	NOUN
dpc-3790	251	16	and	and	CCONJ
dpc-3790	251	17	meta	meta	ADJ
dpc-3790	251	18	-	-	PUNCT
dpc-3790	251	19	analysis	analysis	NOUN
dpc-3790	251	20	.	.	PUNCT
dpc-3790	252	1	j	j	PROPN
dpc-3790	252	2	eur	eur	PROPN
dpc-3790	252	3	acad	acad	PROPN
dpc-3790	252	4	dermatol	dermatol	NOUN
dpc-3790	252	5	venereol	venereol	NOUN
dpc-3790	252	6	.	.	PUNCT
dpc-3790	253	1	2019;33(5):850	2019;33(5):850	NUM
dpc-3790	253	2	-	-	PUNCT
dpc-3790	253	3	856	856	NUM
dpc-3790	253	4	.	.	PUNCT
dpc-3790	254	1	doi	doi	NOUN
dpc-3790	254	2	:	:	PUNCT
dpc-3790	254	3	10.1111	10.1111	NUM
dpc-3790	254	4	/	/	SYM
dpc-3790	254	5	jdv.15489	jdv.15489	PROPN
dpc-3790	254	6	.	.	PUNCT
dpc-3790	255	1	pmid	pmid	NOUN
dpc-3790	255	2	:	:	PUNCT
dpc-3790	255	3	30762909	30762909	NUM
dpc-3790	255	4	.	.	PUNCT
dpc-3790	256	1	12	12	NUM
dpc-3790	256	2	.	.	PUNCT
dpc-3790	256	3	chiricozzi	chiricozzi	PROPN
dpc-3790	256	4	a	a	NOUN
dpc-3790	256	5	,	,	PUNCT
dpc-3790	256	6	balato	balato	NOUN
dpc-3790	256	7	a	a	PRON
dpc-3790	256	8	,	,	PUNCT
dpc-3790	256	9	fabbrocini	fabbrocini	NOUN
dpc-3790	256	10	g	g	NOUN
dpc-3790	256	11	,	,	PUNCT
dpc-3790	256	12	et	et	PROPN
dpc-3790	256	13	al	al	PROPN
dpc-3790	256	14	.	.	PROPN
dpc-3790	257	1	beneficial	beneficial	ADJ
dpc-3790	257	2	effects	effect	NOUN
dpc-3790	257	3	of	of	ADP
dpc-3790	257	4	upadacitinib	upadacitinib	NOUN
dpc-3790	257	5	on	on	ADP
dpc-3790	257	6	alopecia	alopecia	NOUN
dpc-3790	257	7	areata	areata	NOUN
dpc-3790	257	8	associated	associate	VERB
dpc-3790	257	9	with	with	ADP
dpc-3790	257	10	atopic	atopic	NOUN
dpc-3790	257	11	dermatitis	dermatitis	NOUN
dpc-3790	257	12	:	:	PUNCT
dpc-3790	257	13	a	a	DET
dpc-3790	257	14	multicenter	multicenter	ADJ
dpc-3790	257	15	retrospective	retrospective	ADJ
dpc-3790	257	16	study	study	NOUN
dpc-3790	257	17	.	.	PUNCT
dpc-3790	258	1	j	j	PROPN
dpc-3790	258	2	am	be	AUX
dpc-3790	258	3	acad	acad	ADJ
dpc-3790	258	4	dermatol	dermatol	NOUN
dpc-3790	258	5	.	.	PUNCT
dpc-3790	259	1	2023;89(6):1251	2023;89(6):1251	NUM
dpc-3790	259	2	-	-	PUNCT
dpc-3790	259	3	1253	1253	NUM
dpc-3790	259	4	.	.	PUNCT
dpc-3790	260	1	doi	doi	NOUN
dpc-3790	260	2	:	:	PUNCT
dpc-3790	260	3	10.1016	10.1016	NUM
dpc-3790	260	4	/	/	SYM
dpc-3790	260	5	j.jaad.2023.05.001	j.jaad.2023.05.001	PROPN
dpc-3790	260	6	.	.	PUNCT
dpc-3790	261	1	pmid	pmid	NOUN
dpc-3790	261	2	:	:	PUNCT
dpc-3790	261	3	37169293	37169293	NUM
dpc-3790	261	4	.	.	PUNCT
dpc-3790	262	1	13	13	NUM
dpc-3790	262	2	.	.	X
dpc-3790	262	3	craiglow	craiglow	PROPN
dpc-3790	262	4	bg	bg	PROPN
dpc-3790	262	5	,	,	PUNCT
dpc-3790	262	6	liu	liu	PROPN
dpc-3790	262	7	ly	ly	PROPN
dpc-3790	262	8	,	,	PUNCT
dpc-3790	262	9	king	king	PROPN
dpc-3790	262	10	ba	ba	PROPN
dpc-3790	262	11	.	.	PROPN
dpc-3790	262	12	tofacitinib	tofacitinib	PROPN
dpc-3790	262	13	for	for	ADP
dpc-3790	262	14	the	the	DET
dpc-3790	262	15	treatment	treatment	NOUN
dpc-3790	262	16	of	of	ADP
dpc-3790	262	17	alopecia	alopecia	NOUN
dpc-3790	262	18	areata	areata	NOUN
dpc-3790	262	19	and	and	CCONJ
dpc-3790	262	20	variants	variant	NOUN
dpc-3790	262	21	in	in	ADP
dpc-3790	262	22	adolescents	adolescent	NOUN
dpc-3790	262	23	.	.	PUNCT
dpc-3790	263	1	j	j	PROPN
dpc-3790	263	2	am	be	AUX
dpc-3790	263	3	acad	acad	ADJ
dpc-3790	263	4	dermatol	dermatol	NOUN
dpc-3790	263	5	.	.	PUNCT
dpc-3790	264	1	2017;76(1):29	2017;76(1):29	NUM
dpc-3790	264	2	-	-	SYM
dpc-3790	264	3	32	32	NUM
dpc-3790	264	4	.	.	PUNCT
dpc-3790	264	5	  	  	SPACE
dpc-3790	265	1	doi	doi	NOUN
dpc-3790	265	2	:	:	PUNCT
dpc-3790	265	3	10.1016	10.1016	NUM
dpc-3790	265	4	/	/	SYM
dpc-3790	265	5	j.jaad.2016.09.006	j.jaad.2016.09.006	PROPN
dpc-3790	265	6	.	.	PUNCT
dpc-3790	266	1	pmid	pmid	NOUN
dpc-3790	266	2	:	:	PUNCT
dpc-3790	266	3	27816292	27816292	NUM
dpc-3790	266	4	.	.	PUNCT
dpc-3790	267	1	14	14	NUM
dpc-3790	267	2	.	.	PUNCT
dpc-3790	268	1	castelo	castelo	NOUN
dpc-3790	268	2	-	-	PUNCT
dpc-3790	268	3	soccio	soccio	NOUN
dpc-3790	268	4	l.	l.	NOUN
dpc-3790	268	5	experience	experience	NOUN
dpc-3790	268	6	with	with	ADP
dpc-3790	268	7	oral	oral	ADJ
dpc-3790	268	8	tofacitinib	tofacitinib	NOUN
dpc-3790	268	9	in	in	ADP
dpc-3790	268	10	8	8	NUM
dpc-3790	268	11	adolescent	adolescent	ADJ
dpc-3790	268	12	patients	patient	NOUN
dpc-3790	268	13	with	with	ADP
dpc-3790	268	14	alopecia	alopecia	NOUN
dpc-3790	268	15	universalis	universali	VERB
dpc-3790	268	16	.	.	PUNCT
dpc-3790	269	1	j	j	PROPN
dpc-3790	269	2	am	be	AUX
dpc-3790	269	3	acad	acad	ADJ
dpc-3790	269	4	dermatol	dermatol	NOUN
dpc-3790	269	5	.	.	PUNCT
dpc-3790	270	1	2017;76(4):754	2017;76(4):754	NUM
dpc-3790	270	2	-	-	PUNCT
dpc-3790	270	3	755	755	PROPN
dpc-3790	270	4	.	.	PUNCT
dpc-3790	270	5	doi	doi	NOUN
dpc-3790	270	6	:	:	PUNCT
dpc-3790	270	7	10.1016	10.1016	NUM
dpc-3790	270	8	/	/	SYM
dpc-3790	270	9	j.jaad.2016.11.038	j.jaad.2016.11.038	PROPN
dpc-3790	270	10	.	.	PUNCT
dpc-3790	271	1	pmid	pmid	NOUN
dpc-3790	271	2	:	:	PUNCT
dpc-3790	271	3	28325392	28325392	NUM
dpc-3790	271	4	.	.	PUNCT